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8 | Chapter 1
The human brain contains roughly 86 billion neurons (Azevedo et al., 2009). They 
communicate with each other through electrical signaling, an energy-demanding process 
which involves an extensive amount of active pumping of ions over the cell membrane. 
Neuronal signaling therefore forms the largest expense on the brain’s energy budget and 
largely explains why the brain’s relative energy use is about ten times higher than its relative 
mass (Shulman et al., 2004). Furthermore, unlike for example liver or muscle tissue, the 
brain does not maintain an energy reserve. This means that all energy must be supplied 
from the periphery via the blood to the brain without interruption (Berg et al., 2002). 
Consequently, a dysfunctional brain vasculature can severely impair brain function. Indeed, 
abrupt cessation of blood supply, such as after stroke, leads to near instantaneous and 
irreversible brain damage. However, more subtle and chronic cerebrovascular dysfunction 
has also been linked to brain diseases, including Alzheimer’s disease (AD)(Iturria-Medina 
et al., 2016). Whether cerebrovascular dysfunction in this case also plays a causative 
role in disease pathogenesis requires further research. Measurements optimized to 
detect changes in cerebrovascular function could therefore help to further unravel the 
pathophysiology of brain diseases such as AD. Furthermore, they could be an important 
indicator of brain health in general. 
One of the pathological hallmarks of AD is amyloid-β accumulation in the parenchymal 
brain tissue. Amyloid-β is also found in the vessel wall of patients with cerebral amyloid 
angiopathy (CAA). These pathological accumulations of the amyloid-β peptide are referred 
to as amyloidosis. The aim of this thesis is to improve our understanding of the relation 
between cerebrovascular function and amyloidosis. To that end, cerebrovascular function 
measurements will be designed and carried out in animal models of cerebral amyloidosis, 
as seen in AD and CAA.
STRUCTURAL PROPERTIES OF THE CEREBRAL VASCULATURE
The left and right carotids and the left and right vertebral arteries are the feeding arteries 
of the brain. They all combine into one circular vascular structure called the circle of Willis 
(CoW), which is located below the brain and allows for some redistribution of blood in case 
one of the four feeding arteries collapses. From the CoW, several arteries branch off that 
go on to perfuse the brain. Of those, the posterior, middle and anterior cerebral arteries 
curve around the brain and supply cortical brain tissue. While curving around the brain, 
they bifurcate into several smaller branches that spread over the surface of the brain. 
These superficial arteries are often referred to as leptomeningeal arteries. Eventually, these 
vessels penetrate the cortical brain tissue, after which they are referred to as penetrating 
arterioles. From the CoW, other vessels branch off that directly penetrate the brain from 
the bottom part, and supply the lower brain regions, i.e. subcortical brain regions. In 
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1both cortical and subcortical brain tissue, the penetrating vessels further branch into 
a capillary network. At the level of the capillaries, exchange between blood and tissue 
occurs. Further downstream, capillaries gather into venules and thereafter veins, through 
which blood exits the brain again. On the surface of the brain, veins gather into sinuses, 
and eventually leave the head through the jugular veins (Cipolla MJ., 2009). 
On the micro-anatomical level, all different vessel types – from arteries to veins – are 
lined on the luminal side with endothelium. Endothelium consists of a single-cell layer of 
endothelial cells (ECs), which can detect pressure or chemical changes and transmit that 
information to more abluminal cell layers (Wang et al., 2016). In arteries and arterioles, 
a thin layer of elastic fibers, referred to as the internal elastic lamina, separates ECs from 
the next concentric cell layers. This elastic layer gives arteries the capacity to dampen the 
pulsatility of the heartbeat. The next layer in arteries and arterioles consists of vascular 
smooth muscle cells (VSMCs). The size of the vessel determines how many concentric 
cell layers of VSMCs are present. Penetrating arterioles have 1 layer of VSMCs, whereas 
leptomeningeal arteries contain several layers of VSMCs. VSMCs contain contractile 
properties that allow the vessel to change its diameter. This is helpful for blood flow 
regulation to the brain (see below). After the VSMC layer, arteries have another layer of 
tissue, which contains mostly fibers, fibroblasts, nerve terminals and/or astrocytic end 
feet. Capillaries have a much thinner vessel wall. After the endothelium, there is usually 
a single pericyte wrapping around the vessel. Different types of pericytes have been 
described, and some of them also contain contractile properties. Thus, capillaries have 
the capacity to contribute to blood flow regulation to the brain. A unique feature of brain 
capillary endothelium is its high restrictiveness to the passage of molecules between blood 
and brain tissue. This restriction is caused by a tight link between ECs, formed with tight 
junction proteins. This feature of the brain capillary endothelium is generally referred to 
as the blood-brain barrier (BBB), and is important for proper brain function. Lastly, venules 
and veins have somewhat thicker walls again, also with some degree of VSMCs present in 
the vessel wall. However, the amount of VSMCs is much lower than in arteries. Cerebral 
veins do not have valves, as in other parts of the body (Cipolla MJ., 2009). 
This general micro- and macro-anatomical structure of the cerebral circulation is largely 
similar amongst humans and mice (Hagan, 2012).
REGULATION OF BLOOD SUPPLY TO THE BRAIN
Cerebral hemodynamics is a general term used to describe blood flow dynamics in the 
brain. A vital hemodynamic parameter is the amount of blood that passes through a certain 
amount of brain tissue per unit of time, usually referred to as cerebral blood flow (CBF) 
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or brain perfusion. CBF is commonly expressed in mL/100 g/min. Besides CBF, cerebral 
blood volume (CBV) and mean transit time (MTT) are important descriptors of the cerebral 
hemodynamics. The former describes the volume of blood present in brain tissue, the 
latter the time that it takes for blood to pass through the microvascular network. The 
central volume theorem states that CBF is equal the ratio of CBV over MTT, which can 
also be deduced from the respective units. 
Cerebral perfusion pressure (CPP) can be considered the driving force of cerebral perfusion 
with CBF being equal to the ratio between CPP and the cerebrovascular resistance. CPP 
is the difference between the arterial and venous pressure, and is mostly dependent 
on the mean arterial pressure (MAP), as the venous pressure is normally negligible. 
The cerebral vasculature itself poses a certain resistance on the blood flow, which is 
dependent amongst others on the diameter of the vessels and especially the capillaries 
and arterioles. To maintain a constant CBF, the diameter of the vasculature is adapted 
when CPP changes (Powers, 1991), i.e. vasodilation and vasoconstriction. As an example, 
during exercise CPP will be high, which will result in a narrowing of the vessel diameters to 
induce increased vascular resistance to keep CBF constant. Or, while standing up, CPP will 
decrease, which will result in increased vessel diameter to decrease the vascular resistance. 
This process is referred to as cerebral autoregulation and is of vital importance for proper 
brain health (Van Beek et al., 2008). However, under constant CPP, several factors can 
modulate CBF. Such changes are also mediated through changes in the diameter of the 
vasculature. One external factor with a particularly strong influence on CBF is the partial 
pressure of CO2 (pCO2) in the blood. Increases in pCO2 are tightly coupled to vasodilation, 
thereby increasing CBF. The CBF is also responsive to the partial pressure of O2 (pO2), 
but to a lesser extent than to pCO2, and only on the lower range of pO2 values (Ellingsen 
et al., 1987). The influence of the MAP, pCO2 and pO2 on the vascular diameter and the 
resulting CBF is further explained in figure 1. There are still other factors with an influence 
on CBF, such as temperature (Stretti et al., 2014), or certain signaling molecules such as 
acetylcholine (Matsuda et al., 1976) and bradykinin (Unterberg et al., 1984). General 
anesthesia also has a major influence on cerebral hemodynamics, with different types of 
anesthetics d ifferently influencing CBF (Matta et al., 1999) and cerebral autoregulation 
(Smith et al., 1970; Strebel et al., 1995). This is particularly interesting for animal studies, 
as hemodynamic measurements are generally performed under general anesthesia. The 
influence of different anesthesia protocols on the murine hemodynamics will therefore 
be discussed in more detail later in this thesis.
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Figure 1: Influence of the mean arterial pressure (MAP), partial pressure of CO2 (pCO2) and O2 (pO2) on 
brain vessel diameter and cerebral blood flow (CBF). Note that in the MAP-CBF graph (left 
panel), the middle part is flat because constriction of the vessels negates the otherwise 
positive correlation between MAP and CBF, which is termed cerebral autoregulation. 
However, at the left and right sides of the MAP-CBF graph, the cerebral autoregulation is 
exhausted, and vessels either collapse (left), or forcefully dilate (right). An increase in pCO2 
(middle panel) leads to CBF increase through vessel diameter changes. A decrease in pO2 
(right panel) also leads to CBF increase, but only on the lower range of pO2 values. Figure 
adapted from (Silvio Taccone et al., 2013) and (Budohoski et al., 2013).
An internal factor influencing CBF is neuronal activity. Local increases in neuronal activity 
are followed by local increases in CBF, which is referred to as neurovascular coupling 
(NVC). Interestingly, the increase in blood flow during NVC is much higher than what is 
required to compensate for the increased energy demand by neurons. This phenomenon is 
exploited during a type of imaging called blood oxygen level dependent (BOLD) functional 
MRI (fMRI), which is used to study brain activity (Logothetis & Pfeuffer, 2004). This will 
be addressed in more detail later in this chapter.
The brain’s preferred energy substrate is glucose, which is normally the exclusive source 
of energy. However, in times of low glucose supply, the brain can switch to ketone bodies 
as a substitute. Oxidative phosphorylation is the major pathway for glucose metabolism in 
the brain. This is far more efficient in terms of energy yield than its alternative, glycolysis, 
but it requires oxygen. Neurons fully rely on oxidative phosphorylation, but astrocytes 
have been reported to also make use of glycolysis. The latter is counterintuitive given that 
oxygen is normally in excess in the brain and this topic is an area of continued scientific 
investigation. From the whole brain perspective, it is estimated that 90 % of the glucose is 
metabolized through oxidative phosphorylation (Magistretti & Allaman, 2015). Normally, 
the oxygenation saturation of arterial blood is close to 100 %, and on average, the oxygen 
extraction fraction (OEF) is around 37 % (Qin et al., 2011). The product of the OEF and CBF 
gives the brain’s oxygen consumption, the cerebral metabolic rate of oxygen (CMRO2). 
When the lower limit of cerebral autoregulation has been reached, further CPP reductions 
will result in decreased CBF, putting the brain at risk of infarction. Up to a certain extent, 
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the CMRO2 can be, however, compensated by increasing the OEF. A second limit will 
however be reached when further CPP reductions cannot be compensated anymore 
with OEF increases. At this point, brain ischemia will occur, with severe consequences 
for brain function (Powers, 1991).
NEUROVASCULAR DISEASE - GENERAL
An abrupt flow disruption of one of the larger brain arteries is referred to as stroke. Stroke 
prevalence in the Netherlands in 2018 was around 496,300, and 9,213 people died that 
year of stroke. With that, stroke was the third most common cause of death in 2018 in 
the Netherlands (RIVM, 2020). Stroke is usually divided into two types: ischemic and 
hemorrhagic stroke. The former is caused by artery obstruction and the latter by artery 
rupture. The ensuing lack of blood supply leads to metabolic failure and irreversible cell 
death in a few minutes in the core, i.e. tissue that is only supplied by the affected blood 
vessel. For hemorrhagic stroke, the extravasated blood forms an extra immediate risk, 
because within the confinement of the skull the blood may compress otherwise healthy 
brain tissue. Tissue that still partly receives blood from collateral vessels is not as sensitive 
as the core, but if not treated in time, might still become irreversibly damaged. This latter 
type of tissue is called the penumbra region. A fast response is thus key to rescue the 
penumbra region (Lo et al., 2003). Early symptoms of stroke include face drooping (F), 
arm weakness (A) and speech difficulty (S) and can be easily remembered with the F.A.S.T. 
acronym to ensure a timely response (T). 
Diseases that affect the smaller vessels in the brain are collectively referred to as cerebral 
small vessel disease (CSVD). CSVD is a major contributor to dementia and age-related 
disability, but can ultimately also lead to stroke. There are many different types of CSVD, 
of which arteriolosclerosis and cerebral amyloid angiopathy (CAA) are the most prevalent 
forms. Arteriolosclerosis is a systemic disease that also affects for example the vasculature 
in the kidneys. It is associated with hypertension, diabetes and ageing (Pantoni, 2010). CAA 
is also associated with ageing, but it is a brain disease that is characterized by accumulation 
of the amyloid-β peptide in the vessel wall of brain vessels only. Hemorrhagic lesions 
as a result of arteriosclerosis have a tendency to occur in deep brain regions and in the 
brainstem, whereas for CAA, these lesions are restricted to the cortex and subcortical 
white matter (lobar brain regions). This difference in affected brain region usually allows 
for distinction of the two diseases during life (Greenberg & Charidimou, 2018). 
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CAA is a very prevalent disease. It has been estimated that a third of the people over 
60 has CAA pathology (Love et al., 2003; Vinters & Gilbert, 1983). However, CAA is still 
relatively unknown amongst the general public. As such, it has been fittingly termed 
“the biggest disease you never heard of” by the Dutch CAA foundation. For a definite 
CAA diagnosis, brain tissue is necessary, to allow for a histological staining proving the 
presence of accumulation of amyloid-β in the cerebral vessels. However, with the Boston 
criteria for CAA diagnosis, introduced by the group of Dr. Greenberg in Boston, imaging-
based criteria were introduced to arrive at a more standardized diagnosis of “possible” 
or “probable” CAA. This further opened the means to do research in a clinical setting. For 
a possible or probable CAA diagnosis, respectively one or more indications of previous 
lobar vessel rupture have to be detected with imaging. These indications can include 
micro- or macrobleeds located in lobar regions, or cortical superficial siderosis. The 
latter is an MRI finding where a hypointense region overlays one or more gyri, which is 
thought to be the result of leptomeningeal bleeding. Importantly, the finding of bleeds 
in the deeper brain regions precludes the diagnosis probable or possible CAA, because, 
as stated above, such bleedings are likely caused by systemic arteriolar disease, not CAA 
(Greenberg & Charidimou, 2018).
In 2018, dementia was the most common cause of death in the Netherlands, as well as the 
most expensive disease on the Dutch health care budget (RIVM, 2020). Notwithstanding, an 
enormous growth in dementia incidence is expected, given the increasing life expectancy. 
This will be a huge burden on patients, family and society, whereas no treatment is 
available yet. AD is the most common cause of dementia (“2020 Alzheimer’s disease 
facts and figures,” 2020). Like CAA, Alzheimer’s disease is also characterized by amyloid-β 
accumulation, but not necessarily in the vasculature. For AD diagnosis, parenchymal 
amyloid-β accumulation is required, and is one of the two pathological hallmarks of 
the disease. Nevertheless, almost every AD patient also has CAA pathology. The second 
pathological hallmark of AD is intraneuronal accumulation of tau, but tau will not be 
discussed in detail within this thesis. AD and CAA are thus tightly linked through amyloid-β 
accumulation. Novel research findings for one of the two diseases might therefore also 
apply to the other (Greenberg et al., 2020). The connection of the two diseases is further 
underlined by the fact that different genetic mutations in the same gene, the amyloid‑β 
precursor protein (APP), can either lead to AD, CAA or both. One of these genetic variants 
leading to CAA is especially interesting in the context of the research as described in this 
thesis. This is the APP E693Q mutation, leading to Dutch-type CAA (D-CAA), also known as 
hereditary cerebral hemorrhages with amyloidosis Dutch-type (HCHWA-D). Patients with 
this disease mainly live in villages in the coastal area close to Leiden in the Netherlands. As 
such, the Leiden University Medical Center (LUMC) is the main referral center for D-CAA 
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patients. The disease is characterized by very early lobar hemorrhagic stroke, usually 
between the age of 40 and 65. The stroke is fatal 2 out of 3 times. Like sporadic CAA or 
AD, there is no treatment available yet for D-CAA. This lack of treatment is sustained by 
an incomplete understanding of the pathophysiology of the diseases. Further research 
in the disease mechanisms of AD and CAA is thus highly necessary. Unique for D-CAA is 
the possibility to genetically test individuals, and thereby come to a definite diagnosis of 
D-CAA during life without the need of brain biopsies. This as well as the fact that it allows 
for studying the pre-symptomatic phase of CAA, makes D-CAA an extremely helpful model 
for research into CAA (Kamp et al., 2014).
The pathological burden of CAA is highest in the occipital lobe (Yamada et al., 1987) and 
much more severe around arteries than veins (Weller et al., 1998). VSMCs are particularly 
sensitive to amyloid-β, and become dysfunctional and eventually undergo cell death as 
a result of the amyloid-β accumulation in the vasculature (Christie et al., 2001). This can 
also be seen in histological brain slices of (D-)CAA patients, stained for amyloid-β and 
VSMCs, where vessels with amyloid-β accumulation show reduced VSMCs, see figure 2. 
It is still unclear why CAA preferentially accumulates in the occipital cortex and on the 
arterial side of the circulation, but these findings could eventu ally be helpful in unraveling 
the disease pathophysiology. On the micro-anatomical scale, CAA can be divided into two 
subtypes, depending on whether or not there is capillary amyloid-β accumulation along 
the cerebrovascular tree. CAA with capillary involvement is referred to as type 1 CAA, or 
simply as capillary CAA. CAA without capillary involvement is referred to as type 2 CAA 
(Thal et al., 2002). Patients with D-CAA only have capillary amyloid-β accumulation in a 
very advanced disease stage (Maat-Schieman et al., 1996). 
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Figure 2: Microscopic image of a D CAA brain slice. Shown is a cross-section of a vessel that has been 
stained for amyloid β in red and smooth muscle actin, a marker for vascular smooth muscle 
cells (VSMCs), in blue. Normally, VSMCs fully cover an arteriole. However, as can be seen in this 
image, with vascular amyloid β accumulation, VSMCs disappear. Image kindly provided by Dr. 
Laure Grand Moursel.
Amyloid-β as deposited in parenchymal plaques or in the vessel wall are thought to 
originate from neurons (Calhoun et al., 1999). Neurons express amyloid-β precursor protein 
(APP), a membrane protein involved in neuronal cell signaling processes. Amyloid-β is 
derived from APP through two enzymatic cleavages, yielding three fragments, i.e. the APP 
internal cellular domain (AICD), amyloid-β and soluble APP (sAPP). After cleavage, amyloid-β 
and sAPP end up in the extracellular space, while AICD is involved in an intracellular 
signaling cascade. APP cleavage does not always occur at the exact same amino 
acid, and as a result, amyloid-β species with different peptide lengths are created. 
Amyloid-β-40 and amyloid-β-42 are the most prevalent types of amyloid-β, where the 
numbers 40 and 42 indicate the length of the peptide. The ratio between the two has 
shown to play an important role in whether amyloid-β accumulates in the parenchyma 
or in the vasculature. Plaques contain higher amounts of amyloid-β-42, and CAA higher 
amounts of amyloid-β-40. The different amyloid-β species are continuously produced 
during life, but it is unclear whether they have a physiological function (Van Broeck et 
al., 2007). It has been hypothesized that amyloid-β might function as an anti-microbial 
peptide (Welling et al., 2015). However, more commonly, amyloid-β is thought to be a 
mere waste product that needs to be cleared from the brain. 
AD is often considered the result of a disbalance in the production and clearance of 
amyloid-β, where neuronal loss, tau tangle formation and cognitive dysfunction are 
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downstream results of the disbalance. This is referred to as the amyloid hypothesis (Selkoe 
& Hardy, 2016). In some patients, a mutation in APP results in a higher production of 
amyloid-β, such as the KM670/671NL mutation found in two Swedish families. Mutations 
in the presenilin1 (PS1) and presenilin2 (PS2) genes, which encode APP cleaving proteins, 
can also increase amyloid-β production. This increase indeed leads to an unfavorable 
balance between the production and clearance of amyloid-β, with extensive amyloid-β 
accumulation and early cognitive decline as a result. However, in the vast majority of 
the patients, there is no increase in amyloid-β production. However, impaired amyloid-β 
clearance has been reported in these patients (Mawuenyega et al., 2010). This indicates 
that impaired amyloid-β clearance may be an important factor in AD and CAA. There 
are several pathways through which amyloid-β is cleared. First is local degradation by 
catalytic enzymes in the extracellular space (Leissring et al., 2003; Miners et al., 2006). 
Amyloid-β is also taken up and degraded by phagocytic cells (Koenigsknecht-Talboo & 
Landreth, 2005). Lastly, amyloid-β is removed with the help of the vasculature, either by 
direct transportation over the BBB (Bell et al., 2007), or by perivascular drainage (Aldea 
et al., 2019; Iliff et al., 2012). The E693Q Dutch mutation in the APP gene, leading to a 
charge change on the 22nd amino acid in the amyloid-β species, makes the amyloid-β 
more aggregation prone, more toxic to VSMCs and less efficiently cleared over the BBB. 
This is likely related to the early phenotype of D-CAA patients (Greenberg et al., 2020).
MOUSE MODELS 
Mouse models are useful models for mechanistic studies into disease and for testing safety 
and efficacy of novel treatments. When compared to other models for studying human 
disease, such as cell cultures or other animal models like the fruit fly, zebrafish, or rhesus 
macaque, the mouse is relatively similar to the human in terms of anatomy, physiology 
and genetics, while at the same time, the mouse has a short life span and requires little 
housing space. Furthermore, the availability of inbred strains allows for easy control of 
the genetic background. Lastly, the advanced genetic modification tools available for mice 
allow for the introduction of human disease-associated genes into the mouse genome 
(Gurumurthy & Kent Lloyd, 2019). 
Towards creating a mouse model of AD and/or CAA, human variants of amongst others 
the APP and PS1 genes have been introduced into the mouse genome with different 
familial mutations that have been linked to early-onset AD or CAA. Mostly, these genes 
are inserted with a neuron-specific promotor, to restrict expression to neurons. Many 
different types of AD/CAA-like mouse models have been created, by using different 
combinations of transgenes, familial mutations and promotors. In fact, over a hundred 
different types of models already exist, that all recapitulate one or several aspects of AD 
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1and/or CAA (Joanna L. Jankowsky & Zheng, 2017). It is important to keep in mind that no 
single mouse model reflects all the aspects of human AD or CAA. On the other hand, the 
models can be used to study different aspects of AD or CAA in an isolated fashion. Thus, 
if the research question is matched with the proper model, a mouse model can be very 
instrumental. For example, using mouse models, it has been shown that CAA can arise 
when only neurons produce amyloid-β (Calhoun et al., 1999), which was instrumental 
to arrive at the conclusion that vascular amyloid-β has a neuronal origin, not systemic. 
Another example is how mouse models were important for our understanding of the 
complicated relationship between the amyloid-β-40 to 42 ratio, different APOE isoforms 
and amyloid-β accumulation (Fryer et al., 2005; Holtzman et al., 2000). 
Given that mouse models do not fully mimic AD or CAA, use of the term “model of AD” 
or “model of CAA” will be avoided in this thesis, as it can be misleading. Rather, they 
will be referred to as models of amyloidosis, as that is the aspect which the models 
mimic. Specifically, a model will be used with two genes - APP with the Swedish mutation 
(KM670/671NL), and PS1 with the ΔE9 mutation – co-inserted under a neuron-specific 
promotor into the mouse genome (J L Jankowsky et al., 2001). This model is referred to as 
the APPSwe/PS1ΔE9 (or just APP/PS1), and develops both parenchymal and leptomeningeal 
deposits of amyloid-β starting at the age of 6 months. At the age of 12 months, they 
have developed severe plaque pathology, and moderate leptomeningeal amyloid-β 
accumulation (Garcia-Alloza et al., 2006). The capillaries and arterioles are spared in this 
model. This model is one of the most widely used models in AD research. In the research 
described in this thesis, we will also use a different mouse model that contains an APP 
insertion only, also under a neuron-specific promotor. However, the APP insert contains 
three mutations: the Swedish (KM670/671NL), the Dutch (E693Q) and the Iowa (D694N) 
mutation (Davis et al., 2004). The model is referred to as the transgenic Swedish Dutch 
Iowa (Tg-SwDI) model. It develops microvascular amyloid-β accumulation and diffuse 
parenchymal plaques starting at the age of 6 months. By 12 months old, the model has 
developed severe microvascular amyloidosis throughout the brain, and extensive diffuse 
plaque pathology in the cortex only. Of note, another model exists which only contains 
the APP Dutch mutation (Herzig et al., 2004). However, given its very late phenotype – it 
develops leptomeningeal and arteriolar CAA starting at 22-24 months of age, which is 
also approximately the life expectancy of a mouse – this model is considered unpractical.
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TECHNIQUES FOR IN VIVO ASSESSMENT OF CEREBRAL 
HEMODYNAMICS
A wide variety of imaging techniques is available to measure cerebral hemodynamics, 
including autoradiography, X-ray computed tomography (CT), single-photon emission 
computed tomography (SPECT), positron emission tomography (PET), magnetic resonance 
imaging (MRI) and several optical and ultrasound-based techniques. These techniques vary 
widely in terms of invasiveness, the volume of tissue that can be imaged, the possibility 
for absolute quantification of hemodynamic parameters and the spatial and temporal 
resolution. Therefore, it depends on the research question what the preferred imaging 
modality is.
Autoradiography is one of the oldest techniques to measure tissue perfusion. It relies 
on intravenous (i.v.) injection of an inert, radioactive tracer into the blood stream, after 
which the animal model is euthanized and the brain tissue is isolated. The accumulation 
of the tracer within a slice of tissue, which is considered to be proportional to perfusion, 
is subsequently detected using a photographic film. With autoradiography, absolute 
perfusion values can be obtained by comparing the tissue signal to a radioactive blood scale 
(Reivich et al., 1969; Schweitzer et al., 1987). It is therefore considered the gold standard 
perfusion technique in animals. However, the high invasiveness makes it applicable only 
for terminal experiments and it cannot be used in humans. SPECT and PET are relatively 
closely related to autoradiography, because they also rely on i.v. injection of radioactive 
tracers into the blood stream. In contrast, the radiation is now detected in an intact 
body with detectors placed around the subject. As such, SPECT and PET can also be 
used in humans. The downside is, however, that detecting the tracer this way degrades 
the spatial resolution. While with autoradiography, SPECT and PET, the radiation comes 
from internal tracers, with CT, radio waves are introduced from outside. After passing 
through the body, the X-rays are detected. Different tissue X-ray absorption rates create 
contrast between tissue types, with the highest contrast between soft and hard tissue. 
For hemodynamic measurements, inhaled xenon or injected iodinated contrast agents 
are used to enhance the absorption rates of highly perfused tissue. In general, with 
SPECT, PET and CT, the continued circulation of the contrast agents prevents to repeatedly 
estimate perfusion values within a single imaging session. This makes it impossible to use 
them for measuring hemodynamic responses to vascular challenges. Furthermore, the 
different types of radiation associated these imaging techniques always pose a small risk 
of mutagenesis, thus the amount of imaging sessions that can be done is very limited 
(Wintermark et al., 2005). 
Hemodynamic measurements by means of MRI can be performed either with or without 
contrast agents. In general, MRI relies on the detection of the magnetization of protons, 
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1also referred to as hydrogen atoms or spins, whereas differences in the magnetic properties 
of protons and their environment provides the contrast in MR images. MR contrast agents, 
which are usually gadolinium-based molecules, change the magnetic properties of protons 
that are in their direct vicinity. As such, when these agents are injected into the blood 
stream, they change the MR signal from the blood as well as from perfused tissue. With 
fast MRI read-out sequences, perfusion can be estimated in absolute numbers, although 
quantification is still considered to be error-prone (Paldino & Barboriak, 2009; Wintermark 
et al., 2005). Like with SPECT, PET and CT, MR contrast agents continue to circulate after 
injection, preventing to repeatedly estimate perfusion values within a single imaging 
session. Traditionally, the gadolinium-based contrast agents are considered safe, and thus 
repeated imaging sessions seemed to be less of an issue. But recent evidence questions 
this assumption, as potentially toxic gadolinium deposition has been detected in the brain 
tissue of patients that have had repeated MRIs with contrast (Guo et al., 2018). Therefore, 
also with MRI with contrast agents, the amount of imaging sessions should be limited.
Hemodynamics can also be assessed with MRI without the use of contrast agents. The 
two main types of non-invasive MRI for measuring cerebral hemodynamics are arterial 
spin labeling (ASL)-MRI and BOLD-fMRI, while new methods like VASO are still being 
introduced. With ASL-MRI, the magnetization of protons in the vessels upstream of the 
brain tissue is inverted with RF pulses. Thereby, the arterial blood becomes an endogenous 
tracer. During the so-called post-label delay (PLD), the labeled blood protons travel into 
the brain tissue, where they exchange with protons in brain tissue. An image is acquired 
both when inflowing protons are inverted, as well as during a control condition in which 
arterial blood spins are not inverted. Subtraction of these two images results in cancellation 
of the static tissue signal, and thus only perfusion signal remains. The resulting image is 
called a perfusion-weighted image (Alsop et al., 2015). This principle is further illustrated 
in figure 3. Using Buxton’s kinetic perfusion model (Buxton et al., 1998), the ASL signal can 
be converted into absolute CBF values. As opposed to the previously discussed tracers, 
the endogenous tracer created with ASL decays in a matter of seconds. This is both an 
advantage and a disadvantage. At first, this decay allows for repeated CBF measurement 
during one imaging session. As such, perfusion responses to vascular challenges can 
be measured. However, the short decay-time of the label also gives ASL an inherent 
SNR and measurement problem. If the PLD is too long, the signal has decayed before 
it is measured; if the PLD is too short, the tracer has not yet arrived in the brain tissue. 
Usually, there is a small window of opportunity to measure the perfusion signal, and in 
that case, there is no problem. However, in patients with a delayed blood flow velocity, 
the signal may already have decayed before its arrival in the brain tissue. Advanced 
ASL sequences have been developed to allow for estimation of the arterial transit time 
(ATT). Such sequences can help to detect whether the used PLD is long enough, and can 
be a measure of vascular pathology by themselves (Alsop et al., 2015). However, such 
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sequences are not yet available on pre-clinical MRI scanners. Such an MRI sequence will 
therefore be developed in this thesis. 
BOLD-fMRI, like ASL-MRI, provides the possibility to perform repeated hemodynamic 
measurements within one imaging session. However, as the BOLD signal is dependent 
on a mixture of several parameters, i.e. blood oxygenation, CBF and CBV, the parameters 
cannot be determined absolutely. The BOLD signal thus always has to be normalized to 
a baseline condition (Logothetis & Pfeuffer, 2004).
The imaging techniques discussed for hemodynamic measurements so far all generally 
have an excellent tissue penetration depth (decimeters), but a relatively limited spatial 
resolution (millimeters). Completely different in this regard are optical imaging techniques, 
which generally have high spatial resolutions and low penetration depths (both in the 
micrometer range). The variety of optical imaging techniques that exists is endless, but 
most of them are not suited for in vivo hemodynamic measurements, because of their 
limited penetration depth. However, a specific type of optical imaging termed multi-
photon microscopy (MPM) makes use of far-red or infrared wavelengths, which is one of 
the reasons why MPM has a slightly higher tissue penetration depth (up to a millimeter). 
As such, MPM allows for imaging of single vessels at the capillary level in vivo (Bacskai 
et al., 2004). However, MPM is still limited for use in animal models only, as the 1 mm 
penetration depth requires removal of overlying skin and skull. The limited penetration 
is even an issue when imaging isolated brains post-mortem. Therefore, there has been a 
recent increase in interest in tissue clearing techniques for post-mortem imaging. With 
tissue clearing, fats and water are removed from tissue, and replaced with a medium 
that has the same refractive index as the remaining proteins and nucleotides, thereby 
making the tissue transparent. Transparency of the tissue vastly increases the penetration 
depth of the light. Thereby, the full mouse brain can be imaged at microscopic resolution 
(Richardson & Lichtman, 2015). The usefulness of tissue clearing for determining cerebral 

















Figure 3: Principle of Arterial Spin Labeling (ASL) MRI. During the label condition (upper row), the spins 
in the vessels upstream of the brain tissue are firstly inverted with RF pulses. Thereafter, during 
the so-called post-label delay (PLD), the labeled blood spins travel into the brain tissue, where 
they exchange with spins in the brain tissue. Subsequently, an image is acquired. The control 
condition (middle row) follows the same sequence of events, however, the spins are not inverted 
in this case. When the labeled image and control image are subtracted, the static tissue signal is 
cancelled out, and thus only perfusion signal remains. The resulting image is called a perfusion-
weighted image.
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Another optical technique that allows for hemodynamic measurements is Laser Doppler 
Flowmetry (LDF). LDF also makes use of far-red wavelengths, but there is no imaging 
involved. Instead, the beam of light that is reflected by the tissue is spectrally analyzed. 
Flowing red blood cells cause a change in wavelength of the incoming light. The wavelength 
change of the reflected light is proportional to the quantity and speed of the red blood 
cells. This is used to calculate CBF. LDF allows for CBF measurements at very high temporal 
resolution, but it will only provide relative CBF values instead of absolute quantification 
(Rajan et al., 2009).
SCOPE OF THIS THESIS
Here, the goal is to study the effect of amyloid-β accumulation on hemodynamics in the 
brain. Given the advantageous profile of ASL-MRI – its complete non-invasive nature 
allowing repeated measurements at a reasonable temporal resolution, the full brain 
imaging capacities, and its ability to quantify CBF absolutely– this will be the main 
workhorse for estimating cerebrovascular function in this thesis. However, occasionally, 
the ASL-MRI measurements will be supplemented with optical imaging techniques. At 
first, in chapter 2, the development of a novel pre-clinical ASL sequence to measure ATT 
will be described. Thereafter, in chapter 3, the effect of anesthesia on the hemodynamic 
parameters measured with ASL will be evaluated. These optimization steps will set the 
stage for the hemodynamic parameter estimation as described in both a more parenchymal 
model of amyloidosis in chapter 4, as well as a more vascular amyloidosis model in chapter 
5. Lastly, the results will be discussed in chapter 6.
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ABSTRACT
Cerebral Blood Flow (CBF) is a potential biomarker for neurological disease. However, 
the Arterial Transit Time (ATT) of the labeled blood is known to potentially affect CBF 
quantification. Furthermore, ATT could be an interesting biomarker in itself, as it may 
reflect underlying macro- and microvascular pathologies. Currently, no optimized MRI 
sequence exists to measure ATT in mice. Recently, time-encoded labeling schemes have 
been implemented in rats and men, enabling ATT mapping with higher SNR and shorter 
scan time than multi-delay ASL. In this study, we show that time-encoded pseudo-
Continuous Arterial Spin Labeling (te-pCASL) also enables transit-time measurements 
in mice. As an optimal design that takes the fast blood flow in mice into account, time 
encoding with 11 sub-boli of 50 ms is proposed to accurately probe the inflow of labeled 
blood. For perfusion imaging, a separate, traditional pCASL scan was employed. From 
the six studied brain regions, the hippocampus showed the shortest ATT (169 ± 11 ms) 
and the auditory/visual cortex the longest (284 ± 16 ms). Furthermore, ATT was found 
to be preserved in old wild type mice. In a mouse with an induced carotid artery 
occlusion, prolongation of ATT was shown. In conclusion, this study shows the successful 
implementation of te-pCASL in mice, making it possible for the first time to measure 
ATT in mice in a time-efficient manner. 
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INTRODUCTION 
Currently, there is a lack of functional disease biomarkers for the diagnosis of neurovascular 
dysfunction in patients and animal models. This hampers the prediction of clinical events 
such as a vessel rupture or cognitive impairment. Cerebral Blood Flow (CBF) as measured by 
Arterial Spin Labeling (ASL) MRI has shown the potential to develop into such a biomarker.1–3 
However, CBF quantification is influenced by the arterial transit time (ATT), the time it 
takes for the blood to travel from the labeling slice to the brain slice of interest. Taking 
the ATT into account therefore reduces potential bias when comparing CBF between 
groups.4 Furthermore, ATT is interesting in itself, as it may reflect underlying pathologies 
such as increased vessel tortuosity or occlusion.5 No optimized MRI sequence exists at 
the moment to measure ATT in mice. 
ATT maps can be obtained using multi-delay ASL.6 However, these scans are time 
consuming, as each acquisition provides information at a single post-label delay (PLD) 
only. Recently, time-encoded labeling schemes have been implemented in rats and men, 
enabling ATT mapping with higher signal-to-noise ratio (SNR) and lower scan time.7–10 The 
basis of this technique is the sub-division of the labeling period into “blocks” or “sub-boli” 
and the alternation between labeling and control states during the label period in each 
acquisition. The order of the label and control blocks differs over different acquisitions 
and is altogether played out as a Hadamard matrix (figure 1). Decoding of the Hadamard 
matrix enables to calculate perfusion images from the individual blocks of the Hadamard 
matrix. Thereby, time-encoded ASL provides the possibility to monitor the evolution of 
the signal over the separate PLDs from which the ATT can be estimated as well as the 
shape of the label inflow curve. Each individual perfusion image from a sub-bolus provides 
similar information and SNR as a traditional ASL scan with the same labeling duration, 
total scan time, TR, and PLD. Since time-encoded ASL allows the measurement of multiple 
ASL images within the same scan time without SNR penalty, it provides a more effective 
manner to obtain similar information as in a multi-PLD ASL scan. 
In this study, we show that ATT estimation by time-encoded ASL is also feasible in mice. 
Furthermore, we demonstrate that the sequence is sensitive to mechanically induced ATT 
changes and that wild type mice have preserved CBF and ATT up to 25 months of age. 
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Figure 1: (a) Time-encoded pseudo-continuous arterial spin labeling (te-pCASL) and (b) standard 
pCASL labeling schemes. Label (resp. control) sub-boli are represented in red (resp. blue), 
and the imaging readout in green. The duration of every sub-bolus for te-pCASL was 50 ms 
and a final PLD of 30 ms was added between the end of the last sub-bolus and the EPI-
acquisition. The labeling duration for standard pCASL was 3 s followed by a 300 ms PLD.
EXPERIMENTAL
Animals 
All experiments were approved by the local ethics committee and were performed in full 
compliance with the guidelines of the European community (EUVD 86/609/ EEC) for the 
care and use of the laboratory animals. Experiments were performed under DEC permit 
12065 of the Leiden University Medical Center. 
Two groups of wild type (WT) mice were studied: one group of young mice (n = 8; 50 %  
female; mean ± SD age of 5.8 ± 0.40 months) and one group of old mice (n = 8; 50 %  
female; mean age of 25.5 ± 1.2 months). From the group of old mice, two mice (both 
male) needed to be excluded due to insufficient data quality due to severe movements 
during the scan. All mice were on a mixed C57BL/6J and C3H/HeJ background, further 
referred to as B6 C3 mice. Founder mice were ordered from the Jackson Laboratory and 
the breeding was maintained in-house. Animals were housed together in an ML-2 facility 
with a 12 h light/dark cycle and had unlimited access to chow food and water.
All procedures were performed under isoflurane (3.5 %  for induction, 1.5-2 %  for 
maintenance in air:O2 1:1). During scans, respiration rate and rectal temperature were 
monitored and maintained at around 100 bpm and 37°C, respectively. 
One additional B6 C3 young mouse (6.0 months old; male) was used for a carotid 
occlusion experiment to evaluate the sensitivity of the implemented method to 
measure ATT 
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variations. After anesthesia induction with isoflurane, a medial cut was made along the 
chest and the left carotid was disjointed from the surrounding mesenchyme. Subsequently, 
a stitch was used to fully occlude the artery. Then the wound was closed and the animal was 
scanned immediately; the time from wound closure to the first ASL scan was approximately 
30 minutes. The animals were not allowed to recover after the experiments and the brains 
were collected for future experiments. 
MR sequences and experiments
Experiments were performed on a horizontal 7-T preclinical MRI scanner (PharmaScan, 
Bruker, Ettlingen, Germany) with a mouse transmit-receive 23-mm volume coil. 
Anatomical T2-weighted (T2w) images were obtained through a spin-echo sequence (TR/
TE = 2500/35 ms, in-plane resolution 84×84 µm², 0.7-mm slice thickness, RARE-factor = 8, 
acquisition time Tacq = 80 s). Two ASL labeling schemes were implemented: a standard 
pseudo-continuous ASL (pCASL) labeling scheme11 to measure CBF and a time-encoded 
pCASL (te-pCASL) labeling scheme optimized for ATT measurements (figure 1). Both were 
followed by identical axial single-shot spin-echo EPI acquisitions of the brain (TE = 17 ms, 
in-plane resolution = 224 × 224 µm², slice thickness = 1.5 mm, slice gap = 1 mm, three slices 
with the center of the most posterior slice at approximately -3 mm from the bregma and 
the middle slice located at the isocenter of the bore). Since pCASL is known to be sensitive 
to off-resonance effects,12,13 the entire study was performed with a global first order shim 
and the pCASL interpulse phase-increase was optimized during a pre-scan as described 
before.14 Labeling pulses were applied in the neck, at 10 mm from the isocenter with the 
following sequence-specific parameters: 
• For pCASL, a label duration of 3 seconds was followed by 300 ms PLD (figure 1b).
60 pairs of label/control images were acquired within 7 minutes (TR = 3498 ms).
• For te-pCASL, a Hadamard-12 matrix was used as labeling scheme (figure 1a).
The duration of every sub-bolus was 50 ms and a final PLD of 30 ms was added
at the end of the scheme. This resulted in 11 effective PLDs (30, 80, 130 …
530 ms). The scheme was repeated 45 times (TR = 778 ms, Tacq = 7 minutes).
For CBF quantification, maps of the tissue T1 (T1t) were acquired with an non-selective 
inversion recovery (IR) spin-echo EPI sequence (TR/TE = 10000/19 ms, 18 inversion times 
(TI) between 30 ms and 10000 ms, Tacq = 4 min) and labeling efficiency was measured 
3 mm downstream of the labeling plane with a flow-compensated, pCASL-encoded FLASH 
sequence (TR/TE = 225/5.6 ms, 84 µm isotropic in-plane resolution, 1-mm slice thickness, 
NA = 2, Tacq = 3 min 30 s) for each animal. 
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Post-processing 
Inversion efficiency  
The inversion efficiency (α) was derived from a complex reconstruction of the pCASL-





where MC and ML are respectively the complex signals from the control and the label
experiments. A region of interest (ROI) was manually drawn on each common carotid. The
inversion efficiency α was obtained as the mean of the inversion efficiencies measured
independently in each of the two carotids.
Scan registration and brain region delineation
To compensate for possible motion during standard pCASL and te-pCASL acquisitions, all
repetitions were registered to the first EPI acquisition. ROIs for the auditory/visual cortex,
hippocampus, motor cortex, sensory cortex, striatum and thalamus were delineated manually on
an anatomical T2w image of a randomly selected animal (reference T2w image) based on the
Franklin & Paxinos mouse brain atlas15 (figure 7a). The T2w images of the remaining animals were
registered to the above-mentioned reference T2w image and all ROIs were propagated to each
animal’s correspondent T2w image. For each animal, all sequences (te-pCASL, T1t map, T2w image)
were registered to the standard pCASL space. The registration of the T2w images to the standard
pCASL space allowed propagating the anatomical ROIs to all the remaining MRI sequences. Two
independent observers verified the quality of the registration by visual inspection. The
registration was performed using the open source image registration toolbox Elastix16 and was
performed in a coarse-to-fine manner.
T1t map
The T1t map was obtained by fitting the following equation to the signal from each pixel using a
Levenberg-Marquardt algorithm:
𝑀𝑀𝑀𝑀𝑧𝑧𝑧𝑧(𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇) = 𝑀𝑀𝑀𝑀0 ∙ �1 − 2к 𝑒𝑒𝑒𝑒−𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑇𝑇𝑇𝑇1𝑡𝑡𝑡𝑡⁄ �, (2)
where 𝑀𝑀𝑀𝑀𝑧𝑧𝑧𝑧 is the MR signal collected at each TI, 𝑀𝑀𝑀𝑀0 is the magnetization at thermal equilibrium,
T1t is the longitudinal relaxation time constant of tissue and κ is the inversion efficiency. 𝑀𝑀𝑀𝑀0, T1t
and κ are the fitted parameters.
ASL maps - te-pCASL post-processing 
The 45 repetitions of the Hadamard12 matrix were first averaged, after which the matrix was
decoded. The same matrix was employed to determine whether a raw image was added or
subtracted. A more elaborate description of the decoding can be found in Teeuwisse et al.,
201410. After decoding, eleven perfusion-weighted images were obtained at eleven different
PLDs. Buxton’s general kinetic perfusion model17 was fitted voxel-by-voxel to ΔM over time in the
perfusion-weighted images using a Levenberg-Marquardt algorithm, where ATT, CBF and T1app
were the estimated parameters:
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ASL maps - te-pCASL post-processing 
 45 repetitions of the Hadam rd12 matrix were first averaged, ft r which the matrix 
was decoded. The same matrix was employed to i  hether a raw image was 
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added or subtracted. A more elaborate description of the decoding can be found in 
Teeuwisse et al., 2014.10 After decoding, eleven perfusion-weighted images were obtained 
at eleven different PLDs. Buxton’s general kinetic perfusion model17 was fitted voxel-by-
voxel to ΔM over time in the perfusion-weighted images using a Levenberg-Marquardt 
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(3) 
𝜏𝜏𝜏𝜏 is the labeling duration of a sub-bolus; T1b is the longitudinal relaxation time of blood (2230 ms 
at 7 T18) and T1app is the apparent longitudinal relaxation time of tissue. t represents the time
from the beginning of labeling and therefore consists of PLD + 𝜏𝜏𝜏𝜏. This perfusion model consists of
three parts (Figures 3 and 4): in the first part, the labeled blood has not arrived yet, therefore the
ASL signal intensity is zero. The second part is the rising part of the curve, which represents the
inflow of label, while accounting of longitudinal relaxation of the label. During the third and last
part, the signal declines, reflecting only relaxation of the label (outflow is neglected in this
model). To quantify CBF from te-pCASL, the fit’s peak height was retrieved and the CBF was
calculated as described below. Voxels that showed very low transit times (< 30 ms) and/or very
low longitudinal relaxation times (T1app < 100 ms), which are expected to mainly reflect voxels
largely composed of arterial blood, were excluded when calculating the average values over the
ROIs.
ASL maps - CBF quantification
Assuming that 𝑀𝑀𝑀𝑀0𝑏𝑏𝑏𝑏, the magnetization of arterial blood at thermal equilibrium, may be
approximated by 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡/𝜆𝜆𝜆𝜆, where 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡 is the magnetization of tissue at thermal equilibrium and λ
is the blood-brain partition coefficient of water (0.9 mL/g19), the following equation was used to
quantify CBF (mL/100 g/min)17,20: 
CBF = λ∙ΔM∙exp(ATT T1b⁄ )
2∙α T1t∙M0t∙exp(−(PLD−ATT) T1t⁄ )∙�1−exp(−τ T1t⁄ )�
(4)
where ΔM is either the peak-height for te-pCASL or the averaged signal difference between
control and label acquisitions for standard pCASL; T1t is the tissue T1 taken from the T1t map; M0t
is the magnetization of tissue obtained from the IR experiment. For standard pCASL, we assumed
that the ATT was shorter than the PLD. 
Statistical analysis
To validate normality of the data, Kolmogorov-Smirnov tests were performed. Distributions from
all parameters (ATT, CBF measured with te-pCASL and CBF measured with standard pCASL), all
brain regions and both young and old mice were tested separately and did not significantly
deviate from normality. Therefore, a mixed ANOVA was performed to analyze the effect of age,
brain region and the interaction of age and brain region on the measured parameters ATT, CBF
measured with te-pCASL and CBF measured with standard pCASL. Since Mauchly’s test of
sphericity was significant for all of the three parameters, the degrees of freedom for the F-
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(3)
𝜏𝜏𝜏𝜏 is the labeling duration of a sub-bolus; T1b is the longitudinal relaxation time of blood (2230 ms 
at 7 T18) and T1app is the apparent longitudinal relaxation time of tissue. t represents the time
from the beginning of labeling and therefore consists of PLD + 𝜏𝜏𝜏𝜏. This perfusion model consists of
three parts (Figur s 3 and 4): in the f rst p rt, the labeled blood has not arrived yet, therefore the
ASL signal i tensity is zero. The second part is the rising part of the curve, which represents the
inflow of label, while accounting of longitudinal relaxation of the label. During the third and last
part, the signal declines, reflecting only relaxation of the label (outflow is neglected in this
model). To quantify CBF from te-pCASL, the fit’s peak height was retrieved and the CBF was
calculated as described below. Voxels that showed very low transit times (< 30 ms) and/or very
low longitudinal relaxation times (T1app < 100 ms), which are expected to mainly reflect voxels
largely composed of arterial blood, were excluded when calculating the average values over the
ROIs.
ASL maps - CBF quantification
Assuming that 𝑀𝑀𝑀𝑀0𝑏𝑏𝑏𝑏, the magnetization of arterial blood at thermal equilibrium, may be
approximated by 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡/𝜆𝜆𝜆𝜆, where 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡 is the magnetization of tissue at thermal equilibrium and λ
is the blood-brain partition coefficient of water (0.9 mL/g19), the following equation was used to
quantify CBF (mL/100 g/min)17,20:
CBF = λ∙ΔM∙exp(ATT T1b⁄ )
2∙α T1t∙M0t∙exp(−(PLD−ATT) T1t⁄ )∙�1−exp(−τ T1t⁄ )�
(4)
where ΔM is either the peak-height for te-pCASL or the averaged signal difference between
control and label acquisitions for standard pCASL; T1t is the tissue T1 taken from the T1t map; M0t
is the magnetization of tissue obtained from the IR experiment. For standard pCASL, we assumed
that the ATT was shorter than the PLD. 
Statistical analysis
To validate normality of the data, Kolmogorov-Smirnov tests were performed. Distributions from
all parameters (ATT, CBF measured with te-pCASL and CBF measured with standard pCASL), all
brain regions and both young and old mice were tested separately and did not significantly
deviate from normality. Therefore, a mixed ANOVA was performed to analyze the effect of age,
brain region and the interaction of age and brain region on the measured parameters ATT, CBF
measured with te-pCASL and CBF measured with standard pCASL. Since Mauchly’s test of
sphericity was significant for all of the three parameters, the degrees of freedom for the F-
distribution were corrected. The Greenhouse-Geisser-estimate of ε was 0.478 for ATT 
  l ling duration of a sub-bolus; T1b is the longitudinal relax tion time of blood 
(2230 ms at 7 T18) and T1app is the pparent longitudinal relaxation ti  of tissue. t represents 








0 0 < 𝑡𝑡𝑡𝑡 < 𝐴𝐴𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇
2 𝑀𝑀𝑀𝑀0 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑇𝑇𝑇𝑇1𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝛼𝛼𝛼𝛼 𝑒𝑒𝑒𝑒−𝐴𝐴𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇/𝑇𝑇𝑇𝑇1𝑏𝑏𝑏𝑏 �1 − 𝑒𝑒𝑒𝑒
− (𝑡𝑡𝑡𝑡− 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴)𝐴𝐴𝐴𝐴1𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 � ∆𝑡𝑡𝑡𝑡 < 𝑡𝑡𝑡𝑡 < 𝜏𝜏𝜏𝜏 + 𝐴𝐴𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇
2 𝑀𝑀𝑀𝑀0 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑇𝑇𝑇𝑇1𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝛼𝛼𝛼𝛼 𝑒𝑒𝑒𝑒−𝐴𝐴𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇/𝑇𝑇𝑇𝑇1𝑏𝑏𝑏𝑏 𝑒𝑒𝑒𝑒
− (𝑡𝑡𝑡𝑡− 𝜏𝜏𝜏𝜏− 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴)𝐴𝐴𝐴𝐴1𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 �1 − 𝑒𝑒𝑒𝑒
− 𝜏𝜏𝜏𝜏𝐴𝐴𝐴𝐴1𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎� 𝜏𝜏𝜏𝜏 + 𝐴𝐴𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 < 𝑡𝑡𝑡𝑡.
(3)
𝜏𝜏𝜏𝜏 is t e labeli g duration of a sub-bolus; T1b is the longitudinal relaxation time of blood (2230 ms 
at 7 T18) and T1app is the apparent longitudinal relaxation time of tissue. t represents the time
from th b ginning of labeling and therefore consists of PLD + 𝜏𝜏𝜏𝜏. This perfusion model consists of
three parts (Figures 3 and 4): in the first part, the labeled blood has not arrived yet, therefore the
ASL signal int nsity is zero. The second part is the rising part of the curve, which represents the
inflow of label, w ile accounting of longitudinal relaxation of the label. During the third and last
part, the signal declines, reflecting only relaxation of the label (outflow is neglected in this
mo el). To quantify CBF from te-pCASL, the fit’s peak height was retrieved and the CBF was
calculat d as described below. Voxels that showed very low transit times (< 30 ms) and/or very
low longitudinal relaxation times (T1app < 100 ms), which are expected to mainly reflect voxels
larg ly compose  of arterial blood, were excluded when calculating the average values over the
ROIs.
ASL maps - CBF quantification
Assuming that 𝑀𝑀𝑀𝑀0𝑏𝑏𝑏𝑏, the magnetization of arterial blood at thermal equilibrium, may be
approximated by 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡/𝜆𝜆𝜆𝜆, where 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡 is the magnetization of tissue at thermal equilibrium and λ
is the blood-brain partition coefficient of water (0.9 mL/g19), the following equation was used to
quantify CBF (mL/100 g/min)17,20: 
CBF = λ∙ΔM∙exp(ATT T1b⁄ )
2∙α T1t∙M0t∙exp(−(PLD−ATT) T1t⁄ )∙�1−exp(−τ T1t⁄ )�
(4)
where ΔM is either the p ak-height for te-pCASL or the averaged signal difference between
control and label acquisitions for standard pCASL; T1t is the tissue T1 taken from the T1t map; M0t
is the magnetization of tissue obtained from the IR experiment. For standard pCASL, we assumed
that the ATT was shorter than the PLD. 
Statistical analysis
To v li ate normality of the data, Kolmogorov-Smirnov tests were performed. Distributions from
all par meters (ATT, CBF m asured with te-pCASL and CBF measured with standard pCASL), all
brain regions and both young and old mice were tested separately and did not significantly
deviate from normality. Therefore, a mixed ANOVA was performed to analyze the effect of age,
b ain region and the in eraction of age and brain region on the measured parameters ATT, CBF
measured with te-pCASL and CBF measured with standard pCASL. Since Mauchly’s test of
sphericity was significant for all of the three parameters, the degrees of freedom for the F-
distribution were corrected. The Greenhouse-Geisser-estimate of ε was 0.478 for ATT 
. This pe fusi n 
mo,del consists of three parts (Figures 3 a d 4): in he first part, t e labeled bloo  has 
not arrived yet, therefor  the ASL signal intensity is zero. The second part is the risi g 
part of the curve, which represents the inflow of label, while accounting of longitudinal 
relaxation of the label. During the third a d last part, the signal declines, reflecting only 
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the fit’s peak height was retrieved and the CBF was calculated as described below. Voxels 
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(T1app < 100 ms), which are expected to mainly reflect voxels largely composed of arterial 
blood, were excluded when calculating the average values over the ROIs.
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(3)
𝜏𝜏𝜏𝜏 is the labeling duration of a sub-bolus; T1b is the l ngitudinal relaxation time of blood (2230 ms 
at 7 T18) nd T1app is the apparent longitudinal r axation time of tissue. t repr sents the time
from the beginning of labeling and therefore consists of PLD + 𝜏𝜏𝜏𝜏. This perfusion model consists of
three parts (Figures 3 and 4): in the first part, the labeled blood has not arrived yet, therefore the
ASL signal intensity is zero. The second part is the rising part of the curve, which represents the
inflow of label, while accounting of longitudinal relaxation of the label. During the third and last
part, the signal declines, reflecting only relaxation of the label (outflow is eglected in this
model). To quantify CBF fr m te-pCASL, the fit’s peak height was retrieved and the CBF was
calculated as described below. Voxels t at showed very low tran it times (< 30 ms) and/or very
low longitudinal relaxation imes (T1app < 100 ms), which are expected to mai ly r flect voxels
largely composed of arte ial blood, were excluded when calculating the average values over the
ROIs.
ASL maps - CBF quantification
Assuming that 𝑀𝑀𝑀𝑀0𝑏𝑏𝑏𝑏, the magnetization of arterial blood at thermal equilibrium, may be
approximated by 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡/𝜆𝜆𝜆𝜆, where 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡 is the magnetization of tissue at thermal equilibrium and λ
is the blood-brain partition coefficient of water (0.9 mL/g19), the following equation was used to
quantify CBF (mL/100 g/min)17,20: 
CBF = λ∙ΔM∙exp(ATT T1b⁄ )
2∙α T1t∙M0t∙exp(−(PLD−ATT) T1t⁄ )∙�1−exp(−τ T1t⁄ )�
(4)
where ΔM is either the peak-height for te-pCASL or the averaged signal difference between
control and label acquisitions for standard pCASL; T1t is the tissue T1 taken from the T1t map; M0t
is the magnetization of tissue obtained from the IR experiment. For standard pCASL, we assumed
that the ATT was shorter than the PLD. 
Statistical analysis
To validate normality of the data, Kolmogorov-Smirnov tests were performed. Distributi ns from
all arameters (ATT, CBF measured wit te-pCASL and CBF measured with standard pCASL), all
brain regio s and both young and old mice were tested separately nd did not significantly
deviate from normality. Therefore, a mixed ANOVA was performed to analyze the effect of age,
brain region and the interaction of age and brain region on the measured parameters ATT, CBF
measured with te-pCASL and CBF measured with standard pCASL. Since Mauchly’s test of
sphericity was significant for all of the three parameters, the degrees of freedom for the F-
distribution were corrected. The Greenhouse-Geisser-estimate of ε was 0.478 for ATT 
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(3)
𝜏𝜏𝜏𝜏 is the lab ling duration of a sub-bolus; T is the longitudinal relaxati  ti  of blood (2230 s 
at 7 T18) and T1a p is the apparent longitudinal relaxati n ti e of t ssue.  rep sen s the ti e
fro  the begin ing of labeling and therefore consists of PLD + 𝜏𝜏𝜏𝜏. This perfusion odel consists of
three parts (Figures 3 and 4): in the first part, the labeled blood has not a rived yet, therefore the
ASL signal intensity is zero. The second part is the rising part of the curve, which represents the
inflow of label, while accounting of longitudinal relaxation of the label. During the third and last
part, the signal declines, reflecting only relaxation of the label (outflow is neglected in this
odel). To quantify CBF fr te-pCASL, the fit’s p ak height was retrieved and the CBF was
calculated as d scribed b low. Voxels that showed very low transit ti es (< 30 s) and/or very
low longitudinal relaxation ti (T1a p < 100 s), which are expected to ainly reflect voxels
largely co po ed of arterial blood, were excluded when calculating the average values over the
ROIs.
ASL aps - CBF quantification
Assu ing 𝑀𝑀𝑀𝑀0𝑏𝑏𝑏𝑏, the agnetizati n of rterial blood at ther al equilibriu , ay be
ap roxi ated 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡/𝜆𝜆𝜆𝜆, where 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡 is the agnetization of tissue at ther al equilibriu  and λ
is the blood-brain partition coe ficient of water (0.9 L/g19), the fo lowing equation was used to
quantify CBF ( L/100 g/ in)17,20: 
CBF λ∙ΔM∙exp(ATT T1b⁄ )
2∙α T1t∙M0t∙exp(−(PLD−ATT) T1t⁄ )∙�1−exp(−τ T1t⁄ )�
(4)
where Δ is either the peak-height for te-pCASL or the averaged signal di ference between
control and label acquisitions for standard pCASL; T1t is the tissue T1 taken fro the T1t ap; 0t
is the agnetization of tissue obtained fro the IR experi ent. For standard pCASL, we assu ed
that the ATT was shorter than the PLD. 
Statistical analysis
To validate nor ality of the ata, Kol ogorov-S irnov tests were perfor ed. Distributions fro
a l para eter (ATT, CBF e sured wi t - CASL and CBF easured with standard pCASL), a l
brain regi s and b th young and old ice w re tested s parately and did n t significantly
deviate fro  nor ality. Therefore, a ixed ANOVA was perfor ed to analyze the e fect of age,
brain region and the interaction of age and brain region on the easured para eters ATT, CBF
easured with te-pCASL and CBF easured with standard pCASL. Since auchly’s test of
sphericity was significant for a l of the three para eters, the degrees of freedo for the F-
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(3)
𝜏𝜏𝜏𝜏 is the labeling duration of a sub-bolus; T1b is the longitudinal relaxation time of blood (2230 ms 
at 7 T18) and T1app is the apparent longitudinal relaxation time of tissue. t represents the time
from the begin ing of labeling and therefore con ists of PLD + 𝜏𝜏𝜏𝜏. This perfusion model onsists of
three parts (Figures 3 nd 4): in the first par , the l beled blo d has n t arrived yet, therefore the
ASL signal inte sity is zero. The second part is th  rising part of the curve, which represents the
inflow of label, while accounting of longitudinal relaxation of the label. Duri g he third last
part, the signal declines, reflecting nly relaxation of the label (outflow is neglected in this
model). To quantify CBF from te-pCASL, the fit’s peak height was retrieved and the CBF was
calculated as described below. Voxels that showed very low transit times (< 30 ms) and/or very
low longitudinal relaxation times (T1app < 100 ms), which are expected to mainly reflect voxels
largely composed of arterial blood, were excluded when calculating the average values over the
ROIs.
ASL maps - CBF quantification
Assuming that 𝑀𝑀𝑀𝑀0𝑏𝑏𝑏𝑏, the magnetization of arterial blood at thermal equilibrium, may e
approximated y 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡/𝜆𝜆𝜆𝜆, where 𝑀𝑀𝑀𝑀0𝑡𝑡𝑡𝑡 s the magne ization of tissue a  thermal equ libri m a d λ
is the blood-brain partition coefficient of water (0.9 mL/g19), the following equation was used to
quantify CBF (mL/100 g/min)17,20: 
CBF = λ∙ΔM∙exp(ATT T1b⁄ )
2∙α 1t∙M0t∙exp(−(PLD−ATT) T1t⁄ )∙�1−exp(−τ T1t⁄ )�
 (4)
where ΔM is either the peak-height for te-pCASL or the averaged signal difference between
control a  l l isitions for standard pCASL; T1t is the issue T1 taken from the T1t map; M0t
is the mag f tis ue obtained from the IR xp rim nt. For standard pCASL, we assum d
that the T  as shorter than the PLD. 
Statistical analysis
To validate normality of the data, Kolmogorov-Smirnov tests were performed. Distributions from
all parameters (ATT, CBF measured with te-pCASL and CBF measured with standard pCASL), all
brain regions and both young and old mice were tested separately and did not significantly
deviate from normality. Therefore, a mixed ANOVA was performed to analyze the effect of age,
brain region and the interaction of age and brain region on the measured parameters ATT, CBF
measured with te-pCASL nd CBF measure with standard pCASL. Since Mauchly’s test of
sphericity as significant for all of the three parameter , the degrees of freedom for t e F-
distribution were corrected. The Greenhouse-Geisser-estimate of ε was 0.478 for ATT 
where ΔM is either the peak-height for te-pCASL or the averaged signal difference between 
c ntrol nd label acquisitions for standard pCASL; T1t is the tissue T1 taken from the T1t 
ma ; M0t is the magnetization of tissue obtained from the IR experimen . For standard 
pCASL, we assumed that the ATT was shorter than the PLD. 
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Statistical analysis
To validate normality of the data, Kolmogorov-Smirnov tests were performed. Distributions 
from all parameters (ATT, CBF measured with te-pCASL and CBF measured with standard 
pCASL), all brain regions and both young and old mice were tested separately and did 
not significantly deviate from normality. Therefore, a mixed ANOVA was performed to 
analyze the effect of age, brain region and the interaction of age and brain region on the 
measured parameters ATT, CBF measured with te-pCASL and CBF measured with standard 
pCASL. Since Mauchly’s test of sphericity was significant for all of the three parameters, 
the degrees of freedom for the F-distribution were corrected. The Greenhouse-Geisser-
estimate of ε was 0.478 for ATT measurements, 0.413 for CBF measurements with te-pCASL, 
and 0.354 for CBF measurements with standard pCASL. A post-hoc Bonferroni-corrected 
pairwise comparison was performed when the ANOVA showed that there was a significant 
difference. All statistical analyses were conducted with the IBM SPSS statistics 23 software.
RESULTS 
te-pCASL signal time-course
By decoding the Hadamard-encoded ASL signal,7,10 individual sub-bolus images were 
obtained from the te-pCASL measurements for each slice (figure 2). At the early time 
points after labeling, single bright voxels can be seen, indicating the arrival of signal in 
the larger arteries. Quickly thereafter, the ASL signal arrives in larger groups of voxels, 
representing the spread of the labeled blood through smaller vessels. Lastly, the signal 
enters the capillaries and exchanges with the tissue magnetization. On top of these tracer 
kinetics, the signal continuously decays due to longitudinal relaxation. 
Figure 2: Example of perfusion-weighted images (arbitrary units, a.u.) obtained after Hadamard-
decoding, and the corresponding anatomical images (T2w). The number below each map 
indicates the effective post-labeling delay (PLD) in milliseconds. Note that the slices were 
acquired in interleaved order (i.e. slice 1 - slice 3 - slice 2).
Fit to the te-pCASL data
Figure 3 shows examples of the Buxton model fitted to the te-pCASL signal time-course from 
two individual voxels. The estimated parameters for the first voxel were: ATT 121 ms, CBF 
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284 mL/100 g/min and T1app 296 ms and visual inspection confirms that the model fits 
the data. For the second voxel, the estimated parameters were ATT 92 ms, CBF 472 
mL/100 g/min and T1app 319 ms, but visual inspection reveals that the model fits the 
data poorly, as the measured ASL signal seems to show a second wave of arrival of 
labeled blood. 
Figure 4 shows the time-courses averaged over all young mice in the auditory/visual 
cortex and in the hippocampus, which represent the ROIs with highest (284 ± 16 ms) 
and lowest ATT (169 ± 11 ms) respectively. A fit of the Buxton model to the experimental 
data, where ATT, CBF and T1app were allowed to be adjusted to fit the data best, is 
displayed in the same figure (full lines). These fits are compared to theoretical Buxton 
curves (dashed lines), derived from the CBF value from standard pCASL, T1t from the 
inversion recovery experiment and the ATT from te-pCASL (from now on referred to as 
theoretical Buxton curves). In the hippocampus, the ΔM values from te-pCASL reach 
markedly higher values than the ΔM from the theoretical Buxton curves. In contrast, in 
the auditory/visual cortex, the ΔM values from both curves reach about the same 
height. In both brain regions, the decay after the peak is faster in the te-pCASL data 
than in the theoretical Buxton curves: mean decay values retrieved from the fit to the 
te-pCASL data are between 300 ms and 500 ms instead of the 1600-1700 ms measured 
with the IR sequence.
ATT and CBF maps 
Figure 5 shows the CBF and ATT maps of a representative mouse. Next to the CBF 
maps determined with te-pCASL (second row), maps acquired with standard pCASL 
are also shown (first row). In both CBF maps, a clear contrast is observed between grey 
and white matter (corpus callosum), with grey matter showing higher values. However, it 
can also be noticed that CBF values are higher in the te-pCASL measurement as 
compared to those measured with standard pCASL.
Effect of left carotid  occlusion 
Both the ATT and the CBF maps measured in the mouse with a left carotid occlusion 
are affected by the occlusion (figure 6). When comparing the ROIs drawn in the 
hemisphere ipsilateral to the occlusion with their respective contralateral ROIs, ATT 
was found to be slightly increased (11 %  on average), whereas CBF was markedly lower 
(47 %  for standard pCASL CBF and 33 %  for te-pCASL CBF on average). 
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Figure 3: Two examples of the signal intensity (i.e. decoded Hadamard-encoded ASL-signal) 
time courses (crosses) with their corresponding model fits (full lines). The two voxels are 
taken from the same mouse and the same brain region (hippocampus). The estimated 
parameters for the first voxel are (a) arterial transit time (ATT) 121 ms, cerebral blood flow 
(CBF) 284  mL/100  g/min and T1app  296 ms and the model seems to fit the data. For the 
second voxel (b), the estimated parameters are ATT 92 ms, CBF 472 mL/100 g/min and T1app 
319 ms, but the model does not fit the data well.
Figure 4: Signal time-courses of the time-encoded pseudo-continuous arterial spin labeling (te-pCASL) 
signal (mean ± standard deviation, SD). te-pCASL ΔM values in the sub-boli are averaged over 
all young mice for two brain regions (crosses) and displayed together with the fit to the data (full 
lines). Dashed lines represent theoretical Buxton curves with cerebral blood flow (CBF) values 
from standard pCASL, Tissue T1 values from the inversion recovery experiment and arterial 
transit times (ATTs) from te-pCASL. The auditory/visual cortex are depicted in blue and the 
hippocampus in red.
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Figure 5: Cerebral blood flow (CBF) maps obtained in one mouse (3 slices) with a standard pseudo-
continuous arterial spin labeling (pCASL) acquisition (first row) and a voxel-by-voxel fit to 
the time-encoded pCASL data (te-pCASL, second row). The color scales are different in 
order to have a good contrast in both maps. The third row shows the arterial transit time 
(ATT) as obtained from te-pCASL.
Effects of age and brain region on ATT and CBF 
No significant effects of age were observed for the ATT (F [1,12] = 0.056), the CBF 
measured with te-pCASL (F [1,12] = 0.220) nor for the CBF measured with standard 
pCASL (F [1,12] = 0.484) (figure 7).
A significant effect of the brain region on ATT, p<0.001 (F [2.388,28.658] = 92.335) was 
found, with 22 out of the 30 post-hoc brain region comparisons showing statistically 
significant differences.
No additional effects of interaction between age and brain region were observed on the 
ATT (F [2.388,28.658] = 0.264), te-pCASL CBF (F [2.064,24.768] = 0.399) or standard pCASL 
CBF (F [1.770,21.237] = 0.454). 
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Figure 6: Cerebral blood flow (CBF) maps from standard pseudo-continuous arterial spin labeling (pCASL, 
(first row) and from time-encoded pCASL (te-pCASL, second row) and arterial transit time (ATT) 
maps (bottom row) obtained on a mouse with a left carotid occlusion (3 slices). Note that the 
images are represented in radiological convention.
te-pCASL CBF versus standard pCASL CBF 
CBF estimations as measured with the te-pCASL and the standard pCASL sequences in 
all the 14 animals and all the brain regions were compared in a Bland-Altman plot. The 
te-pCASL sequence shows a consistently higher estimated CBF than the standard pCASL 
sequence (figure 8). Furthermore, the difference between the two measurements increases 
with the mean CBF value. 
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Figure 7: (a) Example of anatomical T 2-weighted images with regions of interest: 1- Auditory/visual cortex, 
2- Sensory cortex, 3- Motor cortex, 4- Hippocampus, 5- Striatum, 6- Thalamus. (b) Comparison 
between young (red) and old (blue) mice in different brain regions for arterial transit time (ATT), 
(c) cerebral blood flow (CBF) from standard pseudo-continuous arterial spin labeling (pCASL)
and (d) CBF from time encoded-pCASL (te-pCASL). Bars show mean values ± standard deviation.
Figure 8: Bland-Altman plot comparing cerebral blood flow (CBF) values from time-encoded 
pseudo-continuous arterial spin labeling (te-pCASL) and standard pCASL. All 14 animals 
and all the brain regions are represented. The central line represents the mean of all values 
and the two dashed lines are offset by 2 ± standard deviation from that mean.
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DISCUSSION 
This study demonstrated that the implementation of a time-encoded ASL approach enables 
ATT measurements in mice. Since inflow times in the mouse brain are short and the brain 
regions are small compared to human anatomy, high spatial and temporal resolutions are 
required, which severely limits the perfusion SNR. The above described te-pCASL sequence 
was optimized to keep a balance between spatial resolution, temporal resolution and 
perfusion SNR. The high amount of averaging was a prerequisite for this trade-off (note 
that one Hadamard scheme is already equivalent to six averages of standard multi-PLD 
pCASL performed with a label duration equal to the sub-bolus duration7). This also made 
it preferable to split the perfusion imaging and the ATT measurement into two separate 
sequences. A “Free-lunch-approach” in which ATT-measurement blocks are played out 
during the PLD of a traditional pCASL scan would either lead to too low SNR for the ATT 
measurement to allow accurate ATT measurements or to too long scan times. 
The measured ATT values were different across brain regions. Average ATT values in 
young mice varied from 169 ms (hippocampus) to 284 ms (auditory-visual cortex). To the 
best of our knowledge, only one other study acquired Hadamard-encoded ASL-MRI data 
in animals, which were obtained with CASL in rats.9 In that study, ATT was measured in 
cortical regions of three rats to be between 190 and 310 ms. The values from the time-
encoded sequence and those from the multi-PLD CASL sequence acquired in the same 
animals were well in accordance with each other. In an earlier study, ATT estimates for 
the whole rat brain measured with multi-PLD ASL in a group of 12 rats ranged from 100 
to 500 ms.6 Using a dynamic ASL scheme (DASL), another study reported ATT values in 
rats of around 200 ms.21 Also, a pCASL optimization study in mice, which may not have 
been intended to estimate ATT, does provide a rough estimation of ATT in mice:22 the 
authors optimized a pCASL sequence by varying several parameters settings, including 
the PLD, and analyzed the resulting SNR in the perfusion images. Regarding the PLD, they 
concluded that it ideally should be between 200 and 400 ms, since the perfusion signal 
is highest between these points. Hence, the values found in this study are in agreement 
with previously reported ATT values.
Furthermore, the animal with a unilateral carotid occlusion showed increased ATTs in 
the ipsilateral hemisphere. However, the ATT difference between the ipsilateral and 
contralateral hemispheres was not very large (11%), especially compared to the major 
difference in CBF measured in the same scans. It can thus be questioned whether ATT 
measurements in mice would be suitable to detect milder pathology, such as partial 
occlusion, or increased vessel tortuosity with the setup used in this study. 
In all mice, cortical regions showed longer transit times than subcortical regions. This is 
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consistent with the anatomy of the murine cerebral circulation.23 The major blood supply 
of the murine cerebrum comes from the internal carotid arteries, which end in the circle 
of Willis, located ventrally to the brain. From there, several arteries sprout, which supply 
blood to the different brain regions. Subcortical tissue is supplied with blood through 
arteries such as the posterior cerebral artery (PCA) and the anterior choroidal artery (AchA), 
which directly penetrate the brain tissue from the circle of Willis. The mouse cerebral 
cortex on the other hand, is mostly supplied by the anterior and middle cerebral arteries 
(ACA and MCA respectively), which first curve around the cerebrum before they penetrate 
the brain tissue. In the posterior part of the cerebrum, this cortical-subcortical difference 
is the most profound. The posterior part of the cortex is fed by the most distal parts of 
the ACA and MCA, which wrap around the frontal and medial cortex. On the other hand, 
the PCA and AchA penetrate directly into the subcortical regions in the posterior part of 
the cerebrum, with a much smaller distance to the internal carotids. This could explain 
the large difference in ATT between the cortical and subcortical regions on the most 
posterior slice in figure 5. Furthermore, it could explain the fact that the hippocampus, 
located posteriorly and subcortically, showed the lowest transit times from the regions 
analyzed in this study (figure 7b). 
In all six brain regions analyzed, the mean ATT was smaller than 300 ms. This indicates that 
the PLD-choice of the standard pCASL, 300 ms, was appropriate to reduce contamination 
of the ASL signal from the major arteries and to limit the sensitivity of pCASL to ATT 
heterogeneity.4 However, on the microscale (arterioles, capillaries, parenchyma and 
venules), it remains elusive in which compartment the label resides at the moment of 
detection, both for the CBF measured with standard pCASL, as well as for CBF measured 
with te-pCASL. At the chosen PLD of 300 ms, smaller vessels may still contain labeled blood 
that ultimately moves on to perfuse tissue in a different voxel. Previously, distinctions 
have been made between vascular and tissue transit time.4,24 The te-pCASL sequence 
used here was optimized to see the inflow-phase of the label, and thus corresponds to 
the aforementioned vascular transit time. Due to the fact that ATT is mainly influenced 
by the macro-vasculature, measurement of the tissue transit time may provide additional 
useful information on the microvascular status. The exact definition of tissue transit time, 
whether it indicates arrival of labeled spins in the extravascular space, in the capillaries or 
in the microvasculature that only feeds tissue located within a distance smaller than the 
size of an imaging voxel, varies among studies. In order to measure transit times to the 
microvasculature, vascular crushers can be used to crush the signal coming from flowing 
spins in the arteries just before the imaging read-out,25 with the strength of the crushers 
determining how far down the vascular tree the ASL signal is suppressed. However, this 
approach further lowers SNR, as part of the perfusion signal is also attenuated due to the 
diffusion-weighting of the crushers. Another method exploits the measurement of the T2 of 
the ASL signal, since the T2 of the label depends on whether it is intra- or extravascular.
26–29 
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This approach has the potential to distinguish between labeled spins in vascular and 
extravascular spaces, but has to deal with the difficulties inherent in separating the 
components in biexponential transverse relaxation signals. In rats, the measured transit 
time of labeled spins to the extravascular space was about 370 ± 40 ms longer than the 
ATT,28 providing a ballpark estimate of what could be expected in mice. The transit time 
to the moment labeled spins arrive in vessels that are small enough to only feed local 
tissue, which would be the time of interest to choose the PLD, is likely situated between 
the ATT measured here and this tissue transit time. 
The te-pCASL sequence may be improved in several ways. Tissue transit times may be 
longer than the longest effective PLD used in the te-pCASL labeling scheme of this study. 
It might therefore be useful to adapt the temporal encoding scheme to cover later time 
points. Furthermore, given the low SNR of the te-pCASL measurements in mice, the 
te-pCASL sequence should probably be adapted in combination with higher field strengths 
and/or more sensitive receive coils in order to measure tissue transit times. A second 
technical limitation of the current sequence was the limited number of slices (three). This 
was caused by the long readout time per slice: extending the number of imaging slices 
to four (or more), would result in poor determination of the ATT in the additional slices, 
since the label would already have arrived. This limitation can be overcome by using a 
3D readout, a multiband readout, or stronger and faster gradients.
The ASL signal of the te-pCASL data decreased faster than the T1t measured with the IR 
sequence. This is also the reason why CBF values from the te-pCASL experiment were 
quantified from the fit’s peak height (ΔM), instead of directly using the CBF value provided 
by the fit. There may be explanations at both sides of the signal profile from the te-pCASL 
data for the observed fast decay. Since the te-pCASL sequence is optimized to see the 
inflow-phase of the label, it will be contaminated by vascular signal. This may lead to 
higher values at the early part of the signal profile. This explanation is supported by 
figure 3b and figure 4. In figure 3b, the first peak most probably represents the passage 
of a bolus through arteries feeding more distal brain regions, whereas the second peak 
would represent true perfusion of the voxel, identical to what has been described by 
Chappell et al.30 Nevertheless, after averaging signals across voxels in the cortical ROI and 
across animals this pattern was not visible anymore (figure 4), and thus further research 
is necessary to document these effects. Moreover, a higher signal was measured in the 
hippocampal ROI for the earlier time-points after labeling for the te-pCASL data (figure 
4). Labeled spins detected in these time-points may be located in the larger vessels that 
surround and penetrate the hippocampus,23 but may go on to perfuse a different voxel 
in the later time-points. The signal in the auditory/visual cortex, containing less of these 
large vessels, show comparable peak signal in the te-pCASL data curve and the theoretical 
Buxton curve, which was obtained from the standard pCASL perfusion scan. At the late 
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part of the time profile of the te-pCASL signal, there may be influence by venous outflow, 
which was not taken into account in this study. Underestimation due to venous outflow 
becomes of particular importance with high blood flow31 and high blood T1.
18 In humans, 
this may be less of a problem than in rodents, which have higher CBF and are imaged 
at higher magnetic fields with therefore prolonged blood T1. In rats, using a multi-TI 
FAIR approach, significant outflow of labeled blood from the imaging slice leading to 
accelerated ASL signal decrease was shown for CBF values higher than 100 mL/100 g/
min.32 In a previous DASL study in rats, the authors also measured higher CBF and faster 
signal decay in voxels containing mostly arterial signal.21 
The different designs of the standard pCASL and the te-pCASL sequence ultimately resulted 
in differences between the measured CBF values, which can probably be explained by the 
above described vascular artefacts and venous outflow. In addition, it should be noted 
that the standard pCASL sequence, with its long labeling duration (3 s), may be particularly 
sensitive to the outflow effect, especially in regions with high flow rates. This may lead 
to underestimation of the CBF and can be an additional explanation for the different CBF 
values between standard pCASL and te-pCASL. 
Because of the different objectives of the te-pCASL scan (measurement of ATT) and 
the standard pCASL sequence (measurement of CBF), the labeling durations of the two 
sequences differed to a great extent; 50 ms was chosen for each block of the te-pCASL 
sequence to provide sufficient temporal resolution, whereas 3000 ms was used in the 
standard pCASL sequence to quantify perfusion as suggested in the literature.22 This 
resulted in a large raw ASL signal difference between the te-pCASL data and the standard 
pCASL data (around 24 times higher for standard pCASL, data not shown). Noisy MRI data 
can be biased by the Rician distribution of the noise, but when the SNR is higher than 2, the 
noise distribution is nearly Gaussian.33 Therefore, to ensure that the te-pCASL signal is not 
subjected to a noise dependent bias, we quantified the noise in the decoded Hadamard 
images. The whole-brain average ASL SNR was higher than 2 for all time-points after arrival 
of the label (data not shown), which allows to confirm the normal distribution of decoded 
te-pCASL data. This implies that the ATT as obtained by fitting the Buxton-model can be 
trusted, even though the SNR of decoded te-pCASL data (<5) was much lower than that 
of standard pCASL data (~38).
Another improvement that could be made is to fit a Buxton model extended with dispersion 
of the blood arrival times.34 In figure 4, it can be seen that the second part of the model, 
representing arrival of label, does not accurately fit the data. In particular, in the cortex 
the model is inaccurate. The model assumes that labeled blood arrives non-dispersed, 
and as such it contains a boxcar input function. However, it may be reasonable to assume 
that blood in the center of the vessel travels faster than blood at the vessel wall, resulting 
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in a dispersed arrival. Especially in the cortex, since it has later arrival times, and thus 
the labeled blood has longer time to disperse. Inclusion of dispersed arrival in the model 
would probably lead to a better fit of the model to the data. 
With aging, CBF in the human brain has been shown to decrease, also with imaging 
modalities different from MRI.35–37 In case of neurological disease, such as Alzheimer’s 
disease, CBF is even further reduced.1 Even though the evidence is less strong, 
both vascular and tissue transit times have been shown to increase with age.37 It has 
been reported that CBF in WT mice is maintained, as opposed to several mouse 
models of neurological disease, which show decreased CBF with age.38 Our 
experiments also did not show an effect of aging on the CBF in WT mice. 
Additionally, our results indicated that ATT is also preserved with aging in WT mice. 
Therefore, in future studies it may be of interest to investigate whether there is an 
age-dependent change in ATT in mouse models of neurological disease. 
In conclusion, this study shows the successful implementation of te-pCASL in mice. For 
the first time, ATT was measured in mice and changes in ATT as a function of age were 
assessed. No differences were found in CBF or in ATT between old (25 months) and young 
(6 months) mice. te-pCASL and standard pCASL CBF values were different, probably due 
to a vascular contribution and the venous outflow of labeled spins. 
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ABSTRACT
Arterial Spin Labeling (ASL)-MRI can non-invasively map cerebral blood flow (CBF) and 
cerebrovascular reactivity (CVR), potential biomarkers of cognitive impairment and 
dementia. Mouse models of disease are frequently used in translational MRI studies, 
which are commonly performed under anesthesia. Understanding the influence of the 
specific anesthesia protocol used on the measured parameters is important for accurate 
interpretation of hemodynamic studies with mice. Isoflurane is a frequently used 
anesthetic with vasodilative properties. Here, the influence of three distinct isoflurane 
protocols was studied with pseudo-continuous ASL in two different mouse strains. The 
first protocol was a free-breathing set-up with medium concentrations, the second a 
free-breathing set-up with low induction and maintenance concentrations and the third 
a set-up with medium concentrations and mechanical ventilation. A protocol with the 
vasoconstrictive anesthetic medetomidine was used as a comparison. As expected, 
medium isoflurane anesthesia resulted in significantly higher CBF and lower CVR values 
than medetomidine (median whole-brain CBF of 157.7 vs 84.4 mL/100 g/min and CVR 
of 0.54 vs 51.7 % in C57BL/6J mice). The other two isoflurane protocols lowered the 
CBF and increased the CVR values compared to medium isoflurane anesthesia, without 
obvious differences between them (median whole-brain CBF of 138.9 vs 131.7 mL/100 g/
min and CVR of 10.0 vs 9.6 %, in C57BL/6J mice). Furthermore, CVR was shown to be 
dependent on baseline CBF, regardless of the anesthesia protocol used.
3
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INTRODUCTION
Cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) are emerging as potential 
biomarkers for cognitive impairment and dementia.1,2 They can be measured in the 
clinic3 and in pre-clinical research4,5 by means of MRI-based perfusion imaging. The 
arterial spin labeling (ASL) MRI technique is particularly attractive as it is completely 
non-invasive, using blood water as an endogenous tracer. This enables repeated measures 
for dynamic recordings of responses to stimuli such as a “CO2 challenge” for assessment 
of cerebrovascular reactivity (CVR).
Mouse models are important tools for translational neuroscience and neurology. Although 
MRI studies with awake mice have been performed,6,7 this approach is often tied to ethical 
and technical restrictions that heavily restrict practical application. Therefore, mouse MRI 
is commonly performed under anesthesia. However, anesthesia protocols are known 
to influence cerebral hemodynamics. In order to more clearly relate MRI measures of 
brain hemodynamics obtained from mouse models to clinical data and for meaningful 
comparison with other pre-clinical studies, it is important to understand the hemodynamic 
influence of the different anesthesia protocols used. Furthermore, different mouse strains 
may vary in their response to the anesthesia protocol used.8,9 It is therefore important to 
devise standardized protocols in order to provide comparable and reproducible CBF and 
CVR estimates. Isoflurane is the most widely used anesthetic in imaging studies with mice, 
likely due to its very straightforward method of administration, fast reversibility and the 
minimal long-term side-effects, even upon repeated use in the same animal.10 However, 
isoflurane also has a dose-dependent vasodilatory effect,11 as well as a dose-dependent 
respiratory depressive effect.12,13 Thus it has been posited to reduce the dynamic range 
in ASL-based CVR studies, both directly via its vasodilatory effect and – if not ventilated 
- indirectly via an increase in the partial pressure of arterial pCO2 as a consequence of
respiratory depression.
BOLD-fMRI studies also appear to be impaired by isoflurane in a dose dependent manner, 
as stimulus-evoked BOLD-responses and resting state network organization have been 
shown to be reduced when higher levels of isoflurane were used.14,15 In order to benefit 
from its otherwise favorable characteristics, refinements have been proposed to minimize 
the needed dose of isoflurane. For example, combining it with a low-dose of 
medetomidine permits stable anesthesia at 0.5 % of isoflurane.16 Also, isoflurane has 
been combined with the paralysis agent pancuronium-bromide to support 
mechanical ventilation, with maintenance levels of 1.0 %.17 However, combination 
with paralyzing agents or medetomidine may not always be wanted, due to ethical 
reasons or unresponsiveness of the mouse strain used respectively.9 Alternatively, 
Wells et al. showed that by simply administrating a relatively low concentration of 
isoflurane both during induction (2.0 %)
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and maintenance (1.5 %) - without any other anesthetic - workable CVR values can 
be obtained in an ASL-based CVR study.18
In this work we provide the first comprehensive assessment of CBF and CVR in the mouse 
brain under different anesthetic regimes using pseudo-continuous ASL-MRI in C57BL/6J 
mice. In particular, given the prevalence and unique perks of isoflurane anesthesia, we 
compare three distinct isoflurane-based protocols: i) a free breathing isoflurane protocol 
with doses that reflect commonly used isoflurane concentrations in mouse brain MRI 
studies9,19, defined henceforth as the “medium-dose” protocol; ii) the protocol described 
by Wells et al.,18 where a relatively low dose of isoflurane was used for both induction and 
maintenance, defined henceforth as the “low-dose” protocol; iii) a medium-dose isoflurane 
protocol with mechanical ventilation to counteract the respiratory depressive effect. 
Additionally, we compare the three isoflurane protocols to a medetomidine anesthesia 
protocol, which is known to be vasoconstrictive. Furthermore, we evaluate the low-
dose and ventilated isoflurane protocols in a second mouse strain, partly on a C3H/HeJ 
background, a strain with known respiratory anomalies.20
EXPERIMENTAL
This study was performed in compliance with the guidelines of the European community 
for the care and use of laboratory animals (EUVD 86/609/EEC) and reported conform the 
ARRIVE guidelines.21
Animal procedures. All experiments were approved by the local ethics committee “Instantie 
voor Dierenwelzijn” of the Leiden University Medical Center and were performed under 
DEC permits 11165 and 14073. 
33 wild type C57BL/6J mice (31 males, 2 females) were used at 10.7 months (standard 
deviation [SD] 6.5 months), with a mean weight of 35 grams (SD 6 grams). The second 
wild type strain used in this study was the F2 generation of a cross of C57BL/6J and C3H/
HeJ mice, further referred to as B6C3. 11 B6C3 mice (7 males, 4 females) were used at 
13.5 months (SD 0.5 months), with a mean weight of 46 grams (SD 7 grams). The mice 
were derived from an in-house breeding. Founder mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME, USA). The mice were co-housed in individually ventilated 
cages (2-4 per cage) in a 12 h dark/ light cycle-ML2-facility. They had unlimited chow food 
and water at their disposal and were supplied with bedding material and cage enrichment.
Anesthesia and monitoring of the physiological signals. The following four anesthesia 
protocols were used (dose, route of administration, animal number and age per group 
are summarized in supplementary table 1): 
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1) An isoflurane protocol with commonly used doses in mouse brain MRI studies:9,19
3.5 % induction for 4 minutes and 1.5-2.0 % maintenance; during maintenance
the breathing rate was kept between 80 and 100 bpm by adjusting the isoflurane
accordingly between 1.5-2.0 %. The isoflurane was administered in medical
air enriched with oxygen (air:oxygen 3:1). This protocol is referred to as the
medium-dose isoflurane protocol.
2) An isoflurane protocol with 2.0 % induction for 5 minutes and 1.25 %
maintenance, based on the protocol described in Wells et al.18 However, to restrict 
the accumulation of isoflurane even more, the maintenance concentration was
lowered to 1.25 % (instead of 1.50 % in Wells et al.), which was the minimum
in our hands. Some B6C3 animals required slightly longer induction times to be
sufficiently anesthetized. For both strains, a quick transfer from the induction
box to the animal bed of the MRI setup was necessary to prevent awakening.
The isoflurane was administered in pure medical air, in accordance with Wells
et al.18 This protocol is referred to as the low-dose isoflurane protocol.
3) An isoflurane protocol with 3.5 % induction for 4 minutes, 1.75 % maintenance
and intubation and mechanical ventilation. After induction, the mouse was taken
out of the induction box and transferred to a supine position and supplied with
a nose cone with continued 3.5 % isoflurane administration. The trachea was
subsequently endotracheally intubated, after which the mouse was transferred
to the scanner bed and the isoflurane was then decreased to 1.75 %. There, the
mechanical ventilation was started with a CWE MRI-1 ventilator (Ardmore, USA)
with settings as recommended during the functional MRI in mice workshop in
November 2016 at the animal imaging center of the ETH Zürich, Switzerland: a
rate of 80 bpm, a tidal volume of 1.7 mL and inspiration of 25 %. The animal was
not paralyzed during the scan. Both the gas used during induction and the air
used during ventilation consisted of oxygen-enriched medical air (air:oxygen 3:1).
This protocol is referred to as the medium-dose isoflurane + ventilation protocol.
4) A medetomidine protocol. Here, anaesthesia was also induced with 3.5 %
isoflurane in oxygen-enriched medical air (air:oxygen 3:1) for 4 minutes.
After transfer to the animal bed, the isoflurane was decreased to 2.0 %, and
after finalizing the setup, a subcutaneous catheter was inserted in the flank
of the animal. Then a 0.15 mg/kg bolus of dexmedetomidine-hydrochloride
was given (Dexdomitor®, Vetoquinol SA, Lure, France [a solution without
levomedetomidine]), followed 10 minutes later by 0.30 mg/kg/hr infusion with a
syringe pump (Univentor© 802, Univentor© High Precision Instruments, Zejtun,
Malta). Note that this is equivalent to a 0.30 mg/kg bolus and 0.60 mg/kg/hr
58 | Chapter 3
infusion protocol when a mixture of both active (dexmedetomidine) and inactive 
(levomedetomidine) enantiomers is used. During the 10 minutes between bolus 
and infusion, the isoflurane was decreased to 0 %, but the administration of 
oxygen-enriched air was continued. The protocol is based on the optimal findings 
in the medetomidine optimization study by Adamczak et al.22 This protocol is 
referred to as the medetomidine protocol.
For physiological monitoring, heart and respiration rates were captured respectively with 
a pressure sensitive pad below the animal and a pulse oxygenation probe around the 
hind paw (SA instruments, New York, USA). Temperature was maintained around 36.5 
C with a water bed plugged on a feedback control system (Medres, Cologne, Germany). 
Furthermore, a transcutaneous probe (Radiometer®, Zoetermeer, The Netherlands) was 
applied on the shaved flank of the mouse for non-invasive collection of the transcutaneous 
partial pressure in carbon dioxide (tc-pCO2). As absolute arterial pCO2 values are not 
reflected by the tc-pCO2 values, whereas changes in arterial pCO2 are reflected by changes 
in tc-pCO2,
23 the tc-pCO2 plots are shown as absolute change of tc-pCO2 in mmHg during 
challenge relative to baseline. Due to a technical error during the medetomidine scans, 
7 out of the 11 tc-pCO2 profiles were not captured in this group. For each anesthesia 
protocol, representative CBF, heart rate, respiration rate and tc-pCO2 time-profiles are 
shown in supplementary figure 1. In a few animals, parts of the heart or respiration rate 
time-profiles were not captured properly, as illustrated in supplementary figure 1. Such 
incorrectly sampled data was excluded from the median and interquartile range (iqr) 
calculation of the heart and respiration rates, which is shown in supplementary table 2.
MRI measurements. A 7 Tesla Pharmascan (Bruker Biospin GmbH, Ettlingen, Germany) 
was used with a 23 mm volume resonator.
Anatomical scans. For planning of the pCASL sequence, anatomical T2-weighted magnitude 
images were acquired with a RARE sequence in the axial, sagittal and coronal orientation, 
using the following parameters: TE/TR/FA = 35.0 ms/2,500 ms/90 degrees, matrix 256x256, 
field of view of 21.55 x 21.55 mm, 0.7 mm slice thickness, no slice gap, 1 average, RARE 
factor of 8, and a bandwidth of 36.7 kHz. Additionally, a set of anatomical images with 
the same geometry as the pCASL read-out was acquired for registration purposes.
Cerebral blood flow measurements. A pCASL sequence allowed measuring the cerebral 
blood flow. The pCASL-interpulse phases were optimized to correct for off-resonance 
effects with pre-scans.24 Labeling pulses were applied with 3.5 μT B1, 400/800 μs pulse 
duration/interval and a total labeling duration (τ) of 3000 ms. A post-label delay (PLD) of 
300 ms was included before a single-shot spin echo – echo planar imaging (EPI) read-out. 
The following read-out parameters were used: TE/FA = 16.8 ms/90 degrees, 4 dummy 
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scans, matrix size 96 x 96, FOV 21.55 x 21.55 x 1.5 mm, 3 slices with the middle slice 
position at -0.75 mm Bregma and at the isocenter of the bore and a maximum/average 
labeling gradient of 45.0 / 5.0 mT/m. The labeling slice was always positioned exactly 1.0 
cm from the middle imaging slice, which is around 4 mm upstream of the split of the 
common carotid artery. The TR was 3,520 ms, meaning that each control/labelled pair 
of images took of 7.04 seconds to acquire. An example of the planning and the resulting 
ASL images is shown in supplementary figure 2.
To support CBF-quantification, tissue T1 (T1t) maps were acquired with an inversion recovery 
EPI sequence with 18 inversion times and labeling efficiency (α) was measured in the 
carotids 3 mm downstream of the labeling plane with a flow-compensated, ASL-encoded 
FLASH sequence. 
Timeline of the CBF measurements. CBF time-profiles were acquired for 21 minutes 
separated in 3 fragments of 7 minutes: 7 minutes baseline, 7 minutes 7.5 % CO2 challenge, 
7 minutes back to baseline. This duration was chosen to collect 60 repetitions for each 
fragment of the sequence, thus with a total of 180 repetitions. During the challenge, 
the oxygen concentration stayed the same, i.e. 7.5 % CO2 replaced N2 in the air mixture.
Image processing
Alignment of the pCASL and inversion recovery EPIs. A MATLAB® monomodal rigid-body 
registration (300 iterations) was applied on the label and control magnitude images 
collected by the pCASL sequence to align them to the first label magnitude image of the 
sequence. In the same way, the 18 inversion recovery EPIs were aligned to the first label
magnitude image of the pCASL sequence. The CBF and T1t maps could then be computed 
voxel wise.
Cerebral blood flow quantification. The CBF was quantified in mL/100 g/min using 
Buxton’s general kinetic perfusion model.25 Assuming that M0b, the magnetization of 
arterial blood at thermal equilibrium, may be approximated by M0t/λ, where M0t is the 
magnetization of tissue and λ is the blood–brain partition coefficient of water, i.e. 0.9 
mL/g,26 the following equation was used:
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Where ΔM is the measured difference between label and control acquisition and T1b is 2230 ms,
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chosen previously) was then automatically estimated as follows: an edge-based variational
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These brain regions were then automatically propagated to the anatomical T2-weighted 
magnitude images of the other datasets by applying a monomodal optical-flow registration 
algorithm. The field of transport 
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chosen previously) was then automatically estimated as follows: an edge-based variational
method for non-rigid multimodal registration28 was employed to circumvent potential
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partial derivatives of u and v, respectively. The regularization term alpha was set to 0.5. The 
results of this propagation step was then verified dataset-by-dataset by an operator (LPM).
In each dataset, the in-plane spatial transformation between the anatomical T2-weighted 
magnitude image and the first frame of the pCASL magnitude image (i.e., the reference 
image chosen previously) was then automatically esti ated as follows: an edge-based 
variational metho  for non-rigid multimodal registr tion28 was employed to circumvent 
potential g ometrical distortions induced by the EPI readout. For this purpose, the data 
fidelity term in Eq. (2) (l ft part of the int gral) was rep aced by a multi-modal similarity 
metric which favors the alignment of edges/gradients that are present in both images, as 
described in Chen et al.29 The obtained motion-vector field was subsequently employed 
to adjust the position of the masks of each brain region. Here again the results of this 
propagation step was verified dataset-by-dataset by an operator (LPM).
CVR quantification. The spatial mean of the CBF in each brain region was collected frame-
by-frame, and allowed quantifying the CVR by computing the following estimates: 1) 
baseline CBF from the mean CBF of the 20 repetitions, i.e., 2 min 20 sec, before the 
onset of the CO2 challenge, and 2) CBF during CO2 challenge based on the 20 repetitions 
before the end of the CO2 challenge. The percentage of CVR was calculated by applying 
the following equation:
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geometrical distortions induced by the EPI readout. For this purpose, the data fidelity term in Eq.
(2) (left part of the integral) was replaced by a multi-modal similarity metric which favors the
alignment of edges/gradients that are present in both images, as described in Chen et al.29 The 
obtained motion-vector field was subsequently employed to adjust the position of the masks of
each brain region. Here again the results of this propagation step was verified dataset-by-dataset 
by an operator (LPM).
CVR quantification. The spatial mean of the CBF in each brain region was collected fra e-by-
frame, and allowed quantifying the CVR by computing the following estimates: 1) baseline CBF
from the mean CBF of the 20 repetitions, i.e., 2 min 20 sec, before the onset of the CO2 challenge,
and 2) CBF during CO2 challenge based on th  20 repetitions before the end of the CO2 challenge.
The percentage of CVR was calculated by applying the following equation:
CVR (%) =  100 ∗  � 
mean CBF during challenge
mean baseline CBF
− 1� (3)
Statistical analysis. Estimates are expressed as median (iqr), except for the time-profiles in the
figures, which are given in mean (standard deviation [SD]) to better visualize the group response.
The statistical tests were performed using the IBM SPSS statistics 23 software package (Armonk,
New York, USA). For multiple comparisons, first a Kruskal-Wallis test was used to evaluate
whether the non-parametric unpaired groups belonged to the same distribution. If a significant
difference was found, post-hoc testing was performed with Dunn-Bonferroni tests to assess
which groups differed. Mann-Whitney tests were used when only comparing two groups.
Results
Comparison of the anesthesia protocols in C57BL/6J mice. The CBF time-profiles for the different
anesthesia protocols are displayed in figure 1a and 1b for full brain ROIs and cortical ROIs
respectively. CBF and CVR maps of individual mice representative for their groups and their
respective anatomical T2-weighted images are shown in figure 1c. The lowest baseline CBF
estimates were found using the medetomidine protocol, and the highest when administering
medium isoflurane. The other two isoflurane protocols are in between, without an obvious
difference between the two. Figure 2a and 2b show CBF time-profiles normalized to the baseline
CBF values for the full brain and cortex respectively. The resulting CVR values are compared in
figure 2c and 2d with boxplots for respectively full brain and cortex. Here, an opposite trend is
observed for the anesthesia protocols, with medium isoflurane resulting in the lowest CVR and
medetomidine in the highest CVR. Again, the other two isoflurane protocols result in an
intermediary CVR response, with similar results recorded.
The distribution of CBF and CVR values in both full brain and cortex for the four anesthesia
protocols were significantly different from each other (H(3) = 19.02 & p < 0.001; H(3) = 24.24 &
p < 0.001; H(3) = 12.36 & p = 0.006; H(3) = 14.75 & p = 0.002 respectively for full brain CBF, full
(3)
3
Influence of different isoflurane anesthesia protocols on murine cerebral hemodynamics measured 
with pseudo-continuous arterial spin labeling | 61
Statistical analysis. Estimates are expressed as median (iqr), except for the time-profiles in 
the figures, which are given in mean (standard deviation [SD]) to better visualize the group 
response. The statistical tests were performed using the IBM SPSS statistics 23 software 
package (Armonk, New York, USA). For multiple comparisons, first a Kruskal-Wallis test 
was used to evaluate whether the non-parametric unpaired groups belonged to the same 
distribution. If a significant difference was found, post-hoc testing was performed with 
Dunn-Bonferroni tests to assess which groups differed. Mann-Whitney tests were used 
when only comparing two groups. 
RESULTS
Comparison of the anesthesia protocols in C57BL/6J mice. The CBF time-profiles for the 
different anesthesia protocols are displayed in figure 1a and 1b for full brain ROIs and 
cortical ROIs respectively. CBF and CVR maps of individual mice representative for their 
groups and their respective anatomical T2-weighted images are shown in figure 1c. The 
lowest baseline CBF estimates were found using the medetomidine protocol, and the 
highest when administering medium isoflurane. The other two isoflurane protocols are 
in between, without an obvious difference between the two. Figure 2a and 2b show CBF 
time-profiles normalized to the baseline CBF values for the full brain and cortex respectively. 
The resulting CVR values are compared in figure 2c and 2d with boxplots for respectively 
full brain and cortex. Here, an opposite trend is observed for the anesthesia protocols, 
with medium isoflurane resulting in the lowest CVR and medetomidine in the highest 
CVR. Again, the other two isoflurane protocols result in an intermediary CVR response, 
with similar results recorded. 
The distribution of CBF and CVR values in both full brain and cortex for the four anesthesia 
protocols were significantly different from each other (H(3) = 19.02 & p < 0.001; H(3) = 24.24 
& p < 0.001; H(3) = 12.36 & p = 0.006; H(3) = 14.75 & p = 0.002 respectively for full brain 
CBF, full brain CVR, cortical CBF and cortical CVR). Post-hoc analysis indicated that the 
CBF values in the full brain obtained under medetomidine (84.4 mL/100 g/min [31.4 
mL/100 g/min]) were significantly lower than those obtained with medium isoflurane 
(157.7 mL/100 g/min [41.72 mL/100 g/min]) and significantly lower than those obtained 
under low isoflurane (138.9 mL/100 g/min [26.5 mL/100 g/min]), adj. p = 0.001 and adj. p 
= 0.006 respectively. Regarding the CVR values in the full brain, the same groups differed: 
medium isoflurane (0.5 % [3.1 %]) vs. medetomidine (51.7 % [25.7 %]), adj. p < 0.001; low 
isoflurane (10% [7.1%]) vs. medetomidine, adj. p = 0.036. Most of the other comparisons 
lost their statistical significance after Dunn-Bonferoni correction. For the low isoflurane 
and medium isoflurane + ventilation CBF and CVR comparisons however, even uncorrected 
p-values were not significant (p = 0.688 and p = 0.974 respectively), reflecting their similar
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CBF time-profiles. In the cortical ROIs, statistical testing gave comparable results as in the 
full brain ROIs (data not shown). Median and interquartile ranges of the CBF and CVR 
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Figure 1: Absolute CBF values and CBF maps for the four different anesthesia protocols in C57BL/6J 
mice. a,b) Mean and standard deviation of the absolute CBF profiles in the full brain (a) and 
the cortex (b). c) Representative examples of images acquired at -0.75mm from Bregma. 
In the columns from left to right: anatomical images with cortical ROIs; mean CBF maps 
collected in the last 2 minutes before the onset of the CO2 challenge; mean CBF maps 
collected in the last 2 minutes during CO2 challenge; CVR maps. All the images on a row 
are from the same mouse.
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Figure 2: CVR relative to the baseline CBF for the four different anesthesia protocols in C57BL/6J mice. 
CVR estimates are computed in the full brain (a, c, e) and in the cortex (b, d, f ).
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It should be pointed out that in the medetomidine group, not all of the individual baseline 
CBF profiles were stable yet, even though the medetomidine infusion started 20 minutes 
before the pCASL scan (see supplementary figure 4). It is also to be noted that, unlike 
the isoflurane anesthesia protocols where the CVR is most pronounced in the cortex, the 
CVR obtained using the medetomidine protocol was strongly present throughout the full 
brain. Also observed in the CBF time-profile of medetomidine only, is a continuing CBF 
increase during hypercapnia, suggesting a competition between processes (vasoconstrictive 
medetomidine and vasodilative CO2) influencing the CBF. This is reflected in the time 
to half peak (TTHP) distributions, which were also different between the anesthesia 
protocols, H(3) = 9.701 and p = 0.021 in the full brain and H(3) = 9.105; p = 0.028 in the 
cortex. Only the medetomidine vs. low isoflurane full brain TTHP post-hoc test survived 
the Dunn-Bonferoni correction, with an adj. p = 0.03.
There were no significant differences in the tc-pCO2 rise upon CO2 challenge between 
the different anesthesia protocols (supplementary figure 3, H(3) = 6.167; p = 0.104). 
The median heart rates were lower and respiration rates higher in the medetomidine 
group (supplementary table 2), which was to be expected given the known respiratory 
depressive action of isoflurane12,13 and the known bradycardic action of medetomidine.30
Comparison of the anesthesia protocols in B6C3 vs. C57BL/6J mice. The B6C3 mice 
could not be sedated sufficiently with medetomidine, thus compromising the use of this 
anesthetic for this strain. The application of the low isoflurane protocol in free-breathing 
B6C3 mice showed a higher but non-significant mean baseline CBF in B6C3 mice compared 
to C57BL/6J mice (figure 3; full brain: U = 21.0; Z = -1.405; p = 0.180; cortex: U = 24.0; Z 
= -1.124; p = 0.291). Using the low isoflurane protocol, a significantly lower CVR in B6C3 
mice was found vs. C57BL/6J mice: 3.1 % (4.6 %) vs. 10.0 % (7.1 %) in the full brain (U = 
4.0; Z = -2.997; p = 0.001); and 4.5 % (1.1 %) vs. 12.7 % (9.3 %) in the cortex (U = 7.0; Z = 
-2.716 p = 0.005) (figure 3a-d). Interestingly, the change in tc-pCO2 was also significantly 
lower in B6C3: mean rise of 18.6 mmHg in C57BL/6J mice vs 11.5 mmHg in B6C3 mice 
(Mann-Whitney, p = 0.014) (figure 3e). It is to be noted that B6C3 mice displayed a higher 
group variability in tc-pCO2 rise, with a standard deviation of 6.1 mmHg (normalized 
standard deviation of 53 %) vs. 4.7 mmHg only in C57BL/6 mice (normalized standard 
deviation of 25 %) (figure 3e). When using medium isoflurane + mechanical ventilation, 
the difference in CVR in B6C3 mice vs. C57BL/6J mice was abolished: 6.8 % (12.1 %) vs. 
9.6 % (15.1 %) in the full brain (U = 8.0; Z = -0.940; p = 0.421), and 4.4 % (17.5 %) vs. 12.2 
% (23.5 %) in the cortex (U = 8.0; Z = -0.940; p = 0.421) (figure 4a-d). With mechanical 
ventilation, both strains displayed a similar tc-pCO2 rise, with a mean rise of 13.2 mmHg 
(7.3) vs. 10.8 mmHg (6.8) in B6C3 mice (t-test, p = 0.595) (figure 4e).
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Figure 3: CBF and CVR values for the “low isoflurane” protocol in C57BL/6J mice (blue) vs B6C3 mice 
(red). Time profiles of the CBF acquired in the full brain (a) and in the cortex (b). The CVR 
is significantly different between both strains (c,d). The transcutaneous pCO2 rise was 
significantly different at the time of maximum pCO2 rise (e).
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Figure 4: CBF and CVR for the “standard isoflurane + mechanical ventilation” protocol - C57BL/6J mice 
(blue) vs B6C3 mice (red). a-b) Time profiles of the CBF acquired in the full brain (a) and in 
the cortex (b). c-d) CVR in the full brain (c) and in the cortex (d), which are not significantly 
different in B6C3 vs. C57BL/6J mice. e) tc-pCO2 rise in B6C3 vs. C57BL/6J mice was not 
significantly different.
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End of the hemodynamic capacity reserve with high baseline CBF values
To visualize the dependency of CVR on baseline CBF, a correlation plot between the two is 
shown in figure 5. There is a strong negative correlation between baseline CBF and CVR, 
with high baseline CBF values resulting in a blunted or absent CVR response regardless 
of the protocol used, indicating the maximum of the hemodynamic capacity is reached. 
Only measurements in C57BL/6J mice were used for this plot.
Figure 5: CVR expressed as a function of the baseline CBF in C57BL/6J mice. Every dot represents one 
mouse, where the colour indicates the anesthesia protocol used. Relation is given for the 
full brain (a) and for the cortex (b).
DISCUSSION
The current increase of studies investigating hemodynamics in the mouse brain requires 
a better understanding of the physiological influence of the anesthesia protocols used. 
Our results demonstrate exquisite sensitivity of CBF and CVR to the anesthesia protocol 
employed, findings that reinforce the need for care in the experimental design and 
interpretation of studies of murine cerebrovascular function, where anesthesia is often 
required. Isoflurane is the most widely used anesthestic due to its many advantages, 
but it has the disadvantage of being a dose-dependent vasodilator and a respiratory 
depressant. In this study, we focused on the influence of different isoflurane protocols on 
the hemodynamic measures CBF and CVR to a CO2 stimulus. A medium-dose isoflurane 
protocol was compared with two alternative isoflurane protocols that have been adapted 
to minimize its vasodilatory and/or respiratory depressive properties: a low-dose isoflurane 
protocol and a medium-dose isoflurane protocol with mechanical ventilation. To put the 
results in context, the isoflurane protocols were also compared to the vasoconstrictive 
68 | Chapter 3
medetomidine protocol. All four protocols were tested in the commonly used C57BL/6J 
mouse strain. Lastly, the performance of the adapted isoflurane protocols was also assessed 
in a second mouse strain, namely the mixed background B6C3 strain.
As reported before9, the medium isoflurane protocol resulted in a high baseline CBF, 
thus blunting the CVR. Conversely, the medetomidine protocol yielded the lowest CBF 
and highest CVR, with median CVR estimates over 50 % in C57BL/6J mice. As intended, 
the adapted isoflurane protocols lowered basal CBF compared to the medium isoflurane 
protocol. Consequently, workable CVR values were obtained. There was no observable 
difference between the two adapted isoflurane protocols. This is interesting, because with 
the low isoflurane protocol, both the vasodilatory and the respiratory depressive effects 
are reduced compared to the medium isoflurane protocol, whereas with the medium 
isoflurane + ventilation protocol, only the respiratory depressive effects are reduced. 
Thus it implies that the respiratory depression plays a major role in the outcome of 
the high baseline CBF with the medium isoflurane protocol. Because of its much easier 
implementation, we recommend researchers unexperienced with intubation to use the 
low isoflurane protocol over the medium isoflurane + ventilation protocol for CVR studies 
with perfusion imaging. It should be stressed here, that in our experience, not only the 
low maintenance, but also the low induction is of high importance for maintaining some 
hemodynamic reserve capacity. Compared to the other protocols, the low induction keeps 
the respiration rate higher especially in the beginning of the anesthesia period, and fully 
avoids any spasmodic breathing. Also to be noted is that studies have been reported with 
lower maintenance concentrations than our low isoflurane protocol.6,14 In our hands, we 
could not lower the isoflurane concentration, as animals would then have woken up. 
Perhaps local differences in isoflurane delivery systems can explain differences in lower 
boundaries of isoflurane maintenance. In supplementary table 4, a list of pros and cons 
of the different anesthesia protocols in this study are summarized. 
A wider range of anesthetics has been used for rodent MRI studies than used here. Most 
of these anesthetics have been reported to affect hemodynamic regulation. For example, 
propofol reduces blood pressure and is respiratory depressive.31,32 Other fluorinated gases 
than isoflurane such as halothane and sevoflurane have a similar hemodynamic influence 
as isoflurane.33 Of particular interest are urethane and etomidate. These anesthetics are 
known to have very little effect on hemodynamics.9,34,35 However, urethane is not applicable 
to longitudinal studies, due to the toxicity of the compound. Etomidate sedation has 
been suggested as a widely applicable anaesthesia regime in multiple strains.9,35 It is even 
preferred for anesthesia induction of cardiac patients, due to its lack of hemodynamic 
influence.36 However, the current availability of formulations of etomidate is very limited 
and, to the best of our knowledge, etomidate is only available in a concentration of 2 
mg/mL. This means that injection volumes needed for at least one hour of sedation 
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exceed the animal welfare guidelines.37 A very recent paper showed that it was possible 
to measure unilateral BOLD responses upon a somatosensory stimulus repeatedly in 
the same mouse anesthesized with a novel ketamine/xylazine formulation.38 It would 
therefore be of interest to characterize the absolute CBF and CVR profiles with this new 
ketamine/xylazine formulation. 
Unfortunately, B6C3 mice exhibited an insufficient anesthetic depth with medetomidine, 
thus compromising the use of this anesthetic for this strain. This insensitivity likely 
comes from the C3H strain. Medetomidine has been reported to show limited efficacy 
of anaesthesia not only in C3H mice but also in BTRB T+tf/J mice and CD1 strains9. Therefore, 
if medetomidine use is uncharacterized in a mouse strain, we recommend careful bench 
studies with frequent monitoring of anesthetic depth and physiological measures such 
as heart and respiration rate before starting an MRI experiment with medetomidine. 
Another limitation of medetomidine was the unstable baseline CBF that was sometimes 
observed in the C57Bl/6J mice. This is probably a result of the switch from isoflurane 
induction to medetomidine. The dynamics of CBF stabilization under medetomidine is 
not well-known and this might be interesting for future research. However, since the 
sedation time of medetomidine is limited (around 1 hour starting from the time of bolus 
injection22), it would be risky to delay the start of the pCASL scan, as the animal may wake 
up before the end of the scan. 
A different complication with the CVR measurements was encountered when using the 
low isoflurane protocol in free-breathing B6C3 mice. Here, a CBF response to CO2 was 
nearly absent (3.1 % CVR). Interestingly, when comparing the mean tc-pCO2 increase with 
the same hypercapnia protocol in free-breathing mice, B6C3 mice also had a significantly 
lower tc-pCO2 increase compared to C57BL/6J mice (11.5 mmHg vs. 18.6 mmHg). When 
the B6C3 mice were mechanically ventilated, both the difference in CVR and tc-pCO2 
between B6C3 and C57BL/6J mice were abolished. It has been reported before that C3H 
mice have a low respiratory sensitivity to hypercapnic stimulation.20 However, it seems 
paradoxical that a lower tc-pCO2 increase is measured in free-breathing mice with a lower 
respiratory response to CO2, as a lower respiratory response is expected to less efficiently 
remove CO2 from the body. Further research is therefore necessary to clarify if and how 
the reduced CVR, reduced tc-pCO2 rise and low respiratory sensitivity to hypercapnia in 
the B6C3 mice anesthesized with low isoflurane are related. Whole-body plethysmography 
to measure minute ventilation as well as more reliable pCO2 measurements such as end-
tidal CO2 or blood sampling could give more insight in this matter. Also to be taken into 
account is that factors such as skin perfusion influence the diffusion of CO2 through the 
skin,23 which might in their turn be influenced by the anesthesia protocol used. This may 
bias the tc-pCO2 measurements, which is why we chose not to express CVR per mmHg 
rise of transcutaneous CO2.
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A few limitations specific to this study have to be taken into account. The large age range 
of the animals and the different oxygen content in the low isoflurane protocol (20 % versus 
around 40 % O2 in the other protocols) might have biased the results. However, this bias 
is probably small, as several studies have shown that brain hemodynamic parameters are 
preserved with age in wild type mice,5,39,40 and because the effect of 100 % O2 inhalation 
on the baseline CBF has been shown to be an order of magnitude lower than that of 
hypercapnia.41 Another limit is that due to technical constraints the labeling efficiency was 
only measured in the carotids, and not in the vertebral arteries. This might have introduced 
noise in the CBF values of the flow territory of the vertebral arteries (the posterior part of 
the brain), but this is not expected to be different between groups. Lastly, the absence of 
paralysis in the mechanically ventilated animals sometimes resulted in counter-breathing, 
especially during the CO2-administration, probably explaining the more fluctuating CBF 
time-profile in this group.
In conclusion, this study stresses the importance of careful selection of the specific 
anesthesia protocol for CBF and/or CVR studies in the mouse brain. From the four protocols 
tested, the medetomidine protocol showed the lowest CBF and highest CVR values, as 
expected given medetomidine’s vasoconstrictive properties. However, an important 
limitation is that medetomidine induces insufficient depth of anaesthesia in several mouse 
strains. Despite the known vasodilative properties of isoflurane, CVR studies were possible 
with the two adapted isoflurane protocols, with comparable CVR values in C57BL/6J mice. 
Of these two, the free-breathing low isoflurane protocol may experimentally provide the 
most straight-forward protocol. With this protocol, it is important that the isoflurane dose 
is kept low during both induction and maintenance. Furthermore, CVR was shown to be 
highly dependent on the baseline CBF, with high baseline CBF resulting in blunted CVR.
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SUPPLEMENTARY TABLES








Age in months 
- mean (stdev)
Standard isoflurane 3.5 % 1.5 – 2.0 % 3:1 3 8.6 (3.7)
Low-dose isoflurane 2.0 % 1.25 % Pure air 12 6.5 (4.0)
Standard isoflurane 
+ ventilation
3.5 % 1.75 % 3:1 5 9.2 (3.3)
Medetomidine s.c. 3.5 % 0.15 mg/kg bolus;
0.30 mg/kg/h 
infusion
3:1 8 20.9 (0.5)






CBF during CO2 
challenge
(mL/100 g/min)
CVR (%) Time to half 
peak (sec)
Median IQR Median IQR Median IQR Median IQR
Standard isoflurane
Cortex 173.1 57.8 183.0 45.3 5.7 9.5 31.5 5.3
Full Brain 157.7 32.9 161.3 30.2 2.3 2.1 38.5 5.3
Medetomidine
Cortex 113.9 41.3 160.1 25.4 36.5 30.6 45.5 59.5
Full Brain 91.7 29.3 136.4 28.8 42.3 31.4 45.5 22.8
Low isoflurane
Cortex 143.0 38.3 164.1 28.1 12.7 9.3 31.5 7.0
Full Brain 138.9 26.5 151.5 24.5 10.0 7.1 31.5 7.0
Standard isoflurane 
+ ventilation
Cortex 136.1 14.2 157.1 14.5 12.2 23.5 24.5 12.3
Full Brain 131.7 10.0 141.8 7.8 9.6 15.1 24.5 24.5
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Supplementary table 3. Pros and cons of the anesthesia protocols tested.
Pros Cons
Standard isoflurane - Easiest protocol
- Short imaging session
- No CVR experiment possible
- Respiratory depression
Medetomidine - High CVR measurable - Not suitable for every mouse strain 
- Longer preparation time (injection line, 
injection minipump) 
- Narrow time window for CVR measurements; 
measuring too early results in an unstable 
baseline; too late and the mouse is awake 
- Cardiac depression
Low isoflurane - Accessible protocol for 
any user
- CVR measurable 
- Slightly longer induction time of anesthesia
- Quick transfer to MRI animal bed after 
induction needed
Standard isoflurane + 
mechanical ventilation
- Stable physiology
- CVR measurable 
- Technical skills required for the intubation 
procedure
- Dedicated equipment needed (ventilation 
pump)
- Longer preparation time (intubation 
procedure)
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SUPPLEMENTARY FIGURES


























Medium isoflurane + ventilation
Supplementary figure 1. The transcutaneous pCO2 profiles measured during the pCASL scans in the 
C57BL/6J mice. The profiles are grouped per anesthesia protocol (mean ± 
SD). No significant differences were found between the groups. Note that 
the it takes around 2 minutes before the arterial CO2 has diffused to the 
skin (CO2 was administered from minute 7-14). Also note that 7 out of the 
8 medetomidine profiles have not been captured due to a technical error, 
explaining the absence of the SD line in that group. 
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ABSTRACT
Significance: Cerebrovascular dysfunction is increasingly recognized to play a role in 
the development of Alzheimer’s disease (AD). However, the exact relation between 
cerebrovascular dysfunction and the for-AD characteristic neuropathological amyloid-β 
accumulation is still unclear and further studied in this work. 
Aim: The effect of parenchymal amyloid-β plaques on the structure and function of 
the vasculature is investigated in the APP/PS1 mouse model of amyloidosis using 3D 
microscopy and perfusion MRI.
Approach: For structural imaging, blood vessels and amyloid-β plaques were fluorescently 
labeled in vivo with lectin-DyLight594 and methoxy-XO4, respectively, in 17 months old 
APP/PS1 and control mice. The brain tissue was cleared post-mortem with the CUBIC 
tissue clearing protocol, which allowed microscopic imaging of the vessels and plaques 
in a large 3D volume. Segmentation of the brain vasculature enabled quantification 
of the microvascular Cerebral Blood Volume (mCBV). For functional imaging, in vivo 
pseudo-Continuous Arterial Spin Labeling (pCASL)-MRI was used to measure Cerebral 
Blood Flow (CBF) and Arterial Transit Time (ATT) in 2 years old APP/PS1 and control mice.
Results: mCBV ranged from 2 % to 5 % in the white matter and the thalamus, respectively. 
No mCBV differences were observed between APP/PS1 mice and control mice. Neither 
were any differences observed in the MRI measures CBF or ATT.
Conclusions: Our results indicate that structure and function of brain vasculature are 
not profoundly affected by the presence of amyloid-β plaques, at least not in mice.
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INTRODUCTION
Familial mutations in genes related to the production of the amyloid-β peptide are 
associated with early cognitive decline and extensive accumulation of amyloid-β pathology 
in the brain. These mutations lead to Alzheimer’s disease (AD) with full penetrance.1 This 
is a clear indication that amyloid-β plays an important role in the development of AD, 
at least in familial cases with early onset. The importance of its role in the development 
of sporadic AD, however, is continuously debated. Researchers who are sceptic about 
the amyloid hypothesis, point out that amyloid-β plaque load correlates poorly with 
cognitive decline and that plaques are also found in the healthy elderly.2 Alternative, or 
synergistic, pathogenic mechanisms for AD are receiving more and more attention in 
the recent years, among which is the cerebral circulation. Various imaging studies have 
demonstrated that changes in brain perfusion,3 blood volume4,5 and cerebrovascular 
reactivity6 are associated with AD. In a predictive model based on human imaging data, 
cerebrovascular dysfunction has been estimated to be present early on in the AD onset.7 
AD and cardiovascular disease share genetic risk factors8 and histological studies have 
shown that cerebrovascular pathology such as microinfarcts and atherosclerotic arteries 
is commonly found in AD, more often than in other neurodegenerative diseases.9 Given 
the lack of evidence to hold either amyloid-β or the vasculature fully responsible for the 
development of sporadic AD, it seems likely that it is a multi-factorial disease in which 
amyloid-β, cerebrovascular dysfunction and possibly other factors all play a part. Insight 
into the extent of their roles as well as how amyloid-β and cerebrovascular dysfunction 
influence each other is important to better understand the mechanisms of the disease 
and for the development of therapeutic strategies. However, studying this relation in 
patients is complicated due to a number of reasons. Firstly, although PET and MRI imaging 
techniques exist to directly visualize amyloid-β burden and perfusion in vivo in patients,1,3 
these imaging techniques are not offering sufficient spatial resolution to directly link 
amyloid-β distribution and the microvasculature. Thus, these cellular relations can only 
be characterized end-stage after autopsy. Secondly, the intricate 3D structure of the 
microvasculature complicates its characterization even ex vivo, as conventional histology 
does not allow volumetric imaging. Lastly, amyloid-β can be present in different forms, 
including parenchymal amyloid-β plaques, cerebrovascular amyloid-β and amyloid-β 
oligomers. The latter are soluble, neurotoxic forms of amyloid-β aggregates which in the 
recent years have been shown to correlate better with cognitive decline than parenchymal 
amyloid-β plaques.10 Cerebrovascular amyloid-β is commonly  referred to as cerebral 
amyloid angiopathy (CAA), which has been estimated to co-occur in around 78 % to 
98 % of the AD cases.11 A deeper understanding of the pathophysiology implies that the 
interplay of each structure, i.e., amyloid-β oligomers, cerebrovascular and parenchymal 
amyloid-β, with the brain vasculature is better understood.
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Mouse models can be a useful tool to study the relation between cerebrovascular 
dysfunction and amyloid-β, as tissue can be collected for histology at any age and disease 
stage following in vivo imaging in order to relate imaging outcomes with molecular or 
microstructural phenotypes. Furthermore, the possibility to specifically engineer the 
genome of a mouse has enabled the creation of models that reflect separate disease 
components. By introducing different types of familial AD mutations, models have been 
created that develop either mainly parenchymal plaques,12,13 arteriolar CAA,14 capillary 
CAA15 or oligomers.16 Here, we exploited this benefit of mouse models and studied whether 
the presence of parenchymal amyloid-β plaques influences the morphology or function 
of the brain vasculature. Specifically, we studied the microvascular cerebral blood volume 
(mCBV), the cerebral blood flow (CBF) and the arterial transit time (ATT) in the APPswe/
PS1dE9 amyloidosis model12 at old age and thus with high parenchymal plaque burden. To 
measure the mCBV, the vasculature was imaged post-mortem in 3D with laser scanning 
microscopy after the brain tissue was made transparent with CUBIC (clear, unobstructed 
brain imaging cocktails and computational analysis).17 CBF and ATT were measured in 
vivo with pseudo-Continuous Arterial Spin Labeling (pCASL)-MRI. Our findings indicate 
that the structure and function of the mouse cerebral circulation are not substantially 
disturbed by the presence of parenchymal amyloid-β plaques.
MATERIALS AND METHODS
Animals
This study was carried out in compliance with the European Directive 2010/63/EU on 
the protection of animals used for scientific purposes and reported in compliance with 
the ARRIVE guidelines.18 The experiments were approved by the institution for animal 
welfare of the Leiden University Medical Center in the Netherlands and performed under 
DEC12065. The background strain of all mice in the study was the F2 generation of a 
cross between C57Bl/6J and C3H/HeJ mice. An optical imaging study and an MRI study 
were performed with two separate groups of mice bred in-house. The founder mice were 
acquired at the Jackson Laboratory (Bar Harbor, ME, USA). For optical imaging, 5 APPswe/
PS1dE9 (APP/PS1)[12] transgenic (TG) mice (17 ± 2 months old; 2 female) and 5 wild type 
(WT) controls (18 ± 2 months old; 3 female) were used. In the MRI study, 6 APP/PS1 mice 
(24 ± 1 month old; 6 females) and 6 WT controls (26 ± 1 month old; 4 females) were used. 
The mice were housed together (2–4 per cage) and had access to chow food and water ad 
libitum. The cages were individually ventilated and were provided with bedding material 
and cage enrichment, with a 12 h day/night cycle.
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Microscopy
Brain isolation and tissue processing—Twenty-four hours ante-mortem, the 5 APP/PS1 and 
5 WT mice were i.p. injected with 10 mg/kg methoxy-XO4 (in-house synthesized, 0.05 M 
dissolved in 1:1 DMSO:Cremophor and diluted in PBS to a total volume of 150 μL), a small 
fluorescent molecule that binds to beta-sheets and thereby enables visualization of Aβ 
deposits. The next day, 5 minutes ante-mortem, the mice were i.v. injected with 200 μL 
of 1 mg/mL DyLight 594-labeled tomato lectin (Vector Labs, CA, USA), which binds to the 
endothelium and thereby enables visualization of the vasculature. Subsequently, the mice 
were injected with an i.p. overdose of Euthasol (AST Pharma), followed by opening of the 
chest for intra-cardiac perfusion with 20 mL of ice-cold PBS and 20 mL of ice-cold 4 % PFA. 
The brains were then isolated and fixated further in 4 % PFA. Thereafter, the brain was 
cut in two hemispheres. The left hemisphere was made transparent for imaging, the right 
hemisphere was stored overnight in 30 % sucrose in PBS, snap-frozen in 2-methylbutane 
and stored at -80 °C for later studies. To make it transparent, the left hemisphere was 
treated with the CUBIC clearing protocol, which is described in.19 In short, the hemisphere 
was washed 2 times for 1 hour in PBS at room temperature (RT) to wash away the PFA, 
transferred to a 1:1 mix of PBS and CUBIC solution 1 (25 % urea, 25 % quadrol [N,N,N′,N′-
Tetrakis(2-hydroxypropyl)ethylenediamine, Sigma-Adrich] and 15 % triton weight/weight 
in MiliQ) and incubated with gentle shaking for 6 hours at 37 °C. Thereafter, the 1:1 mix 
was replaced with pure CUBIC solution 1 and incubated for 8 days at 37 °C with gentle 
shaking. During this time, the solution was replaced every 2 days. Afterwards, the CUBIC 
solution 1 was washed away with 6 PBS washes over the course of 6 hours and the brain 
tissue was then incubated overnight at RT with a 1:1 mix of PBS and CUBIC solution 2 
(50 % sucrose, 25 % urea and 10 % TEA [Triethylamine, Sigma-Aldrich] weight/weight in 
MiliQ). The next morning, the mix of PBS and solution 2 was replaced with pure CUBIC 
solution 2, and further incubated for 2 days with gentle shaking at 37 °C. The solution 
was refreshed once after 1 day. The result of the clearing procedure in terms of tissue 
transparency is illustrated in figure 1.
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Before clearing After clearing
3.0 mm
Figure 1: Effect of CUBIC clearing on tissue transparency and penetration depth with imaging. On 
the top left, a hemisphere is shown before clearing; on the top right the same hemisphere 
after clearing. On the bottom left, an orthogonal view from a representative Z-stack is 
shown, acquired in an uncleared hemisphere. On the bottom right, an orthogonal view 
from a representative Z-stack acquired in a cleared hemisphere, with similar acquisition 
parameters. Note the increase in penetration depth when imaging cleared tissue. The 
Z-stacks were acquired at the level of the thalamus, in sagittal orientation, without laser
power compensation over imaging depth.
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Image acquisition—The hemisphere was imaged in sagittal orientation in a 1:1 mix of 
silicone oil (Sigma, product number 175633) and mineral oil (Sigma, product number 
M8410) with a Zeiss LSM 710 NLO laser scanning microscope. A Zeiss 20x Clr Plan-
Apochromat objective (NA = 1.0; WD = 5.6 mm; Corr nd = 1,38) and a motorized stage 
were used, allowing imaging deep into the tissue together with full-brain coverage in 
the XY-direction. The methoxy-XO4 and DyLight594 were simultaneously excited with a 
multiphoton Ti:Sapphire laser (Mai Tai, Spectra Physics) at 800 nm and their emission 
was filtered and detected with a Zeiss non-descanned Binary GaAsP PMT detector (BiG.2) 
equipped with two filters (green 500–550 nm and red 570–610 nm). Even though the 
hardware of the microscope allowed imaging with sub-micrometer axial resolution, the 
axial resolution was limited to 3.32 μm, with a 9.96 μm step size. This was done to find a 
trade-off between data quality on the one hand and acquisition time and file size on the 
other hand, which were around 2.5 days and 10 GB per sample, respectively.
Image processing—The resulting Z-stacks were flat-field corrected using a custom macro in 
ImageJ and stitched with the Grid/Collection plug-in20 in ImageJ, using the stage coordinates 
as initialization. Stage coordinates were extracted from the metadata of the Zeiss (.czi) 
file using a custom Python script. Methoxy-XO4 has a very wide emission spectrum, 
therefore amyloid plaques were visible in both the green and red channel (data not shown). 
DyLight-594 has a narrow emission spectrum and was thus visible in the red channel only. 
To remove the methoxy-XO4 fluorescence from the red channel, the green channel was 
first subtracted from the red channel, also for the WT mice for the sake of comparability. 
Vessel segmentation was performed with the subtracted data using an Otsu threshold. One 
mouse (male, WT) had to be excluded from further analysis, due to wrong segmentation, 
which was the result of a low SNR in the raw data, probably a result of inadequate i.v. lectin 
injection. After segmentation, the blood volume in the brain was mapped using patches 
of 15 x 15 x 5 voxels in which the volume percentage of vessel-segmented voxels was 
determined, resulting in mCBV maps with 50 μm3 isotropic resolution. To retrieve Atlas-
based regions of interest (ROIs), the stitched and shading-corrected data (red channel only, 
before subtraction) was downsampled to 50 μm3 isotropic resolution and registered to 
the Allen Brain template using EVolution, an edge-based variational non-rigid multi-modal 
image registration method.21 Six different ROIs were chosen from the Allen Brain template 
and propagated to the blood volume maps of each individual mouse. This process was 
verified and adjusted if needed by a user (LPM). If a large vessel was present in a brain 
region, this resulted in patches with a high blood volume (> 15 %, see red arrow in 
figure 2). To avoid such macro-vascular contribution to the regional blood volume values, 
only voxels with values below 15 % of blood volume were included in the analysis. The 
impossibility to place the brain tissue exactly orthogonal below the microscope objective 
resulted in oblique optical sectioning (supplementary figure 1). Also, decreasing signal 
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intensity values were observed when deeper parts of tissue were imaged, even though 
the brain tissue was CUBIC cleared (figure 1). This resulted in decreasing mCBV values 
over imaging depth. Together with the oblique optical sectioning, this led to mCBV maps 
with an axial gradient due to differing quantities of tissue present above different tissue 
regions in one slice (supplementary figure 1). Alignment of the tissue in the Z-direction 
with a custom MATLAB script removed this axial gradient, but maintained the gradient 
in the Z-direction, starting after around 10 slices/500 μm (supplementary figure 2). The 
analysis was therefore restricted to the upper 500 μm of tissue.
MRI 
The 6 APP/PS1 and 6 WT control mice were scanned with a Bruker 7 T PharmaScan 
(Ettlingen, Germany) and a 23 mm volume coil, using the same protocol as described 
in.22 The 6 WT mice were the same as used in.22 In short, the following protocol was used:
Animal preparation—the mice were anesthetized with 3.5 % isoflurane (Pharmachemie 
BV, Haarlem, Netherlands) for induction and 1.5-2.0 % for maintenance in a 1:1 mix of 
air and oxygen, to keep breathing rates around 100 bpm. The temperature was kept at 
37 °C with a feedback-controlled waterbed (Medres, Cologne, Germany).
Image acquisition—Anatomical T2-weighted (T2W) images were first acquired in all three 
orientations with a standard Bruker T2RARE sequence for planning the ASL sequences and 
for registration purposes. Thereafter, the pCASL interpulse phase-increase was optimized 
with pre-scans, as described before.23 Then, two pCASL sequences were acquired, one 
optimized for measuring CBF (standard pCASL), the other for measuring ATT (time-encoded 
pCASL [te-pCASL]). The standard pCASL consisted of 60 pairs of label and control scans 
with a labeling duration of 3000 ms, a constant post-labeling delay (PLD) of 300 ms and a 
total scan time of 7 minutes. The te-pCASL consisted of a 45 times averaged Hadamard12-
encoded labeling block with a sub-bolus labeling duration of 50 ms and 11 effective PLDs 
(30 ms till 530 ms with 50 ms spacing per PLD) and a total scan time of 7 minutes. Both 
pCASL scans were followed by a 3-slice coronal spin echo EPI readout with identical 
parameters (17 ms echo time, 0.224 × 0.224 mm² in-plane resolution, 1.5 mm slice 
thickness and a 1 mm slice gap). To aid quantification, an inversion-recovery scan and a 
flow-compensated, pCASL-encoded FLASH sequence were additionally acquired for every 
mouse to measure the tissue T1 and the labeling efficiency, respectively. One mouse (TG, 
female) had to be excluded from further analysis, as it died during the scan, probably a 
result of fragility due to old age.
Image processing—The individual EPIs from both ASL sequences were first aligned to 
the first EPI of the standard pCASL scan to compensate for motion during the scans. 
Six different ROIs (auditory/visual cortex, sensory cortex, motor cortex, hippocampus, 
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thalamus and striatum) were manually drawn on the anatomical images of one arbitrarily 
chosen mouse (reference dataset), and propagated to the anatomical images of the other 
animals after registration to the reference dataset. The anatomical images, T1 maps and 
te-pCASL scans of all mice were registered to the first EPI of their standard pCASL scan, 
allowing the propagation of the ROIs to all MRI sequences. All steps were performed in a 
coarse-to-fine manner using the Elastix image registration toolbox24 and verified by two 
independent observers. Buxton’s kinetic perfusion model25 was used to calculate the CBF 
and ATT. The CBF was derived from the averaged signal difference between the label and 
control (ΔM) scans from the standard pCASL sequence. The ATT was retrieved after fitting 
the 11 effective PLDs from the te-pCASL sequence to the perfusion model.
Statistics
For both the microscopy and the MRI data, a mixed ANOVA was used to test whether 
there was a significant effect of either the genotype or the brain region on the outcome 
measures mCBV, CBF and ATT. Because Mauchly’s test of sphericity was significant in 
the CBF data, the degrees of freedom for the F-distribution were Greenhouse-Geisser 
corrected. For ATT and mCBV data, Mauchly’s test was not significant, thus sphericity was 
assumed for the degrees of freedom of the F-distribution. Statistical testing was done 
using IBM SPSS statistics 23 software (Armonk, New York, NY, USA).
RESULTS
mCBV mapping
A clear improvement in tissue transparency and imaging depth was seen after brain tissue 
was treated with CUBIC (figure 1). Representative WT and TG examples of cerebrovascular 
and amyloid-β plaque labeling are shown in the left column in figure 2, confirming that 
plaques are present in TG mice only. In the vicinity of these plaques, no noticeable 
morphological changes could be observed in the capillary bed at the spatial resolution 
set, see vessels indicated with arrowheads in 2d and additional examples in supplementary 
figure 3. For the quantitative analysis of the mCBV in the volume of hemisphere imaged, 
the cerebrovascular signal was first segmented with the application of an Otsu threshold 
(middle column in figure 2). Thereafter, the density of positively segmented voxels was 
mapped in patches of 50 μm3 isotropic resolution (right column in figure 2). This enabled 
comparison of blood volumes between WT and TG mice. In figure 3, the first slice of the 
aligned mCBV maps of all the mice in the study are shown. mCBV estimates were retrieved 
from 6 different brain regions after registration to the Allen Brain atlas and ranged between 
2-5 % (figure 4). No significant difference in mCBV was found between the APP/PS1 and 
the WT (F[1,7] = 166; p = 0.40), but there was a significant effect of brain region on mCBV 
(F[5,35] = 43.2; p < 0.001), with the highest blood volume in the thalamus (4.9 % average 
in WT), and the lowest in the white matter (2.0 % average in WT).













































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3: Microvascular Cerebral Blood Volume (mCBV) maps of all mice in the study. The left column 
represents wild type (WT) mice, the right column transgenic (TG). All maps represent the 
most superficial mCBV map with respect to the microscope objective.
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Figure 4: Microvascular Cerebral Blood Volume (mCBV) quantification. mCBV is quantified in 6 brain 
regions and full brain. Circles (WT) and squares (TG) represent individual mice, stripes rep-
resent group averages.
CBF and ATT mapping
Characteristic CBF maps for both WT and TG mice are shown in figure 5a. The CBF was 
compared between WT and TG mice in the 6 different brain regions as displayed on an 
anatomical T2W image in figure 5b. Representative ATT maps for both genotypes are 
shown in figure 6a. ATT was also compared between WT and TG mice in the same brain 
regions. No differences were observed in either CBF or ATT between the APP/PS1 mice 
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and the WT mice (F[1,9] = 2.06; p = 0.19 & F[1,9] = 0.056; p = 0.82 respectively). Similar 
as in the mCBV data, there was a significant effect of brain region on both CBF and ATT 
(F[1.70,15.0] = 4.62; p = 0.031 & F[5,45] = 84.2; p < 0.001 respectively).
DISCUSSION
Alzheimer’s disease is characterized by the presence of neuropathological amyloid-β 
accumulations and is associated with cerebrovascular dysfunction.2,7 The exact contributions 
of both on AD onset and their interplay are currently not well known and are difficult 
to study in humans. Mouse models of disease can provide valuable information, as 
microstructural tissue characterization with histology can be performed following in 
vivo imaging. Also, the many different mouse models reflecting different characteristics 
of AD allow studying the relation between different aspects of the disease. Here, we 
performed in vivo MR imaging and post-mortem microscopy in a large 3D volume in the 
APP/PS1 amyloidosis model, which develops extensive amyloid-β plaque accumulation 
in the brain parenchyma and to a lesser extent CAA on the leptomeningeal arteries.26 
The CUBIC clearing protocol together with the implemented image processing pipeline 
allowed characterizing amyloid-β plaques and the microvasculature in 3D, including the 
quantification of the microvascular blood volume in a brain slab of 0.5 mm and direct 
observation of the effect of plaques on the vasculature. In vivo, the perfusion parameters 
CBF and ATT were measured using ASL-MRI. Given the many connections that have been 
made between amyloid-β and cerebrovascular dysfunction, it seems remarkable that in 
this study, no cerebrovascular dysfunction was observed using two imaging modalities 
in aged APP/PS1 mice with high amyloid burden.
In contrast to our finding, a reduction in CBV has been reported in AD patients compared 
to non-demented elderly controls.4,5 A direct capillary loss might underlie this reduction, 
which has indeed been reported in some but not all [30] histology studies based on 
human AD brain tissue. Another possible underlying cause of decreased CBV is capillary 
constriction. Recently, amyloid-β oligomers have indeed been shown to constrict capillaries 
in live human brain tissue, and localized capillary constriction was also observed in post-
mortem fixed AD brain slices [31]. Changes in CBF have been associated with AD as well. 
A wealth of studies have shown this, where in the prodromal phase, CBF was shown to be 
increased, and decreased when clinical symptoms are overt (for a review see [3]). Similar 
capillary affliction as described above may underlie this decrease in CBF in cognitively 
impaired AD patients, but arteriolar dysfunction may also play a role. Reasons for the 
latter could be arteriolar CAA and/or atherosclerosis.9 























cortex Hippocampus Striatum Thalamus
Figure 5: Cerebral blood flow (CBF) maps and CBF values from the MRI data. (a)—CBF maps (three 
slices) are shown from an average wild type (WT) mouse on the upper row and an average 
transgenic (TG) mouse on the second row. (b)—Spatially corresponding anatomical imag-
es are shown, with the ROIs indicated in which CBF was quantified. (c)—The resulting CBF 
values are shown in a graph, where circles (WT) and squares (TG) represent individual mice 
and stripes represent group averages. AV = auditory/visual.
4
























cortex Hippocampus Striatum Thalamus
Figure 6: Arterial Transit Time (ATT) maps and ATT values from the MRI data. (a)—ATT maps (three 
slices) are shown from an average wild type (WT) mouse on the upper row and an average 
transgenic (TG) mouse on the second row. (b)—Spatially corresponding anatomical im-
ages are shown, with the ROIs in which ATT was quantified. (c)—The resulting ATT values 
are shown in a graph, where circles (WT) and squares (TG) represent individual mice and 
stripes represent group averages.
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In mouse models of amyloidosis, it is ambiguous how CBV and CBF evolve. CBF has been 
shown to decrease,32-38 not change36,39,40 or transiently increase41 when compared to 
age-matched WT mice. Studies with some models show reduced capillary density,42,43 
while studies with other models show preserved capillary density.40,41,44 Regarding the 
diameter of the microvasculature, both capillary constriction31 and capillary dilation41 have 
been reported. An important flipside of the wide variety of models available is thereby 
illustrated: results obtained in one mouse model are not generalizable to other models, 
let alone to patients. On the other hand, the different models may help us understand 
the possible consequences of different types of amyloid-β accumulation. Interestingly, 
all studies that report no change or transiently increased CBF are performed with a 
model with a PS1 insertion.36,39-41 The question then arises whether the PS1 insertion by 
some means protects the cerebral vasculature. Important features of models with an 
additional PS1 insertion are a shift in the amyloid-β-40:amyloid-β-42 ratio towards the 
more hydrophobic amyloid-β-42, as well as early and aggressive parenchymal plaque 
development.45 An increase in hydrophobicity of the amyloid-β monomers has been 
hypothesized to lead to increased hydrophobicity of the oligomers, resulting in increased 
binding to cell membranes and increased neurotoxicity.46 In the same way, it could be 
hypothesized that the increased hydrophobicity of oligomers reduces the movement of 
oligomers from the parenchyma to the vasculature, thereby decreasing the constrictive 
effects of amyloid-β on the vasculature. Indeed, in [36], where three amyloidosis models 
were directly compared, two models with CAA and without PS1 insertion showed a CBF 
decrease, and one without CAA and with PS1 insertion did not show a decrease in CBF.
There is much less data available on the relation between ATT and AD. One study in patients 
shows ATT is preserved in AD patients,47 whereas another shows a regional ATT increase.48 
To the best of our knowledge, no pre-clinical studies exist with amyloidosis mouse models 
and ATT. But given the lack of differences in mCBV and CBF, it is not surprising that no 
differences were found in ATT. 
From the brain regions analyzed, the mCBV values found were highest in the thalamus and 
lowest in the white matter, which is in agreement with other studies.49-51 There was however 
a large inter-animal variation in absolute mCBV values. For example, the mCBV values 
in the thalamus were between 3 and 6 % in WT mice, which is unlikely due to biological 
variation only. Some of this high variation may be due to varying quantities of lectin that 
effectively arrived in the brains of the different mice after the 200 μL i.v. injection, thereby 
creating differences in vessel wall labeling efficiency between animals. Correcting for such 
differences is complicated, as it is difficult to disentangle vessel wall labeling efficiency 
differences from true blood volume differences. However, since amyloid-β pathology is 
present in certain brain regions only, blood volumes could be normalized to un-affected 
brain regions such as the hypothalamus or cerebellum. This did not change the outcome 
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however, as the APP/PS1 and WT mice still showed similar mCBV values after normalization 
to the hypothalamus or cerebellum (data not shown).
Despite the large volumes of tissue that were imaged, only a small number of biological 
replicates was used, which is the largest limitation of this study. The absence of significant 
differences between APP/PS1 mice and WT control mice suggests that parenchymal 
amyloid-β plaques have little or no effect on the structure and function of the cerebral 
vasculature, at least in mice. However, trends could be observed towards lower mCBV and 
cortical CBF in the APP/PS1 mice. If these were true, and not due to noise and/or natural 
variation, they could become significant with larger group sizes. The size of the trend 
towards lower cortical CBF in this study (10-20 %) is however not on par with the observed 
CBF decrease in the clinic (42 %).52 Additionally, one important difference between this 
mouse model and AD patients is the lack of cerebral atrophy, despite the high amyloid 
burden. As atrophy is often hypothesized to contribute to cerebral hypoperfusion,53 our 
observations do not discount this possibility.
Furthermore, the age- and gender distribution was not fully equal between the groups, 
where the WT group contained 1 more male and was 1 month older in the microscopy 
study, and 2 more males and 2 months older in the ASL-MRI study. Preferably, age 
and gender would have been completely equal. Indeed, gender is known to influence 
cerebrovascular factors such as stroke risk and outcome.54,55 Furthermore, female mice 
have shown higher rates of amyloid-β accumulation.56 However, baseline brain perfusion 
and blood volume have been reported to be similar in male and female mice,55,57 and all 
transgenic mice showed advanced amyloid-β pathology, making it unlikely that our data 
was heavily biased by the gender difference. Also, brain perfusion has been shown to be 
stable in wild type adult mice,22,36 reducing the likelihood of an age bias. Moreover, there 
was no trend observable in the data towards lower or higher mCBV, CBF or ATT with age or 
gender (not shown). Another limitation of this study is the relatively low resolution used, 
which might not be sufficient to detect small constrictions in capillary diameter, especially 
if these were to be focal constrictions. It should also be taken into account that red blood 
cells could be hindered by such focal constrictions, lowering the local hematocrit, but 
leaving the mCBV, CBF and ATT unchanged. Further research could include imaging small 
areas at higher resolution to be able to detect such small changes. Also, despite the 3 to 
4 mm thickness of imaged tissue, only 0.5 mm was used for mCBV quantification, due to 
dropping SNR values with deeper tissue areas. Possibly, further optimization of the tissue 
clearing and/or imaging could improve the SNR in deeper tissue and thereby improve the 
mCBV mapping. In our hands however, changing the clearing method to a method that 
results in tissue with a lower refractive index (RI) (e.g. ScaleA58 or PACT59) did not give 
better results, due to extensive tissue expansion (data not shown). The expansion strongly 
drives up image acquisition times, whereas effectively, similar sizes of tissue are imaged 
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when corrected for the expansion. Changing to a clearing method resulting in higher 
tissue RI such as 3DISCO60 would be sub-optimal given the RI of the microscope objective 
used here would require the use of solvents that are not compatible with the objective.
In summary, tissue clearing followed by microscopy of the brain vasculature and in vivo 
ASL-MRI was used in this study to measure cerebrovascular morphology and function 
in the APP/PS1 mouse model of amyloidosis with high parenchymal plaque burden. 
No changes were measured with either of the two imaging modalities, indicating that 
structure and function of the in the mouse brain vasculature are not heavily affected 
by the presence of amyloid-β plaques. The observed cerebrovascular dysfunction in AD 
patients may therefore not be much related to the presence of amyloid-β plaques, but 
originate more from other amyloid-β species such as oligomers and CAA, and/or from 
other non-amyloid-β-related factors.
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Supplementary figure 1: Oblique optical sectioning of the microvascular Cerebral Blood Volume 
(mCBV) maps, showing an axial gradient in mCBV values.
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Supplementary figure 2: Aligned microvascular Cerebral Blood Volume (mCBV) maps, showing 
decreasing mCBV values with increasing imaging depth.
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ABSTRACT
Impaired cerebrovascular function is an early biomarker for cerebral amyloid angiopathy 
(CAA), a neurovascular disease characterized by amyloid-β accumulation in the cerebral 
vasculature, leading to stroke and dementia. The transgenic Swedish Dutch Iowa 
(Tg-SwDI) mouse model develops cerebral microvascular amyloid-β deposits, but whether 
this leads to similar functional impairments is incompletely understood. We assessed 
cerebrovascular function longitudinally in Tg-SwDI mice with arterial spin labeling 
(ASL)-MRI and laser Doppler flowmetry (LDF) over the course of amyloid-β deposition. 
Unexpectedly, Tg-SwDI mice showed similar baseline perfusion and cerebrovascular 
reactivity estimates as age-matched wild type control mice, irrespective of modality (ASL 
or LDF) or anesthesia (isoflurane or urethane and α-chloralose). Hemodynamic changes 
were however observed as an effect of age and anesthesia. Our findings contradict 
earlier results obtained in the same model and question to what extent microvascular 
amyloidosis as seen in Tg-SwDI mice is representative of cerebrovascular dysfunction 
observed in CAA patients.
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INTRODUCTION
Cerebral amyloid angiopathy (CAA) is a neurovascular disease characterized by accumulation 
of the amyloid-β peptide in the brain vasculature, which ultimately leads to stroke and 
cognitive decline.1 In both hereditary and sporadic variants of CAA, measurements in 
patients have shown that impairments in cerebrovascular function can be found early 
in the disease process.2,3 These measurements were performed with BOLD-fMRI and a 
visual stimulation paradigm, allowing to characterize the cerebrovascular response to 
neuronal activation in the occipital cortex, where visual processing occurs. The occipital 
cortex is also where CAA burden is highest,4 likely contributing to the sensitivity of the 
fMRI measurement.
Mouse models of cerebral amyloidosis are invaluable tools for testing safety and 
effectiveness of greatly needed novel therapies for amyloid-β-related diseases, including 
CAA. However, for the results to be translatable to the clinic, it is essential that the 
amyloidosis model shows similar structural and functional phenotypes as the patient. 
The transgenic Swedish Dutch Iowa (Tg-SwDI) mouse model is an amyloidosis model 
expressing low levels of the human amyloid-β precursor protein (APP) gene with 3 familial 
mutations, of which the Dutch and Iowa mutations are located in the amyloid-β coding 
region of APP.5 The neuronal expression of the mutated APP in this model leads to early 
amyloid-β accumulation in the brain, starting around 6 months. Amyloid-β accumulates 
predominantly around capillaries in the Tg-SwDI model, which is similar to a subtype of 
CAA pathology observed in pathological examinations of patient tissue and sometimes 
referred to as capCAA.6 It is unknown to what extent amyloid-β accumulation around 
capillaries contributes to the observed impairments in cerebrovascular function in patients. 
Unlike patients, vascular pathology in the Tg-SwDI model is most severe in the thalamus.7 
Previous studies have measured cortical vascular reactivity using laser Doppler flowmetry 
(LDF) after removal of the skull in Tg-SwDI and wild type (WT) mice. They reported, similar 
to CAA patients, early impairments in CVR in Tg-SwDI mice.8,9  It is unknown however, 
whether skull removal has affected the outcome, and whether the thalamus is more 
strongly affected, as the thalamus is not readily accessible with LDF. 
Here, we therefore used the non-invasive arterial spin labeling (ASL)-MRI technique to study 
the cerebrovascular function in the Tg-SwDI brain. With ASL, arterial blood is magnetically 
labeled and used as endogenous tracer flowing into the tissue of interest, which is most 
often the brain. The distribution of the label over the different brain regions reflects local 
tissue perfusion and can be converted into absolute cerebral blood flow (CBF) values, 
expressed as mL/100 g/min. When combined with a hypercapnic challenge, both CBF and 
CVR can be determined for different brain regions. A known unfavorable characteristic 
of ASL is a possible underestimation of CBF in case of slow flow. In that case, a delayed 
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Arterial Transit Time (ATT) – the time that it takes for the label to travel from the labeling 
plane to the brain tissue – could be misinterpreted as decreased CBF. ATT evaluation is 
therefore valuable to prevent a potential underestimation of the ASL-based CBF estimates, 
as well as indicative in itself of vascular pathology.10
The non-invasive nature of ASL was fully exploited in our study with the use of a longitudinal 
study design in which CBF and CVR were repeatedly measured during increasing 
amyloid-β accumulation in the brain vasculature of Tg-SwDI mice. As it is conceivable 
that high microvascular amyloid burden could lead to delayed ATT in Tg-SwDI mice, an 
ATT measurement was added to the protocol by means of a modified ASL sequence 
optimized to capture the inflow of the tracer into the brain tissue.11 To allow for repeated 
measurements, a minimally invasive isoflurane anesthesia protocol was used. Moreover, 
to be able to compare the results to literature, additional end-point measurements were 
performed under a terminal anesthesia protocol with urethane and α-chloralose (U&A). 
Furthermore, a subgroup of mice was used to directly compare ASL-MRI to LDF. The study 
design is summarized in Figure 1.
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Figure 1: Study design. Two different cohorts were used in this study, of which the first was followed 
longitudinally. The timeline of the first cohort is illustrated in the upper part of the figure, 
with scan moments indicated with orthogonal arrows projected onto the time line. The 
most relevant scans performed at these moments are indicated within the boxes adjoined 
to the orthogonal arrows and the type of anesthesia used is indicated in italic on top of 
the boxes. The lower part of the figure illustrates the single time point measurements per-
formed in cohort 2. pCASL = pseudo-continuous arterial spin labeling; te p. = time-encod-
ed pseudo-continuous arterial spin labeling; U&A = urethane and α-chloralose; LDF = laser 
Doppler flowmetry.
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RESULTS
Hypercapnia consistently induced a CBF increase in both WT and Tg-SwDI mice under 
isoflurane anesthesia (Figure 2 and Figure 3), which was mainly located in cortical regions 
(Figure 2)). Surprisingly, the CBF maps and CBF time profiles acquired in the mid-brain of 
the Tg-SwDI mice resembled those of the WT mice at every time point. Hence no significant 
differences were observed in baseline CBF nor CVR between the two genotypes at any 
time point (Figure 3b; see Figure 3-figure supplement 1 for individual animal trends). A 
significant effect of age on CBF was however observed in both WT and Tg-SwDI mice, χ2(3) 
= 13.00, p = 0.005 and χ2(3) = 8.49, p = 0.037, respectively. Post-hoc analysis indicated that 
this was attributable to a decrease in baseline CBF between the ages of 3 and 6 months. 
Between these time points, median (iqr) CBF significantly decreased from 155 (143-159) 
to 121 (112-124) mL/100 g/min in WT mice, p = 0.008. In Tg-SwDI mice, a similar trend was 
observed, from 147 (133-151) to 126 (103-135) mL/100 g/min, p = 0.036, but this was not 
significant (cut-off p-value of 0.017 after Bonferroni correction). From 6 months of age, the 
baseline CBF remained stable inside each group. Age also had a significant effect on CVR 
in WT mice, χ2(3) = 8.33, p = 0.040. No differences were observed with post-hoc analysis 
however, besides a trend towards increased CVR between the ages of 3 and 6 months, 
from 13 (7-17) to 31 (23-37) %, p = 0.038. Age had no significant effect on CVR in Tg-SwDI 
mice, χ2(3) = 6.94, p = 0.074. Additional analysis in cortical and thalamic areas did not 
reveal any difference between WT and Tg-SwDI mice either (Figure 3-figure supplement 
2). Similarly, no differences were observed in brain volume, body weight, change in tc-
pCO2 upon the hypercapnia challenges, respiration rate and inversion efficiency between 
WT and Tg-SwDI mice (Figure 3-figure supplement 1, Figure 3-figure supplement 3 and 
Figure 3-figure supplement 4). Of note, the CBF at 12 months showed higher variability 
in the WT group, and the body weights showed higher variability in the Tg-SwDI group.
Median (iqr) baseline ATT values in the mid-brain were also similar for both WT and Tg-SwDI 
mice, i.e. 206 (186-240) milliseconds (ms) and 223 (202-246) ms respectively at 12 months 
of age (Figure 4). The hypercapnia challenge shortened the ATT to 192 (189-205) for WT 
and 197 (187-207) for Tg-SwDI mice, which was significant for Tg-SwDI mice (Z = -2.20  and 
p = 0.028), but did not reach significance for WT mice (Z = -1.84 and p = 0.066). 
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Figure 2: Average mid-brain cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) 
maps for wild type (WT) and transgenic Swedish Dutch Iowa (Tg-SwDI) mice in cohort 
1. From left to right, the different ages are displayed. From top to bottom, respectively CBF 
maps at baseline, CBF maps during CO2 and CVR maps are displayed, with WT and Tg-SwDI 
mice alternating per row. On the bottom row, an anatomical MRI scan of the same brain
slice is shown. Note that the CBF increase during the CO 2  challenge is most profound in the 
cortex, and that the WT and Tg-SwDI mice show similar CBF and CVR maps. 
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Figure 3: Cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) values acquired in 
the mid-brain in cohort 1. A) displays 21-minute CBF time profiles (mean ± standard de-
viation) that were retrieved in a full mid-brain slice at the ages of 3,6,9 and 12 months old 
shows for wild type (WT) and transgenic Swedish Dutch Iowa (Tg-SwDI) mice. CO2 was 
administered between minute 7 and 14.B ) shows boxplot representations of baseline CBF 
(average of the last 2.3 minutes before the start of CO2 administration) and CVR (ratio of 
average of the last 2.3 minutes during CO 2 to baseline CBF). Circles and squares represent 
individual mice. No significant differences were observed between the two genotypes, 
but there was a significant effect of age (Friedman test, p = 0.005 for CBF in WT, p = 0.037 
for CBF in TG, p = 0.040 for CVR in WT). From the post-hoc analysis, only the drop in CBF 
in WT mice between 3 and 6 months old (p = 0.008) reached the Bonferroni-corrected 
significance threshold (p = 0.017).
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To evaluate if a functional deficit could have been masked by the vasodilatory effect of 
isoflurane during the MRI sessions, additional CBF and CVR measurements were performed 
in the same cohort of mice under urethane and alpha-chloralose (U&A) anesthesia. This 
was done at 12.3 months, 10 days after the last MRI measurement under isoflurane. The 
change of anesthesia protocol resulted in profound hemodynamic changes: baseline CBF 
was markedly reduced and the hypercapnic response was higher in amplitude, but also 
slower (Figure 5a), and more widespread in the brain tissue (Figure 5b). The CBF and CVR 
estimates were indeed significantly impacted by the change in anesthesia protocol (Figure 
5c), with the median CBF (iqr) decreasing from 126 (84-141) to 28 (26-30) mL/100 g/min 
in WT mice, Z = -2.67 and p = 0.008, and median (iqr) CVR increasing from 26 (6-47) to 
233 (193-245) %, Z = -2.67 and p = 0.008. These changes were again comparable to those 
in Tg-SwDI mice, with the median CBF (iqr) and CVR (iqr) respectively changing from 114 
(103-130) to 25 (21-40) mL/100 g/min, Z = - 2.37 and p = 0.018, and from 30 (17-34) to 
265 (178-312) %, Z = -2.37 and p = 0.018. The CBF response at the induction phase of 
U&A anesthesia was also similar in Tg-SwDI and WT mice (Figure 5-figure supplement 1). 
The higher CVR during U&A was unlikely due to a higher CO2 absorption, as the tc-pCO2 
responses to the hypercapnia challenges only increased from an average of 15 mmHG 
during isoflurane to an average of 19 mmHG during U&A (Figure 5-figure supplement 2). 
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Figure 4: Arterial Transit Time (ATT) measurements acquired in the mid-brain of 12-months 
old wild type (WT) and transgenic Swedish Dutch Iowa (Tg-SwDI) mice. On the top 
row, measurements acquired at baseline are displayed, on the bottom row measurements 
acquired while administering 7.5 % CO2. On the left column, graphs display the measured 
arterial spin labeling (ASL) signal (mean ± standard deviation) plotted against increasing 
post-label delay times. In the middle, maps are displayed that show averaged arrival times 
of the ASL signal. The maps were acquired in a mid-brain slice and are averaged for WT 
(top) and Tg-SwDI mouse (bottom). On the right, boxplot representations of the ATT values 
obtained in all mice are displayed, where circles and squares represent individual mice.
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Figure 5: Cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) acquired during 
isoflurane anesthesia and urethane & α-chloralose (U&A) anesthesia. A) displays 
21-minute CBF time profiles acquired in the mid-brain in wild type (WT) and transgenic 
Swedish Dutch Iowa (Tg-SwDI) mice under either isoflurane anesthesia (left, 12 months 
old) or U&A anesthesia (right, 10 days later in the same mice). CO2 was administered be-
tween minute 7 and 14. B) displays mid-brain CBF and CVR maps averaged for WT (top) 
and Tg-SwDI (bottom) mice. Note that the CVR maps during U&A anesthesia are scaled 
differently than the CVR maps under isoflurane due to the marked difference in CVR. C) 
displays boxplot representations of the baseline CBF and CVR group values, where dots 
and circles represent individual mice.
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An additional smaller second cohort of mice was used to cross-validate our MRI findings with 
the previously used LDF readout as imaging modality to assess cerebrovascular function 
in this mouse model.8,9 After a unilateral craniotomy (right side), LDF measurements were 
performed with two probes at the same time: one through the skull in the left hemisphere 
and the other directly above the brain tissue in the right hemisphere. MRI measurements 
were performed directly after the LDF measurement in the same mice and the brain region 
analyzed with the MRI data was restricted to the somatosensory cortex, where the LDF 
measurements were also collected. No differences in CVR could be observed between 
WT and Tg-SwDI mice, neither with MRI, nor with LDF (Figure 6). Of note, removal of the 
skull severely reduced the CVR for both imaging modalities (Figure 6-figure supplement 1).
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Figure 6: Cerebral blood flow (CBF) time profiles acquired with laser Doppler flowmetry (LDF) 
and Arterial Spin Labeling (ASL)-MRI. On the left, 21-minute CBF time profiles acquired 
with LDF in the somatosensory cortex are displayed for wild type (WT) and transgenic 
Swedish Dutch Iowa (Tg-SwDI) mice. In the middle, 21-minute CBF time profiles are dis-
played that are acquired with ASL-MRI in the left somatosensory cortex, after baseline cor-
rection, so the profiles can be compared to the LDF time profiles. On the right are the same 
profiles as in the middle, without baseline correction. 
Lastly, the brain tissue was stained for amyloid-β to assess the degree of pathological 
burden. All Tg-SwDI mice developed extensive amyloid-β plaque pathology by the end of 
the experiment, with mainly diffuse parenchymal plaques in the cortex and microvascular 
plaques in the hippocampus and thalamus, but none of the WT mice displayed any 
amyloid-β deposition (Figure 7). 
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Figure 7: Amyloid-β histology. Shown are representative stainings of wild type (WT) and transgen-
ic Swedish Dutch Iowa (Tg-SwDI) mice of 12.3 months old. The upper row is an overview 
image, the other rows are zoomed in regions from the overview image.
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DISCUSSION
This longitudinal study characterized cerebrovascular function in the Tg-SwDI mouse model 
of microvascular amyloidosis over the full course of amyloid-β pathogenesis. No significant 
impairment in cerebrovascular function could be found in the Tg-SwDI model, no matter 
the age or functional parameter explored. This contradicts previous findings, which showed 
early impairments in cerebrovascular reactivity (CVR) in the cerebral cortex in Tg-SwDI mice 
using LDF.8,9 In our study, cerebrovascular function was first assessed using Arterial Spin 
Labeling (ASL)-MRI and a CO2 challenge, allowing to measure absolute CBF as well as CVR 
in the entire brain. The ASL-MRI perfusion data were acquired longitudinally using a low-
level isoflurane anesthesia protocol to capture the dynamics of decreasing cerebrovascular 
function over increasing microvascular amyloid-β loads. This study setup was substantially 
different from literature studies, where relative CBF measurements performed using LDF 
under a terminal anesthesia protocol with urethane and α-chloralose (U&A), after removal 
of the skull, showed impaired hemodynamics in the Tg-SwDI mouse model.8,9 Therefore, 
additional experiments were performed to determine whether differences in experimental 
design could explain this discrepancy. A likely candidate was the difference in anesthesia 
protocol, as this has been shown to significantly influence CVR experiments.12,13 Another 
likely candidate was the difference in imaging modality, as ASL-MRI and LDF are sensitive 
to different blood components, namely flux of blood plasma (ASL-MRI) or velocity of red 
blood cells (LDF). However, after differences in anesthesia protocol and imaging modality 
were accounted for, cerebrovascular function was in our hands still found to be preserved 
in the Tg-SwDI model. Practically, it is very difficult to replicate an experiment up to the 
smallest detail in a different laboratory, as small differences might remain. However, 
by showing similar findings for two modalities and two anesthesia protocols, including 
the ones used before, we think that our study convincingly shows that microvascular 
amyloidosis in the Tg-SwDI mouse model does not induce cerebrovascular dysfunction. 
Moreover, the robustness to sense local hemodynamic changes could be confirmed based 
on the observed reduced CBF and CVR as a function of age and anesthesia. The CBF time 
profiles of Tg-SwDI mice were in fact remarkably similar to their wild type controls, even 
when CBF was monitored for up to 1.5 hours (Figure 5-figure supplement 1). Everything 
considered, our functional results indicate that the causal link between microvascular 
amyloidosis and cerebrovascular function, which was established in past studies in the 
Tg-SwDI model, is to be mitigated and remains to be fully uncovered.
Some remaining differences between our approach and those of others are however 
useful to mention and could possibly provide explanations for the different outcomes 
found between studies. For instance Chow et al.,8 and also Park et al.,9 used heterozygotic 
Tg-SwDI mice, whereas in this study, homozygotic Tg-SwDI mice were used. Homozygotic 
Tg-SwDI mice have been reported to develop more extensive amyloid-β pathology, but with 
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a similar distribution on the micro- and macro-scale in the brain, and similar amyloid-β-40/
amyloid-β-42 ratios as hemizygous mice.14 It seems however unlikely that the more 
severe pathology would result in a reversal of the functional phenotype. Furthermore, 
the amyloid-β pathology found here (Figure 7) is comparable to what is described in 
the literature for both hemizygous and homozygous mice, namely diffuse parenchymal 
plaques in the cortex and microvascular accumulation in the thalamus and hippocampus.7 
Secondly, we used a higher percentage of CO2 for our vascular challenge, i.e. 7.5 % for 7 
minutes here, versus 5 % for 5 minutes in literature.9 However, it is unlikely that higher 
pCO2 intake would reverse the phenotype of the Tg-SwDI mice. Furthermore, the pCO2 
increase measured here through the skin during U&A is comparable to that reported with 
blood gas sampling in Park et al.9 (approximately 20 mmHg). Possibly, a lower sensitivity 
of the transcutaneous pCO2 measurement versus blood gas sampling could explain why 
our pCO2 increase was not higher. It is also important to mention that in most patient 
studies,2,3 as well as in Chow et al.,8 vascular responses to neuronal activity were measured, 
not baseline perfusion and hypercapnia, which might be differently affected by vascular 
amyloid-β. However, this is not likely to explain the differences in outcomes, as Park et al.,9 
showed impaired responses in Tg-SwDI mice to both hypercapnia and neuronal activity. 
Furthermore, patient studies have also shown baseline perfusion deficits.3 Lastly, in Chow 
et al.,8 and Park et al.,9 a craniotomy was performed right before the LDF measurement, 
whereas here, most of the measurements were performed non-invasively. An attempt 
was made to account for this difference in experimental set-up by preparing an acute 
craniotomy in the second cohort of mice. However, even though the brain surface in these 
animals was visually normal (Figure 6-figure supplement 1) after the craniotomy, edema 
was observed with MRI, and with both imaging modalities marked reductions in CBF and 
CVR were measured in the underlying brain regions in both WT and Tg-SwDI mice. A likely 
explanation for the functional impairments after craniotomy is the occurrence of a cortical 
spreading depression (CSD), which occurs even at minor manipulations on the dura.15 
In mice specifically, CSDs have been reported to cause a CBF reduction of 40-50 %, and 
enhanced resistance to relaxation by acetylcholine.15 It could be hypothesized that the 
presence of amyloid-β in the Tg-SwDI model enhances the sensitivity of the brain tissue to 
a CSD. Thus, when measured just after craniotomy, the unnoticed presence of a CSD might 
give the false idea of direct amyloid-β induced cerebrovascular dysfunction. Interestingly, 
a recent study also reported that skull removal was necessary to detect cerebrovascular 
dysfunction in a different mouse model of amyloid-β accumulation, providing some 
support for this hypothesis.16 Nevertheless, because our wild type mice showed similar 
functional deficits as the Tg-SwDI mice, we currently cannot substantiate this hypothesis. 
It is important to mention that the researcher that performed the craniotomy in this study 
is highly skilled in this procedure, underlining that this is not merely a matter of experience. 
Hence, it is of interest to elucidate in future research if our surgical procedure indeed 
triggers a CSD, and whether Tg-SwDI mice are more susceptible to CSDs.
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Alternatively, our results could indicate that the mouse cerebral circulation is less 
affected by amyloid-β accumulation than the human cerebral circulation. However, other 
amyloidosis models did show early impairments in cerebrovascular function, even in a 
non-invasive set-up, such as the APP23 model.17,18 Because the APP23 model mainly 
shows arteriolar CAA pathology,19 altogether this might indicate that predominantly CAA 
pathology on the arteriolar side of the vasculature is responsible for the observed CBF 
and CVR impairments in patients. It is important to note however, that even without 
CBF limiting pathology, capillary dysfunction could lead to inefficient oxygen extraction 
from the capillary network.20 Indeed, hypoxia-induced factor angiopoietin-4 was found 
to be highly expressed in capCAA patients,21 indicating that possibly capCAA could induce 
hypoxic conditions. It would thus be interesting to validate whether similar conditions 
are found in the Tg-SwDI mouse model.
To the best of our knowledge, this is the first study with ASL-MRI in mice where the CBF 
responses to hypercapnia under isoflurane and U&A anesthesia were directly compared. 
Large differences in hemodynamic parameters were observed, with the very low CBF 
during U&A anesthesia as the most striking observation. The low CBF during U&A is non-
physiological and thus forms a limitation of this study. Interestingly, U&A is considered 
one of the more suitable anesthesia protocols for cerebral hemodynamic studies in mice, 
as this protocol has been reported to have relatively mild hemodynamic effects22,23 and 
to maintain cerebral autoregulation.24 However, these studies did not provide absolute 
CBF estimates, and our results indicate that the stable hemodynamics come together 
with very low baseline CBF, which may not always be favorable and certainly do not 
represent normal baseline physiology. It would be of interest to identify the underlying 
cause for this low CBF. 
This is also one of the few studies where a direct comparison was established between 
hypercapnic CBF responses measured with ASL-MRI versus LDF. The results must 
however be interpreted with care due to the small group size and the ± 0.5-hour delay 
between the two measurements. Both readouts consistently reported preservation of 
cerebrovascular function in Tg-SwDI mice and a severe reduction of CVR after craniotomy, 
but CVR measurements with ASL-MRI were nearly twice as high compared to those 
obtained with LDF. It is unclear where this difference comes from. As the two imaging 
modalities are sensitive to different blood components (plasma or red blood cells), it 
could be argued that local hematocrit changes during hypercapnia could explain this 
difference. Indeed, hematocrit has been reported to decrease during hypercapnia in the 
rat brain,25 but with only a 10 % decrease during a 10 % CO2 challenge, which is too low 
to explain the observed difference. A more convincing explanation could be found in an 
interesting study where ASL-MRI and LDF were performed simultaneously,26 and point 
in the direction of an underestimation by LDF. The authors showed that by varying the 
fiber separation distance in the LDF probe, which changes the measured cortical depth, a 
different CBF response was measured. Consequently, the magnitude of the CBF response 
was either comparable to that measured with ASL-MRI, or up to two times lower, which 
120 | Chapter 5
is comparable to our results. The authors measured CBF responses to electrical whisker 
stimulation through a thinned skull in rats under urethane anesthesia, and concluded 
that when larger cortical depths were measured, LDF underestimated the CBF response. 
It is unclear how these results would exactly translate to our different set-up (smaller 
cortical thickness in the mouse, intact skull, different vascular challenge), but indicates 
that investigating the cortical depth measured with a set-up like ours is a compelling area 
for future research. Interestingly, the absolute CBF responses measured with ASL-MRI by 
He et al.,26 were comparable to those measured here. 
Lastly, another finding in our study that is of interest, is the observation of edema and 
the local reduction in CBF and CVR with MRI after craniotomy. This was observed in all 
animals, while the brain tissue was normal by visual inspection. Normal appearance of 
brain tissue is therefore not enough to conclude that the brain tissue is healthy when 
working with acutely prepared cranial windows.
In conclusion, this study shows that cerebrovascular function in the Tg-SwDI mouse 
model of microvascular amyloidosis is preserved up to 12 months of age, despite the 
high amyloid-β burden observed at that age. This observation was confirmed using two 
different anesthesia protocols and two different imaging modalities. These observations 
call into question to what extent microvascular amyloidosis as seen in the Tg-SwDI mouse 
model is a correct model for cerebrovascular dysfunction as observed in CAA patients, 
and calls for further research to clear up the discrepancy in results.
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Animals
All the experiments were approved by the local ethics committee (“Leiden University 
Medical Center Instantie voor Dierenwelzijn”) and the national ethical committees 
(“Centrale Commissie Dierproeven”) under OZP PE.18.029.002 of AVD116002017859, 
and the experiments have been reported in compliance with the ARRIVE guidelines.27
Two cohorts of homozygous Tg-SwDI mice and age- and gender-matched WT controls 
on a C57Bl/6J background were ordered from the Jackson Laboratory (Bar Harbor, ME, 
USA). The first cohort was used for a hypothesis-driven study. Based on a previous report 
by Park et al.,9 we expected an effect size of 30 percentage points difference - in cortical 
CBF response to a hypercapnia challenge - between Tg-SwDI and wild type mice, and a 
standard deviation of 12 % in both groups. With a power calculation done with G*Power 
software,28 where we assumed an alpha of 0.05 and a power of 80 % for a two-sided 
Mann-Whitney U test, we estimated 4 animals would be needed to detect a significant 
difference in cortical CVR. However, to counteract the possibility of a lower effect size, 
higher standard deviation and/or animal drop-out, we chose to increase our sample size 
with 5 animals per group, thus to 9 animals per group in total. The cohort consisted of all 
male mice which were followed longitudinally, i.e. they were imaged at 3, 6, 9, 12, and 
12.3 months of age. The second cohort was used for an exploratory study and consisted of 
4 Tg-SwDI (2 females) and 4 WT mice (2 females) which were imaged once at 8 months of 
age. No blinding was performed when the mice were imaged. Two of the transgenic mice 
were taken out of the longitudinal study, which was not related to the study itself: the 
first mouse was severely wounded by a cage mate (at 2.5 months of age), the other due 
to ulcerative dermatitis (at 10 months of age). The mice in the longitudinal cohort were 
initially co-housed, however, after the aggression incident at 2.5 months, all mice were 
housed individually to prevent further aggression and to keep the conditions between 
the mice comparable. Two study-related dropouts occurred in the second cohort (1 wild 
type and 1 transgenic), due to failure of the intubation procedure (see below). Housing 
consisted of individually ventilated cages in rooms with a 12-hour day/night rhythm. The 
cages were supplied with cage bedding, cage enrichment (a small roll to hide in and a 
block of wood), and unlimited chow food and water. The body weights of the mice were 
measured monthly. 
Animal preparation – the isoflurane anesthesia protocol during the first 4 imaging sessions 
in cohort 1 was similar to the “low isoflurane protocol” as described in Munting et al., 
2019.13 In this protocol, the isoflurane concentration is kept low both during induction 
(2.0 % for 5 minutes) and maintenance (1.25 %), to limit the vasodilatory effects of the 
anesthetic, which would impact the reactivity measurements. The mouse was freely 
breathing during the scan. During the 5th imaging session, anesthesia was maintained using 
750 mg/kg urethane and 50 mg/kg alpha-chloralose (U&A), similar to the concentrations 
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used by Park et al., 2014.9 Anesthesia induction with U&A was performed using isoflurane 
(3.5 %), which was thereafter decreased to 1.75 %. Then, the trachea of the animal was 
surgically intubated for mechanical ventilation at 80 bpm, 25 % inspiration rate and 1.7 psi 
(MRI-1 ventilator, CWE Inc., USA). Additionally, an i.p. catheter was placed to administer 
U&A anesthesia during the MRI scans. Thirty-five minutes after U&A injection, the isoflurane 
was decreased over the course of 10 minutes to 0 %. During all sessions, transcutaneous 
partial pressure of carbon dioxide (tc-pCO2) was monitored (TCM Radiometer, Denmark) 
with a neonate probe attached to the previously shaved skin on the right flank of the 
mouse.29 Breathing rates were monitored using a pressure-sensitive pad placed below 
the animal (SA Instruments, NY, USA). Temperature was maintained at 36.5 ˚C using a 
feedback-controlled waterbed with rectal probe (Medres, Germany) and the head was 
stabilized with a bite bar and ear bars. 
The second cohort was also anesthetized with U&A, however, in this cohort, the i.p. 
injection was given directly after the induction with 3.5 % isoflurane. Again, isoflurane 
was kept at 1.75 % for 35 minutes after injection, after which it was decreased to 0 % 
over the course of 10 minutes. While still at 1.75 % isoflurane, the trachea was surgically 
intubated for mechanical ventilation and additionally, a craniotomy of 3 mm in diameter 
was prepared over the right somatosensory cortex. The dura mater was left intact and 
kept moist with sterile PBS. Similar physiological monitoring was performed as in the first 
cohort. Fifteen minutes after the isoflurane reached 0 %, the LDF recording was started. 
After the LDF measurement, and before the animal was placed in the MRI scanner, the 
skin was placed back over the exposed skull and brain and sutured to limit susceptibility 
artefacts.
Image acquisition
MRI acquisition – a 7 T Pharmascan MRI scanner (Bruker, Germany) with a 23 mm transmit-
receive volume coil was used. After proper placement of the mouse head in the bore 
was confirmed with a scout scan, 3 standard Bruker T2-weighted RARE scans (TE/TR = 
35.0 ms/2500 ms; 78 × 78 x 700 µm3 resolution) were performed in all 3 directions for 
consistent planning across animals of the subsequent pseudo-continuous ASL (pCASL) 
scans. The coronal slice package with 21 slices was additionally used for quantification 
of the brain volume. The pCASL scan protocol was similar as in Munting et al., 2019.13 In 
short, the phase of the pCASL labeling was first optimized using pre-scans.30 Thereafter, 
CBF and CVR were measured using a 21 minute pCASL scan with 180 dynamics, a labeling 
duration (τ) of 3000 ms, a post-labeling delay (PLD) of 300 ms and a 5 slice spin-echo 
echo planar imaging (SE-EPI) readout with 225 µm2 resolution and 1.5 mm slice thickness 
(no slice gap). 7.5 % CO2 was administered to the mouse from minute 7 till minute 14. 
For the last imaging session (12.3 months) of the mice in the first cohort, the number of 
dynamics of the pCASL scan was extended to 767 (scan duration of 90 minutes) to also 
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capture the effect of switching from isoflurane to U&A anesthesia on CBF. Specifically, 
the following steps were performed during the 1.5-hour ASL scan: at 5 minutes, U&A 
was injected, between minutes 40-50 isoflurane was decreased from 1.75 % till 0 % 
and between minute 72-79, 7.5 % CO2 was administered. At the fourth scan session (12 
months), two time-encoded pCASL (te-pCASL) sequences were additionally acquired 
per mouse for measuring the ATT. The second te-pCASL sequence was performed while 
administering 7.5 % CO2 to the mouse, which allowed measuring the effect of arterial 
pCO2 elevation on the ATT. The scan parameters of the te-pCASL sequence were the same 
as in Hirschler et al., 2018,11 except for the resolution, which was decreased from 225 to 
337 µm2 to increase the signal-to-noise ratio (SNR). A 3 slice SE-EPI readout was used, 
with the same slice orientation as slice 1, 3 and 5 of the standard pCASL scan (thus with 
a slice gap of 1.5 mm). During every imaging session, for CBF quantification purposes, 
the T1 of the tissue (T1t) and the tissue magnetization (M0t) were estimated by collecting 
an additional inversion recovery scan with the same 5 slice SE-EPI readout as the pCASL 
scans. Furthermore, a pCASL flow-compensated FLASH was acquired at the level of the 
carotids, 3 mm downstream of the labeling plane, to measure the labeling efficiency (α). 
An additional T2-weighted (T2W) RARE anatomical sequence was acquired with the same 
slice orientation as that of the pCASL scan for registration purposes. 
LDF acquisition – A PeriFlux system with a PF 5010 LDPM unit and two Laser Doppler probes 
was used for LDF monitoring (Perimed Instruments, Sweden). Both probes were placed at 
the somatosensory cortex, one directly on the exposed skull above the left hemisphere, 
the other approximately 0.5 mm above the exposed brain tissue of the right hemisphere 
(hereafter referred to as the left and right probe, respectively). Extraction of the LDF signal 
profile was done through DASYLab software (version 13, National Instruments, Germany). 
After the last MRI measurement, a subgroup of mice (6 Tg-SwDI and 6 WT) was i.v. injected 
with 200 µL of DyLight-594-coupled lectin (lycopersicum esculentum, VectorLabs, CA, 
USA) in the tail vein for staining of the endothelium. This was followed 3 minutes later 
by an i.p. overdose of pentobarbital after which the mouse was transcardially perfused 
with 20 mL of ice-cold PBS and 20 mL of ice-cold 4 % PFA. The brain was isolated and 
overnight fixed in 4 % PFA. The tissue was thereafter preserved at 4 ˚C in PBS with 0.02 % 
sodium azide until further processing. The other mice followed the exact same steps, but 
without the i.v. lectin injection.
Image processing
T2W processing – One full-brain volume of interest (VOI) was manually drawn on one of 
the 21-slice T2W RARE scans, after which the VOI was propagated to the T2W RARE scans 
of the other datasets (both to other mice and to other time points) using the EVolution 
algorithm.31 To derive the brain volume, the number of voxels in the VOI was multiplied 
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by the voxel volume.
ASL image processing – The ASL image processing pipeline was the same as used in Munting 
et al., 2019.13 In short, the SE-EPI frames within one pCASL scan were aligned using the 
image processing toolbox of MATLAB (version 2018b, Mathworks, USA). Subsequently 
CBF, CVR and ATT were calculated using the MATLAB based “Multi-Image Analysis (MIA)” 
software developed at the Grenoble Institute of Neuroscience (Grenoble, France).32 CBF 
was calculated for each pair of label/control images, expressed in mL/100 g/min, and 
derived using Buxton’s general kinetic perfusion model,33 with the following equation:
where λ is the blood-brain partition coefficient, i.e. 0.9 mL/g,34 ΔM is the signal difference 
of the label and control images from the standard pCASL scans and T1b is the longitudinal 
relaxation time of blood, i.e. 2230 ms at 7 T.35 Baseline CBF was defined as the average 
of the last 20 repetitions (≈ 2.3 minutes) before the start of CO2 administration. CVR was 
defined as the ratio calculated from the average of the last 20 repetitions during CO2, 
over the average of the last 20 repetitions before CO2 administration. To calculate ATT, 
the decoded signal from the te-pCASL scans was used, as described in Hirschler et al., 
2018.11 Cortical, thalamic and full mid-brain  brain (ROIs) were manually drawn on one 
of the T2W RARE scans, after which they were propagated to the T2W RARE scans of 
the other datasets (both to other mice and to other time points) using the EVolution 
algorithm.31 This image registration method was also applied to position the ROIs in the 
corresponding SE-EPIs. This allowed to retrieve CBF, CVR and ATT values for different 
brain regions. CBF time profiles were all filtered using a sliding window of 3 time points 
(after CBF calculation), besides the profiles acquired in cohort 2 in the cortical ROI of the 
hemisphere where the skull was removed (supplementary Figure 5), which were filtered 
with a sliding window of 7 time points. 
LDF processing - The LDF signal time profiles extracted with DasyLab were filtered with 
a sliding window of 3 time points and normalized to the average signal during the first 7 
minutes of the measurement (baseline signal).
Immunohistochemistry (IHC)
The fixed brains were embedded in paraffin, and subsequently cut in sections of 5 µm. 
After deparaffinization with xylene and rehydration through graded ethanol series, the 
slides were cooked for 20 minutes in citrate buffer for antigen retrieval. Slides were then 
stained overnight at 4 °C with anti-amyloid-β antibody (1:1000; Abcam ab2539) followed 
by a one-hour room temperature incubation with biotinylated secondary antibody (1:300; 
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Dako E0431). Immunodetection was visualized using an Avidin-Biotin Complex kit (Vector 
Laboratories, UK), and sections were counterstained with haematoxylin before mounting. 
The slides were digitized with an automatic bright field microscope (Philips Ultra Fast 
Scanner, Philips, the Netherlands) and assessed by one examiner (LPM) for positivity for 
amyloid-β. 
Statistical testing
To test the effect of genotype on CBF, CVR, ATT, and tc-pCO2, Mann-Whitney U tests were 
performed. For the longitudinal cohort, Friedman tests were performed to test the effect 
of age on CBF and CVR, post-hoc followed by Wilcoxon signed-rank tests to determine 
which of the individual age groups differed from each other. Only consecutive age-groups 
were compared to each other to restrict the stringency of the Bonferroni correction 
for multiple comparisons. Wilcoxon signed-rank tests were used to test the effect of 
anesthesia on CBF and CVR and to test the effect of CO2 on the ATT. No statistical testing 
was performed in cohort 2, given the small group size. All tests were performed in the 
SPSS statistics software package, version 26 (IBM, Armonk, NY, USA).
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Figure 3-figure supplement 1: Animal-by-animal cerebral blood flow (CBF), cerebrovascular 
reactivity (CVR), brain volume and body weight progression with increasing age. On 
the top row, CBF trends are displayed, on the second row CVR trends, on the third row brain 
volume and on the last row body weight. The left column shows wild type (WT) mice, the 
right column transgenic Swedish Dutch Iowa (Tg-SwDI) mice. Every animal is represented 
with the same line color in the four graphs. The black dashed line represents the group 
mean.
































































Figure 3-figure supplement 2: Cerebral blood flow (CBF) measurements in cortical (left) and 
thalamic (right) ROIs. On the top row, representative T2 weighted images are shown with 
overlaying areas (in gray) representing the brain regions that were analyzed. The middle 
row shows boxplot representations of baseline CBF (average of the last 2.3 minutes before 
the start of CO2 administration) and bottom rows shows CVR (ratio of average of the last 2.3 
minutes during CO 2 to baseline CBF). Circles and squares represent individual mice.
5
Cerebral blood flow and cerebrovascular reactivity are preserved in a mouse model of cerebral 
microvascular amyloidosis | 131
















































7.5 % CO 7.5 % CO 7.5 % CO 7.5 % CO
3 Months 6 Months 9 Months 12 Months

































7.5 % CO 7.5 % CO 7.5 % CO
Figure 3-figure supplement 3: Change in transcutaneously measured pCO2 and respiration 
profiles during the pCASL measurements. On the first row, the pCO2 time profiles (mean 
± standard deviation) acquired during the pCASL scans in cohort 1 for both wild types 
(WT) and transgenic Swedish Dutch Iowa (Tg-SwDI) are displayed. On the second row, the 
respiration profiles (mean ± standard deviation) are displayed. Note that the respiration 









































Figure 3-figure supplement 4: Inversion efficiency values measured at the different time 
points in cohort 1. In the graphs from left to right, increasing ages are shown. Within each 
graph, wild types (WT) and transgenic Swedish Dutch Iowa (Tg) mice are displayed. 
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Iso decreased to 0%
Figure 5-figure supplement 1: CBF change observed during switching from isoflurane anes-
thesia to urethane and α-chloralose (U&A). 90-minute CBF time profiles (mean ± stan-
dard deviation) are displayed acquired in cohort 1 for wild type and transgenic Swedish 
Dutch Iowa (Tg-SwDI) mice at an age of 12.3 months old. U&A was injected 5 minutes 
after the start of the arterial spin labeling-MRI scan. Isoflurane (iso) was decreased between 
minute 40 and 50. CO2 was administered between minute 72 and 79.
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Figure 5-figure supplement 2: Change in transcutaneously measured pCO2 and respiration 
profiles under different anesthesia protocols. On the first row, the pCO2 time profiles 
(mean ± standard deviation) acquired during the pseudo-continuous arterial spin labeling 
(pCASL) scans for both wild types (WT) and transgenic Swedish Dutch Iowa (Tg-SwDI) in 
the last two time-points of cohort 1 are displayed, with the acquisition under isoflurane on 
the left, the acquisition under urethane and α-chloralose on the right. On the second row, 
the respiration profiles (mean ± standard deviation) for the same time-points are displayed. 
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Figure 6-figure supplement 1: Cerebrovascular reactivity (CVR) measurements with Laser 
Doppler flowmetry (LDF) and arterial spin labeling (ASL MRI) with and without skull 
removal. A) displays CVR time profiles acquired either with LDF (top row) or ASL-MRI (bot-
tom row). The left column shows the CVR time profiles from the intact, left hemisphere, the 
right column the profiles from the right hemisphere after craniotomy. B) shows a photo-
graph of the somatosensory cortex of a representative mouse after craniotomy. C) On the 
top row, a T2 weighted image that was acquired with MRI after craniotomy. On the bot-
tom row, cerebral blood flow (CBF) and CVR images that were acquired in the same scan 
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Summary
Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA) are both characterized by 
cerebral amyloidosis, i.e. deposition of amyloid-β in the brain, and impaired cerebrovascular 
function. The central goal in this thesis was to create a deeper understanding of the 
relation between amyloid-β deposition and cerebrovascular function. To that end, imaging 
techniques for the measurement of cerebrovascular function were optimized and applied 
in mouse models of amyloidosis.
Chapter 1 introduced some of the key concepts of structure and function of the brain 
vasculature during health and disease. Furthermore, different mouse models of amyloidosis 
were introduced, as well as techniques that exist to measure cerebrovascular function. 
One of the techniques, arterial spin labeling (ASL)-MRI, can measure brain perfusion 
quantitatively, dynamically and in a completely non-invasive manner, and was therefore 
the main technique used in this thesis for measuring cerebrovascular function. In chapter 
2, a modified ASL sequence was described that not only measures brain perfusion, but 
also arterial transit time (ATT) of labeled blood into the mouse brain. ATT is an important 
parameter for the quantification of brain perfusion, but a change in ATT can in itself also 
indicate an underlying vascular pathology. With the modified ASL sequence, ATT could 
be time-efficiently measured in the mouse brain for the first time.
Since anesthesia is typically used with mouse MRI, which is known to influence 
hemodynamics, chapter 3 focused on the effect of different anesthesia protocols on the 
murine brain hemodynamics. A low induction, low maintenance isoflurane protocol was 
identified for repeated measurements of brain perfusion both under baseline conditions 
and during hypercapnia.
In chapters 4 and 5, the knowledge from the previous chapters was used to measure 
cerebrovascular function in mouse models of amyloidosis. The APP/PS1 mouse model 
was used in chapter 4. This particular mouse model develops parenchymal plaques and 
limited leptomeningeal amyloid-β accumulation, and thus reflects an AD-like distribution 
of amyloid-β pathology. These APP/PS1 mice surprisingly showed similar CBF and ATT 
values as the WT control group. In chapter 5, the transgenic Swedish Dutch Iowa (Tg-SwDI) 
mouse model was the topic of research, which develops extensive microvascular amyloid-β 
pathology, and thus reflects a more CAA-like distribution of amyloid-β pathology. However, 
also here, no cerebrovascular dysfunction was found, despite previous reports of impaired 
cerebrovascular function in Tg-SwDI mice by other groups. 
The sequence of negative findings regarding cerebrovascular function and amyloid-β 
deposition in this thesis leaves us with additional questions. What is the validity of our 
models? And why do our results differ from those of other labs? In this chapter, these 
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questions will be discussed in more detail. But first, new findings from this thesis will be 
highlighted and put in context. Furthermore, some potentially interesting directions for 
future research will be indicated.
Discussion 
New methodologies
The first part of this thesis mainly focused on the development of new methodologies 
for assessing cerebrovascular function. Firstly, a new time-encoded ASL sequence was 
developed in chapter 2, with which ATT values were measured for the first time in the 
mouse brain. ATT values were found in a range between 169 millisecond (ms) and 284 ms. 
This seems plausible given that similar values have been reported for the rat brain (Thomas 
et al., 2006; Wells et al., 2010). It was also shown that after carotid occlusion, CBF severely 
decreased and ATT mildly increased. This confirms that CBF and ATT measurements with 
ASL-MRI are sensitive to detect changes in vascular condition. Furthermore, the ATT values 
that were found are lower than the typically used post-label delay (PLD) values in pre-
clinical ASL-MRI studies (Duhamel et al., 2012). This indicates that previously carried out 
ASL studies in mice are probably not biased by incomplete arrival of the label, a potential 
source of error in perfusion MRI by ASL in humans (Alsop et al., 2014). Also in contrast 
to humans, is that the CBF and ATT measurements could not be combined in a single 
“free-lunch approach” scan (Teeuwisse et al., 2014). This is because a very high temporal 
resolution was required to measure the fast inflow times of the label in the mouse brain, 
which in turn required a high amount of averaging for sufficient ASL signal. The high 
amount of averaging would however have led to too long scan times when combined 
with the long labeling duration required for a CBF measurement. It is still unclear why 
the signal decay measured with the time-encoded ASL sequence was not consistent with 
the T1 decay as measured with a standard inversion recovery scan, i.e. the T1 decay of the 
ASL signal was much faster. Possibly, ASL signal still residing in the larger arteries plays a 
role, as described previously (Chappell et al., 2010). In this case, after the label is initially 
detected in a certain voxel, it goes on to perfuse downstream tissue located in different 
voxels, thus leading to an artefactual signal decrease in the voxel where it is initially 
detected. It would be of interest for future developments to focus on removing this signal, 
for example by including vascular crushers, or by explicitly modeling the arterial signal 
(Chappell et al., 2010). In the last part of chapter 2, ATT and CBF values were measured 
in the context of ageing, with a group comparison of baseline CBF and ATT values in wild 
type adult mice (6 months) and wild type old mice (24 months old). Both parameters 
were shown to remain stable in the ageing mouse brain. 
Anesthesia is used in the vast majority of pre-clinical MRI studies, given the many 
practical and ethical restrictions associated with MRI in awake mice. Therefore, before 
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performing hemodynamic MRI studies with mouse models of amyloidosis, the effect 
of anesthesia on hemodynamics was first further explored in two strains of wild type 
mice in chapter 3. The study was limited to isoflurane and medetomidine protocols 
only, as these anesthetics allow for longitudinal imaging, in contrast to other anesthetics 
such as urethane, alpha-chloralose or etomidate. However, isoflurane is known to cause 
vasodilatation (Matta et al., 1999), whereas medetomidine causes vasoconstriction (Sinclair, 
2003). In this study, baseline CBF was measured, as well as the CVR to a hypercapnic 
challenge. It was shown that there was no CBF increase detectable to the challenge 
when the anesthetic isoflurane was used at a relatively standard concentration (3.5 % 
for induction, 1.5 % to 2.0 % for maintenance), referred to as the “medium isoflurane” 
protocol. This was in contrast to when medetomidine was used, with which strong CVR 
was observed. However, medetomidine did not induce sufficient depth of anesthesia in 
one of the two mouse strains tested, and furthermore led to relatively unstable CBF over 
time. Adaptations of the standard isoflurane protocol were therefore further explored. It 
was found that with either a lower induction and lower maintenance isoflurane protocol 
(2.0 % and 1.25 % respectively, referred to as “low isoflurane”), or with a protocol with 
mechanical ventilation under medium isoflurane concentrations, CBF increases upon 
hypercapnia were detected, albeit with smaller CVR than when medetomidine was used. 
Interestingly, an equal magnitude of the CVR response was observed between both 
adapted isoflurane protocols. However, when the same procedures were performed on 
a mouse strain with known ventilatory abnormalities – mice on a partial C3H background 
(Tankersley et al., 1994) – no CBF response to hypercapnia could be detected with the 
low isoflurane protocol, but a similar CVR was found as compared to C57Bl/6J mice when 
the ventilation protocol was used. Together, this indicates that respiratory depression is 
likely an important factor in the attenuation of the CBF response to hypercapnia in mice 
anesthetized under medium isoflurane. However, intubation and mechanical ventilation 
requires highly skilled researchers, since it is a difficult procedure, while also dedicated 
hardware is needed. Furthermore, the procedure might cause damage to the mouse 
trachea. As such, the low isoflurane protocol is a much more attractive protocol, as it allows 
for similar CVR measurements, but without the aforementioned complications, as long 
as mice without ventilatory abnormalities are used. Thus, in short, this study identified a 
straight-forward and minimally invasive anesthesia protocol for repeated measurements 
of cerebrovascular function in mice, including a positive CVR upon hypercapnia. For future 
studies it would be interesting to implement a protocol for MRI in awake mice. Awake 
MRI has long been deemed impractical, however, in the field of intravital microscopy, 
awake imaging is becoming more and more standard, with sophisticated set-ups reducing 
the stress for the animals. Awake imaging not only removes the bias that anesthesia 
introduces in hemodynamic measurements, it also allows for studying stimulus-evoked 
neurovascular coupling.
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Chapter 4 also had a more methodological character, as a pipeline was described 
to obtain quantitative values of the microvascular cerebral blood volume (mCBV) at 
microscopic resolution. Normally with microscopy, the high spatial resolution comes 
together with limited penetration depth, thereby limiting the assessed tissue volume 
to only a superficial slice. However, recent advances in tissue processing has enabled 
to optically clear tissue, which greatly increases the penetration depth of light. In this 
chapter, it was assessed whether tissue clearing could be used to image and quantify the 
volume of the microvasculature with a larger coverage. Specifically, the CUBIC clearing 
protocol (Susaki et al., 2014) was applied to create transparent mouse brains in which 
the vasculature had previously been labeled in vivo with an intravenous injection of 
fluorescent lectin. After transparent tissue was created, a laser scanning microscope 
(LSM) was used, with a long working distance objective and an automated stage, to image 
a full hemisphere at high spatial resolution. Lastly, an extensive image post-processing 
pipeline was designed to calculate, for different brain regions, the microvascular blood 
volume (mCBV) as a percentage of the total tissue volume. With cleared tissue, normally, 
a light sheet microscope is used for imaging, as its sheet of excitation greatly speeds up 
acquisition times compared to the point excitation of a laser scanning microscope as used 
in this study. However, there is much less availability of light sheet microscopes at research 
institutes than that of laser scanning microscopes, and no light sheet microscope was 
available at our institute. But with the presented methodology, it was made possible to 
image large volumes of cleared tissue with laser scanning microscopy, albeit at the cost 
of an examination time of 2 to 3 days per hemisphere. From the brain regions analyzed, 
the mCBV values were highest in the thalamus and lowest in the white matter, which 
is in correspondence with other studies (Bohn et al., 2016; Xiong et al., 2017; Zhao & 
Pollack, 2009). An interesting area for future research would be to design a pipeline 
for registering MR images to microscopy images of transparent tissue, acquired in the 
same animal. This would allow to link areas in which dysfunctional measures found with 
MRI, such as reduced perfusion with ASL-MRI, can be linked to underlying pathology as 
visualized with microscopy. 
Cerebrovascular function in amyloidosis models
The second part of this thesis consisted of the application of the newly developed 
methodologies to assess how amyloid-β accumulation affects cerebrovascular function 
in mouse models of amyloidosis. In chapter 4, cerebrovascular function was studied 
in the APPswe/PS1dE9 mouse model (J L Jankowsky et al., 2001) at old age. The model 
develops extensive parenchymal plaques and limited leptomeningeal CAA. CBF and ATT 
were measured (without a hypercapnic challenge), and compared to age-matched WT 
mice. Additionally, mCBV values obtained post-mortem with the implemented tissue 
clearing pipeline were compared to WT mice. However, no differences were found in 
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any of the three parameters. No previous studies have investigated ATT in AD mouse 
models, but regarding CBF and blood volume, there is some controversy in the literature 
about the APPswe/PS1dE9 model. Reports vary from observations of CBF decrease (Cruz 
Hernández et al., 2019), to no change (Delafontaine-Martel et al., 2018; Hooijmans et 
al., 2007), to even CBF increase (Guo et al., 2019). The latter finding was, however, only 
at very young age. Regarding mCBV, there is also controversy, with one study reporting 
decreased mCBV (Zerbi et al., 2013), and another reporting no change (Delafontaine-
Martel et al., 2018). Studies that found perfusion or blood volume changes, reported 
that the change was mainly restricted to the cortex and relatively small (<20 %). Thus, 
when taking these studies together with the results from chapter 4, at worst, APPswe/
PS1dE9 mice have mild cerebrovascular dysfunction. This is in contrast with other models, 
such as the APP23 model (Maier et al., 2014), Tg2576 model (Maier et al., 2014; Niwa et 
al., 2002) or the Tg-SwDI model (Chow et al., 2007; Park et al., 2014), which have been 
reported to have much more severe cerebrovascular dysfunction. Common amongst 
these models is more severe amyloid-β accumulation in the brain vasculature. As such, 
the cerebrovascular dysfunction associated with AD and CAA seems thus to be linked 
to vascular amyloid-β accumulation in particular, as already suggested earlier (Maier et 
al., 2014). Interestingly, another model with also a PS1 insertion -  PS1L166 - also shows 
hardly any vascular amyloid-β accumulation and similarly no cerebrovascular dysfunction 
(Maier et al., 2014). It therefore appears that a PS1 insertion in APP transgenic mice 
somehow leaves the cerebral vasculature unaffected. Likely, this is mediated through a 
shift in amyloid-β-40:amyloid-β-42 ratio towards amyloid-β-42, which is caused by the 
familial mutations in the PS1 insertions. This shifted ratio is known to cause early and 
extensive parenchymal plaque pathology (Joanna L. Jankowsky et al., 2004). It could 
be hypothesized that the early accumulation of amyloid-β in parenchymal plaques also 
reduces the clearance of the peptide via the vasculature, thereby indirectly protecting 
the cerebral vasculature. In short, no cerebrovascular dysfunction was found in this 
thesis in the APPswe/PS1dE9 model, which could be explained by its limited deposition of 
amyloid-β in the vasculature. Therefore, a model with profound amyloid-β deposition in 
the vasculature was assessed in the next chapter. 
The Tg-SwDI model develops vascular amyloid-β accumulation starting at an age of 6 
months. Specifically, amyloid-β accumulates around capillaries in several brain regions, 
including the thalamus, hippocampus and cortex. Thalamic and hippocampal capillaries 
are particularly heavily affected as compared to cortical capillaries, which are more mildly 
affected. However, the cortex is also additionally affected by the accumulation of diffuse 
parenchymal plaques (Davis et al., 2004; Xu et al., 2007). Impairments in cerebrovascular 
function in Tg-SwDI mice had already previously been shown by other groups (Chow et al., 
2007; Park et al., 2014), even at the age of 3 months, which is before vascular amyloidosis 
can be observed. In these studies, CVR was measured with laser Doppler flowmetry 
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(LDF) under a terminal anesthesia protocol with α-chloralose and urethane, where the 
LDF probe was placed on exposed cortical brain tissue after craniotomy. In chapter 5 of 
this thesis, both baseline CBF and CVR were measured non-invasively in Tg-SwDI mice 
and WT controls, with ASL-MRI under the low isoflurane anesthesia protocol. The ASL 
measurements were performed in a longitudinal fashion, from an age when no amyloid-β 
pathology was present (3 months), up to an age when the brain microvasculature was 
heavily affected by amyloid-β pathology (12 months). To better compare our findings to 
previous reports, additional CVR measurements were performed under α-chloralose and 
urethane anesthesia, and with LDF. In contrast to previous studies, no cerebrovascular 
dysfunction was found in this study in Tg-SwDI mice. The mice even showed remarkably 
similar CBF and CVR values as their controls, irrespective of the anesthesia protocol or 
imaging modality used. It is unclear what difference in protocols could be the reason for 
the discrepancy. But one difference that has not been fully accounted for in this thesis, 
is that in the aforementioned studies, part of the skull was removed before carrying out 
the cerebrovascular function measurements, whereas here, the measurements were 
performed non-invasively. We hypothesize that skull removal may in fact be a needed 
second hit to evoke cerebrovascular dysfunction in Tg-SwDI mice, which has also been 
recently reported by another group for a different amyloidosis mouse model (Sharp et 
al., 2019). An attempt was made to support this hypothesis with data. However, in our 
hands, when part of the skull was removed to expose brain tissue for a CVR measurement, 
the CVR was blunted in both genotypes. Furthermore, we noticed pronounced edema 
with MRI in the region of the craniotomy, despite the fact that the brain tissue appeared 
normal by eye. Possibly, a difference in the surgical protocol of others (Chow et al., 2007; 
Park et al., 2014) preferentially affected the cerebral vasculature in Tg-SwDI mice, and 
accounts for the difference in outcome. For future research, it would be interesting to 
examine how different craniotomy procedures affect cerebrovascular function, and how 
this might differently affect vulnerable vessels, i.e. with pre-existing vascular pathology. 
Validity of the models 
The second part of this thesis repeatedly reported the same finding: measurements of 
cerebrovascular function in the models of amyloidosis yielded comparable values as 
their wild type controls. This is, however, not consistent with observations in AD and 
CAA patients, for which there is a large and consistent body of evidence pointing towards 
dysfunction of the brain vasculature (den Abeelen et al., 2014; Dumas et al., 2012; Iturria-
Medina et al., 2016; van Opstal et al., 2017). It is still unclear why the mouse models do 
not reflect this. Perhaps, it could be explained by differences in the underlying amyloid-β 
pathology in the patients versus the animal models. The extent to which the studied 
models reflect the amyloid-β pathology as observed in human patients will therefore be 
further discussed. Alternative possible reasons for the discrepancy will also be indicated. 
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Mice do not naturally develop amyloid-β pathology, because endogenous murine amyloid-β 
is not as aggregation-prone as human amyloid-β (Joanna L. Jankowsky et al., 2007). The 
human amyloid‑β precursor protein (APP) gene is therefore inserted as a transgene in the 
mouse genome to allow for build-up of amyloid-β peptides in the mouse brain. In some 
models, human PS1 or PS2, which code for APP cleavage proteins, are inserted together 
with APP. The inserted transgenes are usually combined with a promotor that drives high 
expression by neurons, and contain one or more familial AD mutations to speed up the 
amyloid-β accumulation in the mouse (Joanna L. Jankowsky & Zheng, 2017). 
APP/PS1 mice and familial AD
The first mouse model used in this thesis contained both APP with the Swedish mutation 
(APPswe) and PS1 without exon 9 (PS1dE9)(J L Jankowsky et al., 2001). Patients with both 
APPswe and PS1dE9 likely do not exist, which already questions whether the model represents 
a specific patient population. For simplicity however, the APP/PS1 model will here be 
compared to PS1dE9 patients, as APPswe is known to only increase amyloid-β production 
(Citron et al., 1994), whereas PS1dE9 is known to also shift the amyloid-β-40:amyloid-β-42 
ratio (Joanna L. Jankowsky et al., 2004). Pathologically, patients with a PS1dE9 mutation 
show early and extensive amyloid-β parenchymal plaque formation. A specific type 
of amyloid-β plaque that sometimes occurs in tissue of these patients is the so-called 
cotton wool plaque. Additionally, the patients also develop CAA, both in parenchymal 
and leptomeningeal vessels (Brooks et al., 2003). The patients develop early and severe 
cognitive decline, but hemorrhages are rare (Verkkoniemi et al., 2000). Not many studies 
have focused on cerebrovascular function in PS1dE9 patients. However, like for other AD 
patient populations, reduced CBF has been reported for pre-symptomatic patients with 
different PS1 mutations, albeit in a small and heterogenous cohort (McDade et al., 2014). 
APP/PS1 mice also have early and extensive parenchymal plaque formation, and they 
also develop CAA to some extent, thus showing some clear pathological similarities to 
the patients. However, cotton wool plaques are not observed in these mice (Joanna L. 
Jankowsky et al., 2004). Furthermore, CAA only occurs in the leptomeningeal vessels, 
not in the parenchymal vessels (Garcia-Alloza et al., 2006). The mice thus do not fully 
recapitulate the pathology of the patient, which could perhaps play a role in the limited 
cerebrovascular dysfunction observed in our studies.
Tg-SwDI mice and familial CAA
The second mouse model used in this thesis was the Tg-SwDI mouse model. It has only 
1 transgene (APP), but the transgene contains three mutations, i.e. the Swedish, Dutch 
and Iowa mutations. Such a triple mutation does not occur in patients. But given that the 
Dutch and Iowa mutations lead to similar structural changes in two neighboring amino 
acids in the amyloid-β peptide (an exchange of a negatively charged amino acid for a 
neutral amino acid), this combination has been deemed a mere amplification of either 
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mutation. As already mentioned, the Swedish mutation causes an absolute increase in 
production of the peptide itself. Interestingly, in contrast to many other models, the APP 
transgene is expressed at very low quantities in Tg-SwDI mice, lower than endogenous 
murine APP. Given that in many amyloidosis models, the phenotype might be biased by the 
unphysiologically high expression of APP, the low expression is a favorable characteristic of 
the Tg-SwDI mouse model. Despite low APP expression, the model develops early capillary 
amyloid-β accumulation, starting at 6 months, which is illustrative of the aggressive 
aggregation properties of the amyloid-β peptide with both a Dutch and an Iowa mutation 
(Davis et al., 2004). It is unsure what patient population the Tg-SwDI mouse model can be 
best compared to, as neither Dutch nor Iowa CAA patients develop such extensive capillary 
CAA. Dutch CAA patients have relatively spared capillaries, and hardly any parenchymal 
plaques. Iowa CAA patients have both affected arterioles and capillaries, as well as some 
degree of parenchymal plaques (Kamp et al., 2014). Tg-SwDI mice thus better resemble 
the Iowa CAA pathology. However, no functional data is available in the Iowa patients, 
given there are very few of these patients, and thus functional effects of the pathology in 
mouse and human cannot be compared. Yet another group of patients, also known as type 
1 CAA or capCAA patients, does develop extensive capillary CAA, albeit sporadically, i.e. 
without any of the familial AD or CAA mutations (Thal et al., 2002). Tg-SwDI mice thus also 
show some degree of pathological similarity to these patients. However, no studies have 
been performed which report cerebrovascular function specifically for capCAA patients, 
probably related to the fact that there are no criteria for in vivo diagnosis of capCAA. It 
is thus unclear whether the preserved cerebrovascular function with capCAA, as found 
here in the Tg-SwDI mice, is comparable to the effect that this pathology would have in 
humans. Possibly, the data here could even be an indication that also in humans, capCAA 
is not likely to severely affect baseline CBF, nor CBF responses to systemic challenges such 
as hypercapnia. However, it is important to mention that capillary dysfunction might 
still lead to inefficient oxygen uptake from the capillary network, even in the absence of 
CBF limiting pathology (Østergaard et al., 2016). Interestingly, angiopoietin-4, a hypoxia 
inducible factor, was found to be highly expressed in brain tissue of capillary CAA patients 
(Chakraborty et al., 2018), thus providing support for the notion that capillary CAA can 
induce hypoxic conditions. 
Late onset AD
No good mouse model exists for an older dementia patient that comes to the memory 
clinic without any genetic history of AD or CAA. Even though AD pathology is the most 
common underlying pathology in patients with dementia, most patients have mixed 
pathologies, which can include amongst others parenchymal and vascular amyloid-β 
accumulation, microbleeds, microinfarcts and Lewy bodies (“2020 Alzheimer’s disease 
facts and figures,” 2020). Furthermore, histories of diabetes, smoking, alcohol abuse, 
etc., can cloud the picture even more. Current mouse models only reflect a minor part 
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of that complex picture. It is thus likely that results obtained in mouse models translate 
poorly to an elderly demented patient. 
In conclusion on model validity, globally, amyloid-β pathology in the mouse models of 
amyloidosis used here are relatively comparable to that observed in familial AD and CAA 
patients: the transgenes with familial AD mutations cause parenchymal plaque formation 
in the mouse, like in a familial AD patient; the transgene with familial CAA mutations 
causes vascular amyloidosis in the mouse, like in a familial CAA patient. However, in 
more detail, pathology in the patients and the models shows differences, such as the 
type of parenchymal plaque and the localization of amyloid-β along the vascular tree. 
These differences could lead to the observed discrepancies regarding the effect of the 
pathology on cerebrovascular function between the patients and the models. However, 
additionally, species-specific differences in molecules that interact with both amyloid-β 
and the vasculature, such as APOE or fibrinogen, could also play a role. Furthermore, 
artefacts related to the unphysiologically high expression of APP or the double or triple 
mutations might also be involved. The lack of vascular dysfunction in the mouse models 
of amyloidosis used here, is not a unique discrepancy between the models and patients. 
For example, a wide variety of novel or repurposed treatments have been tested in mouse 
models and yielded positive results such as reduction of amyloid-β accumulation and 
improvement of cognition. However, all these treatments failed when tested in humans. 
Either they were not safe, or they failed to show any efficacy in improving the outcome 
markers (Sabbagh et al., 2013). Other examples of discrepancies between the models 
and patients are the lack of macro-bleeds in CAA-like mouse models, or the lack of true 
tau tangle development in AD-like mouse models (Joanna L. Jankowsky & Zheng, 2017).
Alternative models
Given the limited translatability of the findings in the amyloidosis models used here, one 
may wonder if there are better models for amyloidosis as observed in AD and CAA. Other 
models do exist, such as other animal models, or in vitro models. Other animal models 
include other mouse models, rats, and even monkeys. One interesting alternative mouse 
model is the APP23 model, a model which overexpresses APP with only the Swedish 
mutation, thus not containing any mutation in the amyloid-β coding regions. The model 
shows late-onset, but prominent arteriolar CAA (Calhoun et al., 1999). In a previous study 
(Maier et al., 2014), two different mouse models of amyloidosis were studied at different 
ages with ASL-MRI for baseline perfusion measurements (with a FAIR sequence, which is 
different from the pCASL sequence used here). Additionally, PiB-PET measurements were 
performed for detection of amyloid-β deposition. The authors showed that only the APP23 
model developed a perfusion decrease, which coincided with an increase in amyloid-β 
deposition as measured with PiB-PET. The wild type mice and a parenchymal amyloidosis 
model both showed preserved perfusion up to a high age. Thus, perhaps arteriolar CAA 
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is the main driver for cerebrovascular dysfunction, at least in mice. Unfortunately, the 
APP23 model could not be obtained in Leiden while the research in this thesis was carried 
out. It would thus be interesting for future research to further assess cerebrovascular 
function in the APP23 mouse model, including CVR and ATT, and compare whether these 
measures are earlier or later affected than baseline CBF. Rat models with AD and CAA-
like pathology also exist, and they have in general been reported to better reflect human 
aspects of AD or CAA. For example, rat models with tau tangles already exist (Cohen et al., 
2013), as well as models with vessel ruptures (Zhu et al., 2020). Furthermore, the range 
of cognitive tests that can be applied are much larger in rats than in mice, which would 
allow assessing the effect of the pathology on cognition, as well as the effect of novel 
treatments on cognitive performance. However, the genetic modification possibilities 
for rats are still lagging those of mice, and housing of rats is more expensive, but these 
disadvantages could be overcome. One could also consider higher order animals as models 
of AD or CAA, such as monkeys. However, this puts in much more weight on the ethical 
side, which may not be worth the gain in model improvement.
Recent developments in cell culture techniques are also promising. Induced pleuripotent 
stem (iPS) cells, derived from AD and CAA patient’s skin cells, have already been 
differentiated into neurons, and grown in a 3D cell culture environment. The results are 
truly fascinating, and include 3D human cell cultures that produce amyloid-β plaques and 
tau tangles (Choi et al., 2014). As an advantage over animal models, such models have 
a genetic background that is the same as in humans. Species-specific protein isoforms, 
such as aggregating amyloid-β in the human versus non-aggregating amyloid-β in the 
mouse, are not an issue in these models. Such models are therefore advantageous in 
certain conditions, for example when performing a target engagement screen for novel 
drugs, for which the outcome heavily relies on protein isoforms. In the near future, 
hopefully these models will start to replace some of the more standardized safety and 
target engagement screens of novel drugs for which animals are now still used. However, 
more fundamental research, such as research focusing on the relation between amyloid-β 
accumulation and cerebrovascular function, cannot be carried out in such in vitro models, 
as they lack perfusion and a functioning vasculature. Even if artificial perfusion would be 
included in the near future in an in vitro model, this will still be very different from a living 
brain, supplied with oxygenated blood by the heart and lungs, with systemic regulation, 
autoregulatory capabilities and neurovascular coupling. We should never stop to strive for 
replacing animal studies with in vitro studies, and hopefully the need for animal studies 
will reach zero one day. However, the painful truth is that proper in vitro models that 
reflect the complexity of organ systems are not available, neither at the moment, nor in 
the near future. A proper in vitro model will also not suddenly appear when a government 
decides to make a country free of animal testing in e.g. 2025. 
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In conclusion, mouse models of amyloidosis reflect human AD or CAA only up to a limited 
extent. Translation of findings from the mouse to the human should thus always be done 
with care and may be sometimes be invalid. Newer and better options are however 
becoming available. Likely, screens for target engagement of novel drug compounds 
in animal models will be replaced by in vitro models, and rat models will likely replace 
mice for research questions that require a more realistic model of AD or CAA. However, 
research questions that require sophisticated genetic modification tools, such as enabling 
optogenetic control of specific cell types, will probably continue to be performed in mice 
for some time, given the advanced tools available for genetic modification in mice.
Reproducibility in research
Another problem in this thesis was the discrepancy of our studies with the results of other 
pre-clinical studies. This is again a problem that is not unique to vascular dysfunction in 
mouse models of amyloidosis. Shockingly low numbers of reproducibility were reported 
in studies that were dedicated to reproducing findings from other labs. In the fields 
of oncology, drug target discovery and psychology, the reproducibility estimates were 
11 % (Begley & Ellis, 2012), 20-25 % (Prinz et al., 2011) and 39 % (Collaboration, 2015), 
respectively. Furthermore, in a Nature survey from 2016 amongst 1576 researchers, 52 
% responded that there is a reproducibility crisis going on in research (Baker & Penny, 
2016). However, with more than half of the surveyed researchers in 2016 indicating that 
there is a crisis going on, surprisingly little has been done since. A long list of causes has 
been put forward in the Nature publication, of which selective reporting and pressure to 
publish have been deemed the most important. Another long list of potential remedies 
was proposed, of which better understanding of statistics and better mentoring were 
rated as likely the most effective.
Personally, I do not think that the highest rated remedies are going to be very effective. 
A better understanding of statistics and better mentoring are not going to fundamentally 
change the way that data acquisition is performed. It seems to me that the real problem 
is that there is not enough incentive to actually perform reproducibility checks before 
starting new research. If one lab decides that their researchers must first replicate the 
previous findings which are key for their new hypothesis, before actually continuing to 
carry out the research needed to test their new hypothesis, then this will significantly slow 
down the research output of that lab. In the long run, this will mean that the lab will not 
be able to compete with other labs in terms of funding. It is therefore much better to start 
testing new hypotheses immediately, which independent of its outcome, and whether it 
actually builds on previous research or not, thereby already has the important value of 
newness attached to it. This will lead to the publication of new scientific papers, which 
will subsequently lead to new funding. As a result of this system, the outcome of the 
research lines from different labs have become disconnected, with a lack of understanding 
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of the underlying reasons for the outcome of the individual experiments from other labs. 
Improving the understanding of statistics of (young) researchers, requires teaching one 
or several courses, which is relatively easy to do, and may give a feeling that we are doing 
something to tackle this crisis. Sometimes, it may even lead to a researcher interpreting 
his or her data differently. However, if the process of data collection remains the same, I 
fear that this is not going to turn around the shockingly low numbers of reproducibility. 
One lab cannot change on its own, because then it will just succumb in the competition. 
Perhaps mandatory components on reproducibility could be included in grants, where 
researchers have to report the results of their replication studies before continuing with 
their new hypothesis. It may seem initially that this will slow down “scientific progress”. 
However, on the long run, it may significantly reduce the $28 billion per year that is spent 
on irreproducible research in the USA alone (Freedman et al., 2015). Only in a collaborative 
effort, in which reproducibility becomes engrained in the way we do science, will we be 
able to resolve the crisis. Small steps are already taken in that direction, with initiatives 
such as FAIR (findable, accessible, interoperable and reusable) principles to support reuse 
of data (Wilkinson et al., 2016), and the introduction of meta-analyses in the pre-clinical 
research community (Sena et al., 2014) 
In summary, in this thesis, the methodology for pre-clinical assessment of cerebrovascular 
function was further refined. Additionally, several cerebrovascular function measurements 
were performed in mouse models of amyloidosis, but no differences were found when 
compared to their healthy controls. Despite the negative connotation of that finding, 
it is another small step towards better understanding the exact relationship between 
cerebrovascular dysfunction and amyloid-β deposition in AD and CAA patients.
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De ziekte van Alzheimer en de ziekte cerebrale amyloïde angiopathy (CAA) worden beiden 
gekenmerkt door opstapeling van het amyloïd-β peptide in het brein, ook wel amyloïdose 
genaamd. Ook worden beide ziektes gekenmerkt door een verminderd functioneren van 
de hersenvaten. Het doel van het onderzoek in dit proefschrift was om de kennis over 
de relatie tussen amyloïdose en het functioneren van de hersenvaten uit te breiden. Om 
dit doel te bereiken werden technieken uit de medische beeldvorming, ook wel kortweg 
aangeduid met “imaging”, verder geoptimaliseerd voor het meten van het functioneren 
van de hersenvaten, en vervolgens toegepast in muismodellen met en zonder amyloïdose. 
In hoofdstuk 1 werden een aantal belangrijke begrippen geïntroduceerd over de 
samenstelling en het functioneren van gezonde en aangedane hersenvaten. Daarnaast 
werden verschillende soorten muismodellen met amyloïdose geïntroduceerd. Ook 
werden verschillende imaging technieken besproken die het functioneren van de 
hersenvaten kunnen meten, met extra nadruk op de techniek “Arterial Spin Labeling” 
(ASL), de meest gebruikte imaging techniek in dit proefschrift. ASL is een MRI-techniek 
die de hersendoorbloeding in absolute waardes kan meten zonder dat daarbij invasieve 
handelingen zoals injecties van contrastvloeistof vereist zijn. Het bloed in de halsslagaders 
wordt daartoe magnetisch gelabeld, waarna het als endogeen contrastmiddel gebruikt 
wordt om de hersendoorbloeding te meten. Een aanpassing op de al bestaande 
ASL-techniek werd beschreven in hoofdstuk 2, waarmee niet alleen de hoeveelheid 
bloed, maar ook de aankomsttijd van het bloed in verschillende breinregio’s van het 
muizenbrein gemeten kan worden. Deze bloedaankomsttijd is een belangrijke parameter 
bij de berekening van de hersendoorbloeding, maar kan op zichzelf ook een belangrijke 
graadmeter zijn om vasculaire pathologie te detecteren. Met de aangepaste ASL-techniek 
kon de bloedaankomsttijd voor het eerst in het muizenbrein gemeten worden op een 
tijdsefficiënte manier.
Anesthesie is praktisch onvermijdelijk bij het uitvoeren van MRI in muizen. In hoofdstuk 3 
werd daarom het effect beschreven van verschillende soorten anesthesie op de dynamiek 
van de bloedtoevoer naar het muizenbrein. Een specifiek anesthesie protocol waarbij 
gebruik gemaakt wordt van lage isofluraan concentraties werd beschreven, waarmee 
herhaalde metingen van hersendoorbloeding gedaan kunnen worden, zowel onder normale 
conditie als onder hypercapnie.
In hoofdstukken 4 en 5 werden de opgedane kennis en de ontwikkelde imaging technieken 
van de voorgaande hoofdstukken gebruikt om het functioneren van de hersenvaten 
in muismodellen met amyloïdose te meten. Hoofdstuk 4 richtte zich op het APP/PS1 
model, waarin amyloïd-β zich voornamelijk opstapelt in het hersenparenchym (tussen 
de hersencellen), net zoals bij patiënten met de ziekte van Alzheimer. Opvallend was 
dat het functioneren van de hersenvaten in deze muizen niet verschilde ten opzichte
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van muizen zonder amyloïd-β opstapeling. In hoofdstuk 5 werd het Tg-SwDI muis-
model gebruikt. Dit model vertoont hevige microvasculaire amyloïd-β opstapeling, 
zoals ook voorkomt bij sommige patiënten met CAA. Echter, wederom werd geen 
verschil gevonden tussen het functioneren van de hersenvaten van deze muizen ten 
opzichte van muizen zonder amyloïd-β opstapeling. De bevindingen van dit 
proefschrift werden in hoofdstuk 6 verder bediscussieerd. 
Verder onderzoek is nodig om uit te vinden of de negatieve resultaten in dit proefschrift 
verklaard kunnen worden door een beperkte validiteit van de muismodellen, of dat 
parenchymale en microvasculaire amyloïdoise geen belangrijke rol spelen bij het 
verminderd functioneren van de hersenvaten in patiënten met AD en CAA. Ondanks dat 
negatieve bevindingen niet heel spannend klinken, dragen ze wel bij aan het beter begrijpen 
van de precieze verhouding tussen amyloïdose en het functioneren van de hersenvaten. 
Uiteindelijk zal dat belangrijke informatie kunnen zijn om een broodnodige therapie te 
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